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Abstract 
The renin - angiotensin system plays a central role in the maintenance of blood 
pressure. Angiotensin II, the main effector of this system, results from the action of 
angiotensin - converting enzyme (ACE) on angiotensin I. Angiotensin II, maintains 
vasomotor tone via its vasoconstrictor action, and also increases salt and water 
retention by stimulating the release of aldosterone. ACE inhibitors, such as 
captopril, enalapril and lisinopril, are highly effective in the treatment of 
hypertension and congestive cardiac failure. 
Previous studies have suggested that angiotensin converting enzyme (ACE) 
production may be enhanced during pharmacological inhibition of the enzyme. 
Little is known, however about the mechanism of this induction. After 
demonstrating increases in circulating ACE protein in cardiac failure patients 
receiving the ACE inhibitor captopril, a rat model was used to study this effect. A 
sensitive enzyme linked immunosorbent assay for rat ACE was developed and a 
partial cDNA for rat ACE cloned to enable examination of ACE mRNA and protein 
expression during enzyme inhibition with enalapril. Rat lung ACE mRNA increased 
by 156% (p<0.05) and ACE protein doubled within 3 hours of administering a 
single dose of enalapril. Testicular ACE mRNA also increased by 300% (p<0.05) 
within 2 hours and returned to pretreatment levels by 6 hours. The angiotensin II 
antagonist saralasin similarly caused a significant (p<0.0001) 800% enhancement 
of mRNA expression. Aldosterone pretreatment of rats prior to enalapril 
xiii 
administration was found to abolish this mRNA induction. These findings indicate 
that increased ACE expression during inhibition results from reduced levels of 
angiotensin II with consequent reduced stimulation of the angiotensin 11 receptor 
and its effects, such as aldosterone release. This suggests that ACE levels are 
regulated by a negative feedback loop involving the distal components of the 
renin-angiotensin system, namely angiotensin II and aldosterone. In situ 
hybridisation and immunohistochemical techniques were employed to localise the 
site of this inductive· response in rat tissue sections. It was found that lung 
macrophages were markedly induced to produce ACE, as was ACE in 
seminiferous tubules. ACE induction was also noted in the expected sites of renal 
tubular epithelium and glomerular tissue. Interestingly, ACE expression was also 
enhanced in cardiac valves. 
In these studies it has been conclusively demonstrated that new ACE expression 
is induced by enzyme inhibitor therapy. A variety of techniques have been 





1.1. HISTORICAL PERSPECTIVE 
The foundation for the discovery of the renin-angiotensin system was the work 
of Goldblatt and his colleagues in the early 1930's demonstrating that 
experimental hypertension had a renal basis (Goldblatt, 1947). In attempting to 
isolate a circulating hypertension factor, attention focused on renin which, as 
early as 1898 (Tigerstedt and Bergman, 1898), had been shown to be able to 
cause marked elevations in blood pressure. Confusion, however, arose from 
the finding of Friedman and his co-workers (Friedman et al., 1938), that renin 
itself did not cause vasoconstriction in the isolated dog tail. 
Clarity was obtained from the work of two groups who independently found that 
renin acted on a substance in plasma producing a potent vasopressor which 
the one group called angiotonin (Munoz et al., 1939) and the other termed 
hypertensin (Braun-Menedez, 1940). Only in 1958 was the hybrid term 
angiotensin agreed upon (Braun-Menedez and Page, 1958). 
Angiotensin-converting enzyme (ACE) was discovered in 1954 (Skeggs et al., 
1954). In these early studies, Skeggs and his co-workers demonstrated the 
existence of two forms of angiotensin which they called hypertensin I and 
hypertensin II. Their studies also revealed the presence of a "hypertensin-
converting enzyme" in equine plasma, capable of converting hypertensin I to 
hypertensin II. These and further studies by Helmer (Helmer, 1955) suggested 
that hypertensin II was the true vaso-constrictor and established that 
angiotensin-converting enzyme (ACE) produces the final effector of the renin-
angiotensin system - angiotensin II (Skeggs et al., 1954a & 1954b and 1956a, 
1956b & 1956c; Lentz et al., 1956). 
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These early studies also elucidated some of the most important properties of 
ACE; its chloride dependence, metalloprotein nature and specificity in the 
removal of intact dipeptides from the C-termini of peptide substrates. 
More than a decade passed before further discoveries were made on ACE. 
This was largely due to the absence of a simple chemical assay for the 
enzyme. Ng and Vane (Ng and Vane, 1967 & 1968) found that the lungs, and 
not plasma, was the major site for the production of angiotensin II. They went 
on to propose that ACE may also inactivate the vasodilator bradykinin. This 
proposal was supported by the finding that bradykinin potentiating factor could 
inhibit ACE. Bradykinin potentiating factor was a mixture of uncharacterised 
peptides that Ferreira had isolated from the venom of the South American pit 
viper Bothrops jararaca which he showed could inhibit the degradation of 
bradykinin (Ferreira, 1965 & 1966). 
These findings rekindled interest in ACE which had been rediscovered twice 
during the preceding decade, firstly by Elisseeva and Orekhovich who 
extracted an enzyme they called "carboxycathepsin" from beef kidney 
(Elisseeva and Orekhovich, 1963) and later by Erdos and Yang who identified 
a dipeptidyl carboxypeptidase in human plasma (Erdos and Yang, 1967) which 
they called "kininase 11" to distinguish it from kininase I, a circulating 
carboxypeptidase which inactivates bradykinin. 
The development of simple chemical assays utilising model NH2-protected 
substrates (Piquilloud et al, 1970; Cushman and Cheung, 1971; Yang et al, 
1970) greatly assisted in the purification of ACE from a variety of animal 
tissues, including human. 
The isolation of pure enzyme resulted in much progress toward the 
understanding of the biochemistry of ACE as well as its tissue distribution and 
biological roles. This led to the development of potent orally active inhibitors of 
the enzyme which are currently widely used in the treatment of hypertension 
and congestive cardiac failure. 
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1.2. BIOCHEMISTRY 
1.2.1. Physiochemical Properties 
ACE appears to be similar in most mammalian species in that it is an acidic 
glycoprotein consisting of a single large polypeptide chain which initially was 
thought to contain 1 mol/mol of zinc (Soffer, 1981 ). Subsequent information 
obtained from study of cloned ACE has shown this not to be true as will be 
detailed later. Analysis of the enzymes purified from different tissues of various 
mammalian species revealed that, within a particular species, the structure of 
ACE appears to be identical at all anatomical loci except for the testis (Lanzillo 
et al., 1985) and perhaps the brain (Strittmatter et al., 1985). 
In most mammalian tissues ACE has been shown to have a molecular weight of 
between 140000-160000. ACE has a high carbohydrate content which resulted 
in spuriously higher molecular weights on gel filtration, thus complicating the 
determination of its molecular weight (Andrews, 1965). This form has been 
termed the "lung" or somatic form of ACE, reflecting its widespread distribution. 
A smaller form, of approximately 90000 MW (human) and 100000 (rabbit), is 
found within the testis. 
ACE has a relatively high percentage of acidic amino acid residues, partially 
explaining its low isoelectric point. The pl lies between 4.3 and 5.2 (Soffer, 
1976; Nakajima et al., 1973; Stewart et al., 1981 )). Varying degrees of 
sialylation may explain this range of pl values. Hydrophobic residues account 
for 44% of the amino acid content and the polar to apolar residue ratio ranges 
from 1.2 (Das & Soffer, 1975) to 1.4 (Weare et al., 1982) - thus suggesting 
moderate hydrophobicity. 
N-terminal sequence data has been obtained for bovine, rabbit, pig and human 
ACE (Ehlers & Riordan, 1990). The results demonstrate considerable 
interspecies homology at the N-terminus. In contrast, limited C-terminal 
sequence data has been obtained from only two species, rabbit and human. 
The differences between these are profound and may be due to variations in 
the purification techniques employed. Although ACE has been isolated from a 
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variety of body fluids, this soluble ACE is thought to result from specific 
cleavage of membrane bound enzyme. Evidence for this has been obtained 
from the experience in purification of enzyme from tissues which typically 
requires solubilisation during purification (Soffer, 1981 ). This is either 
accomplished by using non-ionic detergents (Ehlers et al., 1986) or trypsin 
which is thought to cleave off a short C-terminal membrane embedded anchor 
peptide (Weare et al., 1982). Comparison of molecular weights between 
naturally occuring soluble ACE (in blood or seminal plasma) and solubilised 
ACE from human lung and kidney, either through the use of Triton X-100 or 
trypsin revealed no difference (Lanzillo et al., 1985). It was noticed however, 
that detergent solubilised ACE showed an increased tendency to aggregate, 
suggesting that detergent solubilisation of the enzyme results in the retention of 
the short hydrophobic membrane anchor sequence. In a study of porcine ACE 
(Hooper et al., 1987) no difference was found between detergent or trypsin 
solubilised porcine kidney ACE. When the enzyme was solubilised by Triton X-
100 in the presence of EDTA (thought to inhibit endogenous solubilising 
activity), however, a hydrophobic protein was obtained. These results provided 
evidence for the anchoring of ACE through its C- terminus. 
Study of the rabbit testicular enzyme showed that it differed in both the C- and 
N- terminal sequences when compared to the lung enzyme (Iwata et al., 1982). 
This result, taken with those of competitive radioimmunoassays suggesting 
immunological identity of lung and testicular ACE (Soffer et al., 1987), indicated 
that testicular ACE possibly consisted of a portion of the somatic enzyme. 
Proof of this relationship between lung and testicular ACE was subsequently 
obtained from the cloning and sequencing of ACE cDNA. These studies will be 
detailed later in this review. 
1.2.2. Carbohydrate content 
Rabbit ACE has been found to contain approximately 26-30% cabohydrate 
(Das & Soffer, 1975 and Das et al., 1977). Up to 188 sugar residues have been 
found to be present per protein molecule. These consist of fucose, mannose, 
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galactose, N-acetylglucosamine and sialic acid in the ratio 1 :7:6.9:6.8:1.75 for 
lung ACE and for the serum enzyme in the ratio 1 :6.3:8.2:8.3:7.5. It is 
interesting to note the higher content of sialyl residues in the serum enzyme 
suggesting that sialyl deficient enzyme molecules are selectively removed from 
the circulation by hepatic asialoglycoprotein receptors recognising sialic acid 
deficient, galactosyl terminating glycoproteins (Hudgin et al., 197 4 & Ashwell , 
1974). Human kidney ACE has been found to contain 24-28% carbohydrate by 
weight with ratios of fucose to mannose to N-acetylglucosamine to galactose 
being 1.6:3.0:4.5:4.4 with only trace amonts of sialic acid being present (Weare 
et al., 1982). Human pulmonary ACE contains approximately 20 sialic acid 
residues per molecule, supporting the endothelial origin of serum ACE. 
Evidence that ACE may be differentially glycosylated in different organs has 
been demonstrated in the pig which contains a smaller enzyme in the striatum 
(170000) compared to that in the kidney (180000). However, on 
deglycosylation, enzyme from both sources was shown to have identical 
molecular weights (Hooper et al., 1987). The rabbit testicular enzyme contains 
20% carbohydrate and differs from the rabbit lung form in its relatively large 
content of galactosamine and the absence of fucose (El-Dorry et al., 1982). 
Recent data (Ehlers et al., 1992) has found that the unique N-terminal 
sequence of human testicular ACE, not shared by the somatic enzyme, is 
heavily 0-glycosylated. 
1.2.3. Metal content 
ACE has been shown to be a metalloenzyme containing 1 gram atom of zinc 
per mole of protein. This has been confirmed in rabbit lung ACE (Das et al., 
1975), equine serum ACE (Fernley, 1977) and canine pulmonary ACE (Conroy 
et al., 1978). With ACE, in contrast to other metallopeptidases, zinc appears to 
be less tightly bound, dissociating readily below pH 7 (Bunning and Riordan, 
1981 and Kleemann et al., 1986). The metal content of testicular ACE has not 
been determined but testicular ACE appears to be less sensitive to the action 
of metal chelators (Velletri et al., 1985). 
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More accurate methods have recently been utilised to re-examine the metal 
content of ACE and it has been demonstrated that there are two zinc atoms per 
enzyme molecule allowing both active sites of the somatic enzyme to be 
functional (Ehlers and Riordan, 1991 ). 
1.2.4. Active site residues 
Four functional residues at or near the active site of rabbit pulmonary ACE 
have been determined by chemical modification (Bunning et al., 1978). These 
active residues are tyrosine, arginine, glutamine and lysine. In another study, 
(Fernley, 1977) tyrosine was also implicated as a functional residue at the 
active site of equine ACE. Similarly, glutamate has been shown to be an active 
site residue in bovine pulmonary ACE (Harris and Wilson, 1983). These 
residues have also been shown to be present at the active site of testicular 
ACE. 
Recently, recombinant ACE has been expressed with mutations at the putative 
active site corresponding to the short consensus sequence of zinc 
metallopeptidases His-Glu-X-X-His (Wei et al., 1991 ), confirming that mutations 
in this region result in a loss of enzymatic activity. 
1.2.5. Catalytic Properties 
ACE has been found to be able to cleave a wide range of substrates in vitro, 
some as long as the r., chain of insulin to those as short as N- terminal blocked 
tripeptides. It was originally thought that there were certain rigid substrate 
requirements for ACE action including a free C-terminal carboxyl group, the 
absence of a C- terminal dicarboxylic acid and the absence of a penultimate 
praline residue (because of the inability of ACE to cleave imide bonds). It has 
now been found that only the last of these appears to be invariable. In fact, 
ACE has such a wide substrate specificity that it has been used as a tool for C 
terminal sequence analysis of polypeptides (Krutzsch, 1980 & Beckner and 
Caprioli, 1980). ACE appears to sequentially cleave dipeptides from the 
carboxy-teriminal ends of peptide substrates (Ehlers and Riordan, 1990). 
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ACE has also been shown to be able to cleave peptides having a C-terminal 
blocking group such as nitrobenzylamine which is released upon cleavage 
(Hersh et al., 1983). 
Another situation in which ACE has been shown to cleave blocked peptides is 
its action on amidated neuropeptides such as Substance P (Yokosawa et al., 
1983) and substance K (Thiele et al., 1985). While substance K degrading 
activity could not be shown for porcine striatal or kidney ACE, striatal ACE from 
rat brain does possess this unique activity and, owing to its slightly smaller size 
as compared to the lung enzyme (165000 vs.175000), has been described as a 
brain isozyme of ACE (Strittmatter et al., 1985). However, this has been 
disputed and the smaller size of this brain "isozyme" has been attributed 
instead to differential glycosylation rather than differences in polypeptide length 
(Hooper and Turner, 1987). 
While ACE normally cleaves dipeptides from carboxy terminal ends of peptide 
substrates, tripeptidyl caboxypeptidase activity has been reported for ACE in 
the cleavage of substance P (Thiele et al., 1985), Arg9-bradykinin (lnokuchi 
and Nagamatsu, 1981) and Luteinizing Hormone-releasing hormone (LH-RH) 
(Skidgel and Erdos, 1985). Even the enzyme specificity for peptide bonds is not 
absolute as esterase activity has also been shown (Keung et al., 1980). 
When considering the wide range of substrates shown in vitro to be cleaved by 
ACE where both non-physiological conditions and prolonged cleavage times 
may be employed, it must be remembered that true in vivo substrate specificity 
under physiological conditions is regulated by a complex combination of 
substrate affinities, chloride dependence, hydrolytic rates and the concentration 
of biologically relevant substrates. 
When one observes the kinetic similarity between natural peptides such as 
angiotensin I and bradykinin, their C-terminal peptide analogues and 
analogous C-terminal dipeptide competitive inhibitors, the importance of the 
amino acid residues on either side of the cleaved peptide bond, and their 
determining role in binding and substrate specificity, becomes evident (Cheung 
et al., 1980). Thus while the selectivity of ACE appears to depend on the C-
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terminal sequence of its substrate, it has also been shown that this can be 
significantly modified by sequence alterations distant from the active site 
toward the N-terminus of the substrate. For example, it was found that Des 1 _ 
Asp angiotensin I is a better ACE substrate than angiotensin I (Gaynes et al., 
1978), based on its more favourable Vmax to Km ratio (Tsai et al., 1975 and 
Chiu et al., 1976). Similar findings have also been made with tetradecapeptide 
renin substrate and its C-terminal nonapeptide homologue (Dorer et al., 1975) 
and also bradykinin and its higher C-terminal homologues (Dorer et al., 197 4). 
In both cases the shorter peptides were found to be hydrolysed at rates as 
much as 13 and 22 times faster, respectively. 
It must be realised that substrate specificity of ACE is a complex process 
particularly when its anion activation is considered. Most studies on substrate 
specificity have depended on structure-activity studies of snake venom peptide 
inhibitors and of more recently developed metal coordinating ACE inhibitors 
rather than on substrates themselves. 
Moreover, studies have utilised fixed time sampling assays to detail the kinetic 
parameters for natural substrates such as angiotensin I and bradykinin and 
numerous synthetic N- blocked tripeptides. These assays are not generally well 
suited to precise kinetic analyses and thus only when a continuous 
spectrophotometric ACE assay was developed by Holmquist et al. (1979), was 
it possible to rigorously study ACE catalysed peptide hydrolysis. This assay 
depended on Furanacryloyl blocked tripeptides in which a decrease in 
absorbance accompanies hydrolysis, and the first such tripeptide to be used 
was Fa-Phe-Gly-Gly (Bunning et al., 1983). 
1.2.6. Anion activation and the importance of pH 
It has long been known that the catalytic mechanism of ACE is dependent on 
anion activation (Skeggs et al., 1954). It was subsequently found that the anion 
requirements vary between substrates and are affected by pH. For example the 
comparative activating potencies of anions for Z-Phe-His-Leu hydrolysis 
(Piquilloud et al., 1970) are er > N03-> 8( > F > i- and for Fa-Phe-Gly-Gly 
(Bunning and Riordan, 1983) was er> 8( > F > N03- > CH3coo-. It appears 
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that there are stringent anion size requirements governing the degree of 
activation, because despite bromide, nitrite, iodide and acetate all appearing to 
bind ACE at least as well as chloride by kinetic criteria, these are only 52%, 
14%, 10% and 2% as effective as chloride, respectively. 
There is also substrate dependence of anion activation since angiotensin I and 
some tripeptide substrates such as Hip-His-Leu have a strong requirement for 
chloride whereas bradykinin can be hydrolysed in the absence of chloride at 
approximately 37% of the optimum rate (Dorer et al., 197 4 ). It has also been 
found that where the substrate is tightly bound to ACE there is less 
dependence on chloride for hydrolysis and in fact supraoptimal concentrations 
of chloride have been shown to inhibit hydrolysis (Cheung et al., 1980). Thus it 
appears that, where a substrate binds tightly to ACE, activation by small 
amounts of chloride could be due to enhanced binding of substrate. 
Shapiro et al. (Shapiro et al., 1983) have classified substrates according to 
their dependence on anion activation by studying hydrolysis of a group 26 
Furanacryloyl tripeptides. Three classes of substrate have been described; 
Class I substrates for which Fa-Phe-Gly-Gly is typical, are relatively weakly 
binding (Km values 0.16-4.1 mM) but have high turnover numbers (Keat 32-617 
sec-1) with hydrolysis showing an absolute requirement for chloride, 
demonstrating an essential activator mechanism at neutral pH. Apparent 
activation constants (Ka') are in the range of 75-150 mM for chloride for Class I 
substrate hydrolysis. Class II substrates are tight binding (Km 6.5-110 µM) 
having much lower Ka' values (2.9-5 mM) and all appear to be hydrolysed by a 
non essential activator mechanism. The kinetic mechanisms for Class I and 
Class II substrates are diagramatically shown in the figure below. Class Ill 
substrates demonstrate intermediate values of Km (49-520 µM) with activation 
constants of between 18 and 30 mM and are hydrolysed by a more complex 
non essential activating mechanism. 
pH dependence of the activation constants for chloride differ markedly between 
each of the three classes, varying 60 fold over the pH range 6-9 for Class I, 3-
fold for Class II, and 19-fold for Class Ill substrates. While for Class II 
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substrates these findings can be related to the amino acids found at the C-
terminus of the peptide, no distinguishing features for Classes I and Ill can be 
clearly discerned, except that none contain charged residues. In contrast to 
Class II substrates, all Class Ill substrates posess an alanyl residue as the 
penultimate amino acid. These findings have been demonstrated for both rabbit 
lung (Shapiro et al., 1983) and human kidney ACE (M.R.W.Ehlers, personal 
communication). 
Bradykinin, with its positively charged ultimate residue, appears to be a Class II 
substrate, which as mentioned previously, undergoes significant ACE 
hydrolysis even in the absence of chloride. In contrast, angiotensin I, may be 
both a Class I and Class II substrate, depending on the ionisation state of the 
penultimate histidine residue (Shapiro et al., 1983). With rabbit ACE it has 
been shown that angiotensin I behaves as a Class I substrate, having an 
absolute requirement for chloride (Bunning et al., 1983). Angiotensin I 
hydrolysis by human kidney ACE follows a non-essential activation mechanism 
in which it has been shown that the requirement for chloride is markedly pH 
dependent, increasing with increasing pH (Ehlers and Kirsch, 1988). 
Sulphate has been shown to potentiate the chloride activation of ACE. Initially it 
was thought that this effect was simply due to the change in ionic strength and 
only recently has this phenomenon been kinetically studied using rabbit lung 
ACE and the substrate Fa-Phe-Gly-Gly (Bunning and Riordan, 1987). While 
sulphate decreases the apparent binding constant for chloride (lowering 
apparent Km value) it does not change kcat· Sulphate, therefore, potentiates 
the effect of chloride which appears to activate the enzyme by enhancing 
substrate binding. Sulphate on its own however, is unable to activate the 
enzyme. 
1.2. 7. Effects of Metal Substitution 
ACE, being a zinc metalloprotease can be inhibited by metal chelators such as 
EDTA (Cushman and Cheung, 1971) and the removal of zinc abolishes activity 
completely (Bunning and Riordan, 1981 ). Experiments in which enzyme is 
stripped of zinc and replaced by various divalent cations revealed that the 
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resulting activity is markedly ion and substrate dependent. For example while 
co2+-containing ACE demonstrates 120% activity compared with zn2+ enzyme 
for the substrate Fa-Gly-Leu-Ala it only shows 55% of the zinc enzyme activity 
for the substrate Fa-Phe-Gly-Gly (Bicknell et al., 1987 & Bunning and Riordan, 
1981 & 1985). Zinc dissociates from the enzyme at low pH and therefore, in 
acidic conditions, zinc must be added in order to maintain activity (Bunning et 
al., 1983). Supraoptimal zinc concentrations have been shown to inhibit ACE. 
This effect has been seen for rabbit ACE particularly in alkaline conditions and 
for human kidney ACE throughout the pH range (Ehlers and Kirsch, 1988). 
1.2.8. Catalytic Mechanism 
On the basis of structure-activity studies on ACE using numerous snake venom 
peptide inhibitors, ACE was originally considered to be a dipeptide-releasing 
carboxypeptidase similar in many respects to carboxypeptidase A (CPA) 
(Cushman et al., 1977 & Ondetti et al., 1977). Subsequently, when it was found 
that zinc was required for activity and that arginine, tyrosine and glutamate are 
important active site residues, ACE became defined as a zinc 
metallocarboxypeptidase closely related to CPA but also part of a family of zinc 
metallopeptidases including CPA, thermolysin, bacterial neutral proteases, 
aminopeptidases, collagenases and others (Bunning et al., 1978). 
A catalytic mechanism for ACE appears to include the necessity for a positively 
charged arginine residue which binds to the C-terminal carboxyl group of the 
substrate followed by cleavage of an amide bond which is catalysed by both 
the electrophilic effect of the zinc ion and nucleophilic attack of the 
gammacarboxylate group of either the glutamate and/or a zinc hydroxide. Thus 
it would appear that for substrate binding and correct alignment of enzyme to 
' 
substrate to be achieved there is a necessity for; 1.) binding of the substrate C 
terminal carboxyl with the enzyme arginine residue; 2.) coordination of the 
scissile amide carbonyl with the zinc atom; 3.) the formation of a hydrogen 
bond between the tyrosine at the active site and the terminal peptide carbonyl; 
and finally,4.) interaction of the 
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side chain of the C-terminal three substrate amino acid residues with as yet 
undefined binding subsites. 
Radiationless energy transfer studies with a fluorescent substrate (Bunning and 
Riordan, 1981) have demonstrated that zinc is not required for substrate 
binding and appears to function solely in the hydrolytic step of catalysis. This is 
further supported by the knowledge that metal replacement mainly affects kcat 
causing little alteration in Km (Bunning and Riordan, 1985). 
Despite similarities between ACE and other zinc metallopeptidases, a unique 
feature of ACE not explained by the proposed catalytic mechanism above, is 
the marked activating effect of chloride and other monovalent anions. It has 
recently been noted however, that CPA is inhibited by chloride and other 
anions by a partially competitive mechanism, arginine being implicated as the 
most likely anion binding site (Williams and Auld, 1986). CPA does not have an 
active site lysine which has been demonstrated to be the anion binding site of 
ACE (Bunning et al., 1978). It appears that anion activation is the result of 
enhanced enzyme substrate binding (Shapiro et al., 1983). Similarly it has 
been shown that inhibitor binding is enhanced by chloride (Shapiro and 
Riordan, 1984). It has been suggested (Shapiro, 1983) that the active site 
lysine of ACE in conjunction with chloride promotes binding. This may be 
achieved by an improvement, in the presence of the anion, in the alignment of 
the other active site residues enhancing substrate binding. Some evidence for 
this effect of chloride causing an active site conformational change does exist 
as it has been found that chloride results in a small alteration of the near and 
far ultraviolet absorbance (Oshima et al., 1974) and also enhances the 
efficientcy of radiationless energy transfer between ACE tryptophan residues 
and an active site bound danzyl inhibitor (Martin et al., 1987). 
A potential biological role for anion activation has been suggested (Ehlers and 
Riordan, 1990), where apart from promoting a more favourable conformational 
change in the active site it may also play a regulatory role depending where the 
enzyme is acting. Whereas perhaps not true for ACE on endothelium 
throughout the body, ACE in the renal tubule brush borders and on intestinal 
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microvilli is certainly exposed to significant ion fluxes and this may have the 
effect of regulating ACE activity. 
1.3. THE RENIN ANGIOTENSIN SYSTEM. 
The renin angiotensin system (RAS) was initially thought to be merely a 
circulating endocrine system. The role of ACE was considered to be limited to 
the conversion of angiotensin I to angiotensin II which took place in the 
pulmonary vasculature. Although the RAS does act as a circulating endocrine 
system, involved in the production of the vasoconstrictor angiotensin II, there is 
now firm evidence that it also has important local autocrine and paracrine roles 
in a variety of tissues. The local tissue RAS provides tonic control of vascular 
resistance and influences local tissue function whiie the circulating RAS serves 
in short term cardiorenal homeostasis (Dzau, 1988). It has even been 
suggested that the RAS acts on intracellular events, ie. an intracrine system 
(Re, 1984). Other diverse roles for the RAS, unrelated to cardiorenal 
homeostasis, are reproduction and immunity (Weinstock, 1986; reviewed in 
Ehlers and Riordan, 1989). As has been mentioned previously in the section on 
substrate specificity, ACE is also thought to hydrolyse non angiotensin 
peptides such as substance Pin vivo (Strittmatter et al., 1985). These functions 
will all be covered in the following section. 
In considering the role of ACE in the RAS, brief mention should be made of the 
RAS cascade and its components. The biochemical cascade forming the renin 
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Renin (EC 3.4.23.15) is an aspartyl (or acid) protease closely related to pepsin, 
cathepsin and chymosin. The mouse, rat, and human (Rougeon et al., 
1981; Imai et al., 1983; Sou brier et al., 1983) renin genes have been cloned. 
The renin gene consists of nine exons in the mouse and rat, differing from the 
human gene which has ten exons . Renin is synthesised as SSkDa precursor 
molecule which is then converted to 44kDa active renin either during packaging 
in the Golgi apparatus or in renin granules. Renin is synthesised and stored in 
granules contained in the juxtaglomerular apparatus of the kidney (Barajas, 
1979), but it has become increasingly apparent that renin is also synthesised in 
extra-renal sites such as the brain (Dzau et al., 1986) and the adrenal glands 
(Deschepper et al., 1986). Renin only acts on its specific substrate 
angiotensinogen, to form angiotensin I (the substrate for ACE to form 




Angiotensinogen is an alpha 2 globulin synthesised by the liver. The gene for 
angiotensinogen has been cloned (Okhubo et al., 1983). Heterogeneity has 
been demonstrated in the purified protein which has a molecular weight of 
between 61 and 65 kDa and is glycosylated (Menard et al., 1983; Tewksbury, 
1983). As with renin, there is evidence that angiotensinogen is synthesised at 
extrahepatic sites such as the brain and kidney (Campbell and Habener, 1986). 
Angiotensinogen levels have been shown to be increased by oestrogens, oral 
contraceptives, glucocorticoids, thyroid hormones and post nephrectomy - and 
appears to be decreased during ACE inhibitor therapy (Rasmussen et al., 
1981 ). 
1.3.3. Angiotensin converting enzyme 
The biochemistry of ACE has been extensively covered above and its tissue 
distribution and functions are detailed in section 1.4. 
1.3.4. Angiotensin I, II and Ill 
Angiotensin I is a decapeptide that results from the action of renin on 
angiotensinogen. Having no apparent biological activity, angiotensin I is rapidly 
converted by ACE to angiotensin II, the biologically active octapeptide effector 
of the RAS. It has been shown that administration of ACE inhibitors causes an 
accumulation of angiotensin I (Johnston et al., 1979). While it is likely that most 
conversion of angiotensin I to angiotensin II takes place in the pulmonary 
vasculature, there may also be significant local formation across peripheral 
vascular beds. Angiotensin II has a short half life of between 15 and 30 
seconds in the circulation before being destroyed by a series of 
aminopeptidases or angiotensinases. Action of aminopeptidase A on 
angiotensin II results in angiotensin Ill which is formed in very low 
concentrations in humans but in greater concentrations in the rat (Semple et 
al., 1976). Angiotensin Ill may have some biological role in the brain and 
adrenal. It does possess some biological activity on vasculature, although less 
potent than angiotensin II, and in stimulating the production of aldosterone. 
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Angiotensin II can also be formed by the action of enzymes other than ACE on 
angiotensin I. Although in the rat angiotensin II appears to be formed by ACE, 
this is not so in the human heart where a major angiotensin II forming serine 
protease, belonging to the chymase family of leukocyte proteinases, has been 
isolated (Urata et al., 1990). It has also been shown that kallikrein or 
kallikreinlike enzymatic activities can result in the formation of angiotensin II 
directly from angiotensinogen (Gonda et al., 1989). 
1.4. TISSUE DISTRIBUTION AND BIOLOGICAL ROLE OF ACE 
AND THE RAS. 
ACE is widely distributed in virtually all mammalian organs and body fluids. The 
tissue distribution has, however been shown to differ between species. In the 
rat, highest ACE specific activity is in the epididymis, testis and lung, with the 
lowest levels in the kidney, heart and liver (Cushman and Cheung, 1971 ). 
Quantitatively different values were obtained in a survey of 24 post-mortem 
human tissues (Lieberman and Sastre, 1983). Highest levels were found in the 
kidney which has subsequently proven to be a most convenient source in the 
purification of ACE (Ehlers et al., 1986). Lower levels were found in the lung, 
prostate, colon, testis and adrenal. ACE is found primarily in three types of 
cells; endothelial, epithelial and neuroepithelial (Defendini et al., 1983). This 
grouping provides a convenient system for classifying ACE distribution. 
Endocrine cells and the ACE of other sources w:11 be termed "Miscellaneous" 
below. As described earlier, ACE is mostly membrane bound acting outside the 
cell, although ACE has been located in intracelluler cytoplasmic membranes as 
in sperm cells (Brentjens et al., 1986) and possibly neuroblastoma cells 
(Okamura et al., 1981 ). 
1.4.1. Endothelial ACE 
ACE is widely found in the vasculature of virtually all organs consistent with its 
plasma membrane localisation on endothelial cells (Caldwell et al., 1976). In 
this location ACE is well positioned to convert angiotensin I to angiotensin II 
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and to inactivate bradykinin. Owing to the vast capilliary surface found in the 
lung it has long been considered that the lungs are the major site for the 
formation of angiotensin II (Ryan, 1982). This view has been more recently 
revised following findings suggesting that the peripheral tissues are the major 
source of angiotensin II (Campbell, 1985). 
1.4.2. Epithelial ACE 
In humans, and probably all mammals, epithelial ACE located in the kidney, 
choroid plexus, prostate and epididymis is bathed in an effluent and is well 
placed to.act on soluble substrates in flux. 
1.4.2.1. Kidney 
ACE in the human kidney has been localised to the brush border of proximal 
tubular cells (Danilov et al., 1987), glomerular endothelium (Danilov et al., 
1987) and juxtaglomerular cells (Celia and lnagami, 1981 ). Other components 
of the RAS have also been located in the kidneys of rats: renin mRNA and 
protein have been located by in situ hybridisation and immunohistochemistry in 
the juxtaglomerular apparatus (Deschepper et al., 1986), and angiotensinogen 
mRNA has been located in the rat proximal tubule (lngelfinger et al., 1990). A 
variety of roles have been suggested for renal ACE: it may a) cleave dipeptides 
from absorbed oligopeptides and transport them into the cytoplasm (Defendini 
et al., 1983); b) it could be involved in sodium and fluid reabsorbtion (Harris et 
al., 1984); or c) its action could regulate the glomerular filtration rate by causing 
vasoconstriction of afferent and efferent vessels (Celia and lnagami, 1981 ). 
1.4.2.2. Intestine 
All the components of the RAS have been shown to be present in the intestine; 
angiotensinogen and renin have been located in the walls of the splanchnic 
arteries (Desjardins - Giasson et al., 1981) and ACE has been found on the 
endothelium of mesenteric vessels (Erdos and Skidgel, 1987) and intestinal 
brush border (Bruneval et al., 1986). ACE has been localised in the rat 
intestine in the mucosae of the duodenum and jejunum (Duggan et al., 1989). A 
more restricted distribution of the enzyme was found in the ileum and colon. 
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ACE was also detected in the muscle layers of all regions especially at the 
mucosa muscularis-junction. In the same study, angiotensin II receptors were 
detected only in the muscularis layer of particularly the colon and to a lesser 
extent the ileum and duodenum. The authors concluded that ACE in the 
intestinal mucosa could play a role in the hydrolysis of absorbed peptides while 
ACE and the angiotensin II receptors in the muscularis suggest a role in 
intestinal motility. It is well established that angiotensin II stimulates the 
contraction of intestinal smooth muscle. 
1.4.2.3. Choroid Plexus 
The apical membranes of the epithelial cells of the choroid plexus are 
particularly rich in ACE (lgic et al., 1977). It is bound to the microvillus luminal 
plasma membranes and comes into contact with the cerebrospinal fluid (CSF) 
which bathes the plexus (Defendini et al., 1983; Strittmatter et al., 1984; Rix et 
al., 1981 ). Apart from the large amounts of ACE on the surface of the choroid 
plexus, angiotensinogen is present in significant quantities in the CSF (Printz et 
al., 1982) and renin is located in the cytoplasm of the choroid epithelium (Slater 
et al., 1980). When components of the RAS are administered into the 
ventricles, dipsogenic and hypertensive effects are seen (Fitzsimmons, 1979). 
lntracerebroventricular application of various ACE inhibitors lowers blood 
pressure in stroke prone spontaneously hypertensive rats (Phillips and Kimura, 
1986). Controversy exists, however, as to whether ACE inhibitors gain accesss 
to the CNS during systemic administration. While initially it was thought that 
captopril does not cross the blood-brain barrier (Hutchinson et al., 1982), some 
studies have shown inhibition of ACE in brain tissue homogenates following 
systemic ACE inhibitor treatment (Nakata et al., 1987). Furthermore, when 
angiotensin I and renin were injected into the ventricles of rats treated with oral 
captopril, decreased dipsogenic and hypertensive effects were noted (Unger et 
al., 1983), suggesting that ACE inhibitors may cross into the CSF and inhibit 
CSF ACE. 
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1.4.2.4. Prostate and epididymis 
The human prostate contains high levels of ACE activity which are increased in 
benign prostatic hypertrophy (BPH)(Yokoyama et al., 1980). ACE is secreted 
into the prostatic duct from the tubular epithelium and so is found in the seminal 
plasma (Yokoyama et al., 1982). High levels of ACE are also present in the rat 
epididymis (Cushman and Cheung, 1971) where ACE from the luminal surface 
of epithelial cells is released into the lumen in particulate form (Strittmatter et 
al., 1985). The role of ACE in the male genital tract is entirely unknown. 
Evidence suggests that the ACE derived from the prostate and epididymis is of 
the somatic form: a) failure to purify the smaller testicular form of ACE from 
seminal plasma (El-Dorry et al., 1983); b) immunoprecipitation of epididymal 
ACE with a monoclonal antibody to somatic ACE that does not recognise the 
testicular form (Strittmatter and Snyder, 1984 ); and c) co-migration by 
polyacrylamide gel electrophoresis of epididymal ACE and the somatic lung 
enzyme (Strittmatter and Snyder, 1984). 
1.4.2.5. Placenta 
Human placental syncytiotrophoblastic microvilli contain ACE (Johnson et al., 
1984) which is thought to regulate the passage of angiotensin I and other 
peptides at the maternal-fetal interface (Johnson et al., 1984). 
1.4.2.6. Heart 
Strong evidence exists for the presence of a local renin angiotensin system in 
the heart. Cardiac angiotensinogen gene expression has been demonstrated in 
rats (Campbell and Habener, 1986), and also in mice (Dzau et al., 1987). It 
appears that angiotensinogen is expressed at far higher levels in the atria 
compared to the ventricles. Similarly, renin gene expression has been 
documented in both mice (Dzau et al., 1987) and in rats (Suzuki et al., 1988). In 
contrast to angiotensinogen, renin expression appears to be higher in 
ventricles than in the atria. Although there are, as yet, no published reports of 
in situ cardiac ACE mRNA expression, localisation of ACE in cardiac tissues is 
well documented using a variety of techniques. Most recently, using a radio 
inhibitor ligand binding technique to localise ACE in the rat heart (Yamada et 
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al., 1991 ), it was determined that higher levels of ACE are present in the atria 
as compared to the ventricles with higher levels being noted in the right atrium 
compared with left. ACE was localised in the myocardium with only low levels 
being detected in the endocardium. Interestingly, extremely dense ACE 
labelling occurred throughout the full thickness of all cardiac valves, suggesting 
that this may be an important site for the conversion of circulating angiotensin I 
to angiotensin II and the metabolism of other peptides. 
Various functions of an intracardiac RAS include the control of coronary vaso-
constriction, positive inotropic and chronotropic actions (Lindpainter and 
Ganten, ·1991 ), and the stimulatory effect of an activated RAS on the 
sympathetic nervous system of the heart. A further role for angiotensin II is it's 
potential action as a growth factor. It has been noted that angiotensin II 
stimulates increased DNA and RNA turnover and new protein synthesis in vitro 
(Baker and Aceto, 1990). Two possible mechanisms for this effect have been 
suggested; the first is direct interaction of angiotensin II with nuclear chromatin, 
(Robertson and Khairallah, 1971 ), and secondly, activation of the nuclear 
proto-oncogene c-fos which plays an important role in the regulation of cell 
proliferation and protein synthesis in cardiac muscle (Taubman et al., 1989). 
1.4.3. Neuroepithelial ACE 
Certain regions of the brain have been found to contain ACE, with highest 
levels being found in the choroid plexus and subfornical organ, lower levels in 
the caudate putamen, globus pallidus, substantia nigra, and pituitary and the 
lowest levels in the hypothalamus (Defendini et al., 1983). 
Angiotensin II receptors have been found in the subfornical organ and also in 
the magnocellular nuclei of the hypothalamus, suggesting that ACE in these 
sites is responsible for the local generation of angiotensin II. Angiotensin II has 
been shown to stimulate the release of vasopressin by the hypothalamus (Lang 
et al., 1983). In the pituitary, where it appears that ACE may produce 
angiotensin II from circulating angiotensin I (Strittmatter and Snyder, 1987), 
angiotensin II causes the release of both ACTH and prolactin (Steele et al., 
1981 ). 
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Basal ganglia ACE does not appear to be involved in angiotensin II production 
as no angiotensin 11 receptors are present in this region (Mendelsohn et al., 
1984). There is evidence that a striatonigral ACE is associated with tachykinin 
metabolism as it is uniquely able to cleave substance K (Thiele et al., 1985). 
1.4.4. Endocrine ACE 
1.4.4. 1. The testis 
The testes contain the unique 90 000 MW enzyme which has been localised to 
the cytoplasmic droplets of sperm (Yotsumoto et al., 1984). ACE, along with 
other components of the RAS, has also been demonstrated in the Leydig cells 
(Pandey et al., 1984). It is thought that ACE may be a factor in male fertility by 
affecting sperm motility and capacitation through bradykinin inactivation and 
may also modulate steroidogenesis and/or regulate cell growth and 
differentiation. 
1.4.4.2. The ovary 
All components of the RAS have been localised in mammalian ovaries 
(Bumpus et al., 1988). Angiotensin II receptors have been shown to be 
localised on the granulosa and theca cells of developing follicles and thus 
appear to be involved in the control of follicular function and steroidogenesis. 
1.4.4.3. Adrenal 
Renin (Deschepper et al., 1983) and angiotensinogen (Campbell and Habener 
1986) messenger RNA's have been demonstrated in the adrenal. Angiotensin II 
receptors are present in all zones of the adrenal gland and angiotensin II has 
been shown to stimulate aldosterone, corticosteroids and other steroids as well 
as the release of catecholamines from the adrenal medulla (Peach et al., 1971 
and Nakamura et al, 1985). ACE is found in association with blood vessels in 
the adrenal cortex and also large quantities of the enzyme have been 
demonstrated in the adrenal medulla (Strittmatter et al., 1986) which, by 
producing angiotensin II which interacts with meduilary angiotensin 11 receptors, 
stimulates the release of catecholamines (Peach et al., 1971 ). 
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1.4.5. Miscellaneous ACE 
1.4.5.1. Serum 
ACE in serum is thought to be derived from endothelial ACE either through non 
specific sloughing or perhaps by specific cleavage by an, as yet, undefined 
enzyme. Details of it's carbohydrate content and physicochemical properties 
have been discussed above. Circulating levels of ACE may be elevated in a 
variety of diseases including leprosy, primary biliary cirrhosis, diabetes 
mellitus, silicosis and hyperthyroidism (Studdy et al., 1983). The disease with 
which serum ACE i~ most commonly associated however, is sarcoidosis, in 
which measurements of elevations in the activity of the circulating enzyme have 
proven useful in the diagnosis and follow-up of patients with this disease 
(Ainslie and Benatar, 1985). 
1.4.5.2. Mononuclear phagocytic cells 
Studies in patients with sarcoidosis have revealed that ACE activities are 
markedly elevated in serum and in lymph nodes. More detailed localisation has 
revealed that ACE is to be found in the epithelioid and giant cells of sarcoid 
granulomata (Silverstein et al., 1979), where angiotensin II has also been found 
(Silverstein et al., 1978). 
The involvement of ACE in immunity has been extensively studied in the model 
of murine schistosomiasis where it has been shown that granulomas contain all 
components of the RAS (Weinstock and Blum, 1984). Angiotensin II receptors 
are expressed on granuloma macrophages (Weinstock and Kassab, 1984 ), and 
angiotensin II stimulates phagocytosis (Weinstock and Kassab, 1984) and 
recruits splenic mononuclear cells to the developing granulomas by a 
chemotactic mechanism (Weinstock and Kassab, 1986). These studies have 
demonstrated that ACE plays an immunoregulatory role in granulomatous 
inflamation by a mechanism involving angiotensin II production and/or 
inactivation of bradykinin and various neuropeptides (Weinstock, et al., 1986). 
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1.5. ACE REGULATION 
Little is known about the regulation of ACE both in terms of its biosynthesis, 
control of existing enzyme and it's metabolism. Several studies have 
demonstrated hormonal control of the enzyme and some studies have 
suggested the existence of endogenous ACE inhibitors which will be discussed 
below. 
1.5.1. Hormonal control 
1.5.1.1. Sex Hormones. 
Cushman and Cheung (1971) in their survey of ACE activity among various 
tissues in the rat, found that high levels of ACE in the epididymis and testis 
were only attained at maturity, being low in immature rats, and that 
hypophysectomy prevented the maturity related increase in ACE activity. 
Subsequently it was shown (Velletri et al., 1985), that even mature rats which 
were hypophysectomised lost their testicular ACE activity over a period of two 
to three weeks after the operation, suggesting that continued stimulation by the 
pituitary is required for the maintenance of testicular ACE activity. This 
conclusion was further strengthened in the same study where it was shown that 
hormonal replacement with FSH/LH (follicle stimulating hormone/leutinising 
hormone), HCG (human chorionic gonadotrophin) or testosterone immediately 
following surgery, maintained ACE at near normal levels. In the rat testis, ACE 
biosynthesis is under hormonal control but it is not known whether androgens 
directly induce ACE in existing germinal cells or whether they stimulate 
germinal cell maturation and thus non specifically increase ACE synthesis 
(Velletri et al., 1985). 
1.5.1.2. Corticosteroids. 
ACE induction by corticosteroids has been demonstrated in cultured alveolar 
macrophages (Friedland et al., 1977), cultured human monocytes (Friedland et 
al., 1978), cultured endothelial cells and rat lung in vivo (Mendelsohn et al., 
1982). In alveolar macrophages and human monocytes, enzyme induction 
appears to be due to new messenger RNA and enzyme biosynthesis as it was 
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inhibited by actinomycin D and cycloheximide. In-vitro it has been shown that 
peripheral blood monocytes can be induced to produce ACE in the presence of 
autologous lymphocytes and the existence of a soluble ACE inducing factor 
produced by lymphocytes has been determined (Conrad and Rohrbach, 1987). 
These findings may be of relevance in an understanding of the development of 
sarcoid granulomata. 
1.5.1.3. Thyroid Hormones. 
Patients with hyperthyroidism have elevated levels of serum ACE that return to 
normal following therapy (Yotsumoto et al., 1982; Smallridge et al., 1983). 
ACE levels were found to be reduced in hypothyroidism and it appears that 
thyroxin (T4) and ACE levels in serum fluctuate in parallel during the evolution 
of sub-acute and silent thyroiditis (Smallridge et al., 1983). The source of the 
increased ACE activity in serum may be due to induction of ACE production by 
thyroid hormones of vascular endothelial cells. A recent study (Dasarathy et al., 
1990) showed that bovine endothelial cells could be stimulated to produce 
increased quantities of ACE in culture in the presence of tri-iodothyronine. 
1.5.2. ACE induction by specific ACE inhibitors 
In a study assessing the effect of the ACE inhibitor captopril on blood pressure, 
plasma renin activity, and ACE activity in hypertensives (Larochelle et al., 
1979), it was noted that while therapy resulted in a decrease in blood pressure, 
papadoxically plasma ACE activity after seven days of treatment remained 
unchanged and in some cases even appeared to rise. Captopril has an 
opposite effect on ACE activity versus concentration when captopril is allowed 
to degrade either through storage of the sample or by chemical destruction 
using N-ethylmaleimide (Boomsma et al., 1981). 
Studies in rats demonstrated ACE induction using both captopril and enalapril 
and the inductive response depends on an intact adrenal gland. Also, in 
endothelial cell culture captopril induces ACE production. These studies will be 
discussed in more detail in the introduction to the experimental studies on ACE 
induction. 
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1.5.3. Endogenous ACE inhibitors 
Little is known about how ACE, once produced, is controlled physiologically. 
While, as has been discussed in the section on the anion dependence of ACE, 
that ACE could be regulated by ionic fluxes, it is interesting to consider that 
specific endogenous inhibitors of the enzyme could exist. The first evidence 
suggesting the possible presence of such inhibitors was in a study (Lieberman 
and Sastre, 1983) where it was noticed that ACE activity in a variety of tissues 
could be increased by dilution of the homogenate. It was found that maximal 
increase in activity between 80 and 200% over the undiluted sample was 
achieved at a 1 in 8 dilution. Similarly, an ACE inhibitor was found in human 
serum (Lieberman and Sastre, 1986) with a prevalence of 25% of 280 serum 
samples tested. The serum inhibitor appears to be heat labile, have a 
molecular weight of over 50000 and also possesses the rather unique property 
of producing irreversible inhibition after the loss of a low molecular weight 
component, possibly an ion, since loss of inhibition by further dilution no longer 
occured after dialysis of the sample against saline. However, to date there 
have been no further reports supporting these findings. 
Recently endogenous peptide inhibitors of ACE have been purified from a 
number of sources. The first of these to be isolated was an ACE inhibitor from 
porcine plasma (Hazato and Kase, 1986). This inhibitory peptide has the amino 
acid sequence leucyl-valyl-leucine and demonstrated an IC 50 for rabbit lung 
ACE of approximately 3x1 o-6 M. Another potential endogenous inhibitor for 
ACE is des-leu 10 - angiotensin I which is generated from angiotensin I by a 
releasable platelet peptidase (Snyder and Wintroub, 1985), and suggests that 
potential pathways exist by which cells such as platelets can generate an 
endogenous inhibitor of ACE at local vascular sites thus controlling angiotensin 
II generation in vascular tissue (Snyder and Wintroub, 1986). 
An endogenous inhibitor was also inadvertently found in rat heart tissue 
(Ikemoto et al., 1989) when it was noted that endogenous inhibition of ACE 
took place during tissue oxidation. The exact isolation of this inhibitor was 
elusive and awaits further study. 
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1.6. MOLECULAR BIOLOGY OF ACE 
The first study on the molecular biology of ACE (El-Dorry et al., 1982) was an 
attempt to study the differences between pulmonary and testicular ACE. When 
reticulocyte lysates were primed with poly A containing RNA from mature rabbit 
testes the newly synthesised peptide was 35% smaller than that programmed 
by pulmonary RNA. Furthermore, testicular ACE was not produced if the 
reticulocyte lysates were primed with RNA from immature testes, in contrast to 
the pulmonary dependent product which was promoted by RNA from both 
immature and mature lungs. This suggests that the distinguishing structural and 
regulatory properties of testicular ACE are determined pretranslationally. These 
differences were thought to be due either to tissue-specific differential 
processing of primary messenger RNA transcripts from a single gene, or tissue-
specific isozymes arising from different genes. 
Recently, great strides have been made in the molecular characterisation of 
ACE with the isolation of cDNA clones for somatic and/or testicular ACE from a 
variety of species; rabbit (Roy et al., 1988), mouse (Bernstein et al., 1988), and 
human (Soubrier et al., 1988; Ehlers et al., 1989). It was soon realised that 
somatic ACE in all species studied consists of two homologous domains each 
containing a putative metal binding site and that testicular ACE is identical to 
the C-terminal half of somatic ACE except for a unique 35 amino acid residue 
at its N-terminus (Ehlers et al, 1989; Lattion et al., 1989). Similar conclusions 
were also drawn from a study of rabbit ACE cDNA (Kumar et al., 1989) where 
various oligonucleotide probes were synthesised and used to probe the 
structure of pulmonary and testicular ACE. It was found that the two isozymes 
possesed a segmental mosaic structure which suggested that a single gene 
may be the source of both forms of ACE. This conclusion had already been 
proposed following work on the human ACE cDNA (Soubrier et al., 1988). It 
was considered that the somatic ACE gene was the result of ancestral 
duplication of a smaller gene corresponding to the testicular form. 
Northern blots of mRNA from cultured human umbilical vein endothelial cells 
revealed a 4.3 kb hybridisation product and similar studies of testicular mRNA 
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detected a 3 kb product (Soubrier et al., 1988). In the rabbit a 5-kb ACE mRNA 
was found in lung tissue and a 2.6-kb mRNA species was detected in testicular 
tissue (Roy et al., 1988). In northern analysis of mouse testicular ACE, a single 
hybridisation signal was obtained of 2.7 kb (Howard et al., 1990), in the same 
study mRNA hybridisation signals of kidney ACE were obtained at both 4.2 and 
5.1 kb. In this study, techniques such as polymerase chain reaction (PCR) 
revealed multiple RNAs suggesting incomplete splicing - the relevance of this 
finding is unknown. 
The first genomic study was the analysis of DNA just 5' to the cDNA sequence 
for both human and mouse ACE (Shai S-Y et al., 1990). This revealed potential 
corticosteroid binding site consensus sequences and other potential regulatory 
motifs. Mouse testicular ACE cDNA starts with an exon not present in somatic 
ACE cDNA (Howard et al., 1990). Transcription for the testis isozyme begins 
within the 12th intron of the gene, 7206 base pairs (bp) 3' to the translation 
start site for somatic ACE. A search for a potential unique testis specific 
promoter revealed a TA-rich region 25 bp upstream of the transcription start 
site of testis ACE. 
A rabbit (Kumar et al., 1991) 18.3-kb genomic DNA clone was found to 
hybridise to oligonucleotide probes specific for both somatic and testicular 
ACE. As has been reported for mouse ACE, rabbit somatic and testicular ACE 
are transcribed from two different initiation sites of the same gene. The 
genomic sequence revealed a unique pulmonary coding sequence followed by 
a unique testicular sequence which is then followed by a sequence common to 
both isozymes. Generation of the somatic ACE mRNA involved the splicing out 
of the unique testicular sequence as an intron. Transcription of the testicular 
isozyme starts within this intron. Using a variety of techniques, including DNA 
sequencing, RNA protection assays and primer extention assays, the exact 
transcription initiation start sites were determined and the sequence odtained 
for the region upstream of these sites. Analysis of the sequence upstream of 
the transcription start site for somatic ACE, revealed a TATA box 26 bases 
upstream of the start site. Transcription factor 110 is known to bind to this motif; 
also a SP-1 binding site was found in this region (Mitchell and Tijan 1989). 
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Further upstream three more SP-1 sites and an AP-1 binding site were found. 
In contrast, the only binding motif found upstream of the initiation site for 
testicular ACE was a TTATT sequence 27 bp 5' to this site. Genomic sequence 
analysis of the human ACE gene has shown (Hubert et al., 1991) that this gene 
spans 21 kb and comprises 26 exons. The two homologous domains of the 
enzyme are coded for by exons 4-11 and 17 -24. Each contains the 
metalloprotease consensus sequence H-E-X-X-H in exon 8 and 21. 
Ribonuclease protection assays revealed the transcription initiation site with a 
typical TATA box at -37. The hexanucleotide sequence of a glucocorticoid-
responsive element was found at the following four positions far upstream of 
the transcription initiation site; -1213,-935,-794 and -686. The transcription start 
site for the testicular isozyme is within intron 12, similar to the findings in the 
mouse gene as detailed above. A TATA like sequence (TA TT) is also present 
15 bp upstream of the start site. Other potential regulatory sequences include a 
sequence similar to the cAMP responsive element consensus sequence at 
position -44 and a steroid responsive sequence was found at position -190 but 
this may not be functional (Testut et al., 1993). The increased ACE mRNA and 
activity of cultured bovine endothelial cells following ACE inhibitor 
administration must still be explained (Dasarathy et al., 1992). 
The potential age of the duplication of the ancestral shorter gene was studied 
by comparing the approximate rate of divergence between human, mouse and 
rabbit exons 7 and 20 and concluded that this event occurred between 118 and 
194 million years ago. 
A recent study (Langford et al., 1991) has shown that testicular ACE in fact 
does utilise its own unique promoter rather than the somatic ACE promoter, 
with subsequent splicing out of the non-testicular sequence. Transgenic mice 
carrying a 698 bp fragment of the mouse testicular ACE promoter linked to the 
P.i-Galactosidase reporter gene was found to express P.i-galactosidase protein 
and RNA only in the testes. Histological examination for P.i-galactosidase in 
sections of testicular tissue revealed staining mostly rn the elongating 
spermatids and later stages of spermatogenesis. This is consistent with 
immunohistochemistry for ACE in similar sections. Thus clear evidence for a 
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testis specific promoter within the region immediately upstream of the 
transcriptional start site was presented. 
Recombinant native and mutated ACE have recently allowed greater insight 
into the C-terminal anchor peptide sequence (Ehlers et al., 1991; Wei et al., 
1991 a) and the enzyme's active sites (Wei et al., 1991 b). 
In a study utilising recombinant human testicular ACE, Ehlers et al. (Ehlers et 
al., 1991) transfected Chinese Hamster Ovary cells (CHO cells) with either full 
length human testis cDNA or a deletion mutant in which a stop codon was 
inserted preventing· the formation of the putative anchor peptide. Cells .. 
transfected with the full length cDNA produced both membrane bound and 
secreted ACE (isolated from the medium). In contrast, cells transfected with the 
mutant produced virtually only secreted ACE. Both forms of the enzyme had 
similar enzymatic activity, were indistinguishable on SOS-PAGE, and phase 
separation studies confirmed that membrane bound ACE is hydrophobic and 
could be converted to a hydrophilic form, similar to the anchor-minus mutant 
ACE, by trypsinisation. Amino acid analysis also demonstrated the similarity 
between soluble hydrophylic ACE and mutant anchor-minus ACE. Similar 
studies on the somatic enzyme (Wei et al., 1991 a) showed that naturally 
produced soluble ACE was catalytically and immunologically indistinguishable 
from recombinant mutant ACE lacking a C-terminal anchor sequence. The 
conclusion of both these studies was that soluble ACE is derived by specific 
proteolytic cleavage of membrane ACE by an as yet unidentified enzyme. 
Investigation of the catalytic domains of the somatic enzyme has also been 
made possible by the production of recombinant ACE (Wei et al., 1991b). In 
order to study each of the catalytic domains of the enzyme, deletions or point 
mutations were introduced in these domains and transfected into CHO cells. It 
was found that both domains are catalytically active and can cleave Hip-His-
Leu and angiotensin I. Also, both domains have an absolute requirement for 
zinc, are activated by chloride, are inhibited by specific inhibitors and can 
function independently. There are differences in the catalytic activity of the two 
domains as evidenced by differing catalytic constants and differing patterns of 
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chloride activation. For example, at high chloride concentrations the C domain 
hydrolyses substrates faster than the N domain. The most likely residues for 
zinc binding are His-361,365 and His-959,963 and Glu-362 in the N domain 
and Glu-960 in the C domain. A rigorous re-analysis of the Zn2+ stoichiomet_ries 
of somatic and testis ACE revealed that, contrary to earlier data, somatic ACE 
indeed contains 2 mol Zn2+ per mol enzyme, whereas testis ACE contains 1 
mol/mol Zn2+ (Ehlers and Riordan, 1991 ). Furthermore, an extensive survey of 
diverse conventional and unconventional peptide substrates, indicated that with 
the notable exception of luteinising hormone-releasing hormone (LH-RH), 
virtually all peptides are hydrolysed identically by the somatic and testis 
isozymes. LH-RH, however, is hydrolysed significantly faster by somatic ACE, 
particularly by an unusual, N-terminal, tripeptidyl endopeptidase cleavage, 
which is 300-fold faster than for testis ACE (Ehlers and Riordan, 1991 ). These 
studies strongly suggest that somatic ACE contains two active sites, of which 
the C-terminal site - identical to the testis ACE site - hydrolyses "conventional" 
substrates, whereas the N-terminal site may confer an additional, as yet 
unidentified substrate specificity (Ehlers and Riordan, 1991; Wei et al., 1991 b). 
It appears that circulating ACE levels may be under genetic control (Rigat et 
al., 1990 and Tiret et al., 1992). Southern blot analysis of DNA from a group of 
subjects revealed a polymorphism which correlated well with serum ACE levels, 
highest levels of ACE being seen in subjects homozygous for the deletion of 
approximately 250bp. Intermediate ACE levels were noted in those 
heterozygous for the polymorphism and lowest levels corresponded to those 
subjects in which both alleles contained the 250bp fragment. It seems therefore 
that this 250bp sequence in some way either affects the proteolytic cleavage of 
the enzyme from endothelial surfaces or affects its stability in the circulation. 
This polymorphism has been shown to be a risk factor for myocardial infarction 
(Cambien et al., 1992). More recently, this polymorphism has been found to be 
associated with left ventricular hypertrophy (Schunkert et al., 1994), idiopathic 
or dilated cardiomyopathy (Raynolds et al., 1993) and to determine the 
expression of ACE in T-lymphocytes (Costerousse et al., 1993). It has also 
recently been determined that ACE DNA polymorphisms in spontaneously 
hypertensive rats are related to blood pressure and that ACE is 
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a candidate gene for primary hypertension (Hilbert et al., 1991 and Jacob et al., 
1991 ). 
1.7. ACE INHIBITORS 
From the earliest studies it was noted that ACE could be inhibited by metal 
chelators such as EDTA. This allowed the metalloenzyme properties of ACE to 
be defined as has been detailed (Section 1.2.3.). 
The ability of an extractable factor from the venom of the South American Pit 
Viper (Bothrops jararaca) to enhance the action of bradykinin was discovered 
by Ferreria (1965) and was named Bradykinin Potentiating Factor (BPF). Other 
snake venoms from the Bothrops species were also found to contain this 
activity. BPF also inhibits ACE in a dog lung homogenate (Bakhle, 1968) thus 
unifying the fields of ACE and bradykinin research. 
1.7.1. Miscellaneous peptide inhibitors 
A number of molecules including albumin and its fragments (Klauser et al., 
1979), fibrinolytic fragments (Saldeen et at., 1981 ), insulin and the beta-chain 
of insulin (lgic et al., 1972) can act as non-specific inhibitors of ACE in vitro. 
Also, any one substrate or its split products can competitively inhibit an 
enzyme's action on another substrate. Hence, angiotensin I, bradykinin and 
Hip-Phe-Arg are to varing degrees inhibitory of the action of ACE on Hip-His-
Leu (Cheung et al., 1980). Angiotensin homologues, such as angiotensin II and 
Ill, and [des-Asp 1] angiotensin I and angiotensin analogues are all inhibitory 
toward ACE (Tsai and Peach, 1975 & 1977; Chiu et al., 1976). 
1.7.2. Multibinding active site-directed reversible inhibitors. 
Although the snake venom peptides are potent and specific inhibitors of ACE, 
they are not ideal inhibitors of the enzyme due to their large size and limited 
bioavailability. Since no knowledge was available on the catalytic mechanism 
of ACE, a more complete active site model had to be found in order to design 
and synthesise specific and potent active site-directed inhibitors. 
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Carboxypeptidase A, whose active site and catalytic mechanism are well 
understood (Quicho and Lipscomb, 1971) is, like ACE, is a zinc metalloenzyme 
with similarities in substrate specificities in that it requires a free C-terminal 
carboxyl group. Thus a hypothetical model was proposed in which ACE was 
considered to be a kind of dipeptide-releasing carboxypeptidase posessing an 
active site and catalytic mechanism similar to that of carboxypeptidase A 
(Cushman et al., 1977 & 1978; Ondetti et al., 1977a & 1977b). Important 
components of this model were a site for the binding of the charged C-terminal 
carboxyl of the substrate, most likely the cationically charged side chain of an 
arginine residue, a binding site for the C-terminal dipeptide of the substrate, 
recognition sites for substrate amino acid side chains and a catalytic zinc atom 
located opposite the penultimate peptide bond of the substrate. Susequently 
the validity of this model was confirmed by the finding of arginine, glutamic acid 
and tyrosine at the active site of ACE and also the presence of a zinc atom. A 
molecule capable of interacting with all these binding sites would be a potent 
inhibitor. Support for this idea was provided by the finding that 
carboxypeptidase A can be inhibited by a potent competitive inhibitor D-2-
benzylsuccinic acid (Byers and Wolfenden, 1972 & 1973). Thus a similar 
succinyl containing molecule was synthesised specifically to inhibit ACE. It was 
realised at this stage that the succinyl group specifically interacts with the zinc 
atom of the enzyme, a feature fundamental to the action of the active site 
directed inhibitors. The first such molecule to be produced was succinyl-L-
proline, a weak but specific ACE inhibitor. 
Amongst other compounds studied is one which contains terminal dipeptide 
sequences of the snake venom inhibitor BPPsa (a bradykinin potentiating 
peptide) (Ondetti et al., 1971, 1972). The knowledge that the carboxyl group of 
the carboxyalkanoyl chain interacts with the zinc atom gave rise to compounds 
incorporating a sulphydryl group, known to interact stongly with zinc. This 
resulted in a group of inhibitory compounds the most potent of which was 
designated SQ 14,225 or captopril. Captopril is a specific inhibitor of ACE with 
a Ki = 1. 7nM for rabbit pulmonary ACE. It does not inhibit either 
carboxypeptidase A or B (Ondetti et al., 1979), carbonic anhydrase or liver 
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alcohol dehydrogenase (Ondetti and Cushman, 1981 ). Leucine 
aminopeptidase, a zinc containing enzyme, is inhibited by captopril with an 
IC50 of 5.4 µM (Cushman et al., 1977). When smooth muscle preparations 
were exposed to concentrations of captopril 20000 times higher than that 
required to inhibit ACE, there was no alteration in the response to angiotensin 
II, acetylcholine, norepinephrine, isoproterenol, dopamine, serotonin, 
histamine, prostaglandins, nicotine or barium ion (Rubin et al., 1978). 
Although clearly effective in enhancing the inhibitory action, the presence of a 
sulphydryl group such as found in captopril is possibly not ideal in the in vivo 
setting · in which the sulphydryl group could contribute to undesirable side 
effects. The sulphydryl group is also unstable in that it can undergo facile 
oxidation and disuphide exchange reactions (Patchett and Cordes, 1985). 
Patchett et al. (1980) re-examined the alkanoyl amino acid 2-methylglutaryl 
praline, first described by Cushman et al. (1977), for ways to improve its 
inhibitory potency. Captopril does not make use of two of its potential binding 
sites: the S1 binding site and a hydrogen bonding site for the amide nitrogen of 
the normally scissile peptide bond. A range of synthetic N-carboxyalkyl 
dipeptides were examined in an attempt to utilise these extra sites and two of 
the most potent inhibitors were, N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-
proline (enalaprilat) and N-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline 
(lisinopril), both with an IC50 of 1.2 x 1 o-9 M. It is interesting that enalaprilat 
closely resembles the C-terminal tripeptide sequence of the snake venom 
peptide BPPsa which, with an IC50 = 3.6x1 o-6 M, is 1000 fold weaker than the 
IC50 of enalaprilat or lisinopril. If the metal binding carboxyl group is removed 
from enalaprilat or lisinopril, the IC50 approximates that described for BPPsa 
(Patchett et al., 1980). 
Rigorous kinetic methods were utilised to define some of the fundamental 
properties of the enzyme inhibitor complex by examining the interaction 
between purified rabbit ACE and enalaprilat, lisinopril, captopril and certain 
other analogues (Bull et al., 1985; Riordan and Shapiro, 1984a and 1984b ). In 
summary their findings were; 
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1. These inhibitors are slow binding but tight binding. (Slow binding is 
observed at low substrate concentrations and inhibition can still be 
meansured in the absence of substrate and is still slow. Tight binding 
implies that substantial inhibition is obtained at concentrations of inhibitor 
similar to those of enzyme). 
2. As it could not be shown that initial reaction rates were either independent 
of inhibitor concentration or decrease with increasing inhibitor 
concentration, two possible mechanisms are suggested. Either there is 
slow formation of an enzyme inhibitor complex or a two stage process 
exists in which competitive inhibition results in the fast formation of an 
initial enzyme inhibitor complex followed by a rate determining 
rearrangement of this complex to form a second more stable complex. 
3. The mechanism of inhibition is defined as competitive as the rate 
constants for the formation of the enzyme inhibitor complex decrease with 
increasing substrate concentration. 
4. The enzyme inhibitor complexes posess extremely low dissociation 
constants resulting in long half lives. 
5. In support of the already described function of the metal-binding 
carboxylate in the overall binding affinity of enalaprilat it is not suprising 
that the affinity of enalaprilat for ACE in which the zinc has been removed 
by dialysis against EDTA, is 20000 times reduced as compared to the 
holoenzyme. The zinc deficient apoenzyme still binds substrate 
confirming that zinc is not involved in substrate binding but in the 
hydrolytic step of catalysis. 
6. Chloride affects the binding affinity of enalaprilat to ACE: in the absence 
of chloride binding is 0.5% of that found at saturating levels of chloride 
ion. 
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7. Binding is pH dependent and is maximal at pH 6.0, suggesting that either 
the protonation state of the secondary nitrogen atom of the inhibitor or 
that ionisations of the enzyme alone determine binding affinity. 
Subsequently, many other ACE inhibitors have been synthesised which, 
although posessing different groups, probably all interact with ACE in a manner 
similar to that originally proposed by Cushman, Ondetti and their colleagues. 
Chapter 2 
PURIFICATION OF ANGIOTENSIN CONVERTING 
ENZYME FROM TISSUE 
2.1. OBJECTIVE: 
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To establish a quick, effective method to purify ACE from human and rat 
tissues. 
2.2. INTRODUCTION 
Historically, the purification of ACE from tissue has always been a difficult task 
(Soffer, 1981) despite its abundance in certain tissues. In real terms ACE is 
present in very small amounts in relation to other tissue proteins, for example, 
in rabbit lung, ACE constitutes only 0.1 % of total protein (Soffer, 1981) while in 
rabbit serum ACE constitutes only 0.0017% of protein (Soffer, 1981 ). 
Therefore, in order to purify the enzyme to homogeneity, purifications of at 
least 1000 fold must be achieved for the lung enzyme and 60000 to 100000 
fold for serum ACE. 
Despite these difficulties, ACE has been successfully purified from many 
different species and tissue sources. Since this study is primarily concerned 
with rat ACE, and to a lesser degree human ACE, I shall concentrate my 
dicussion on purification of ACE from these species. 
For most species, the lung has been the most favoured source of ACE where it 
is relatively abundant due to its endothelial localisation in the extensive 
pulmonary vasculature. This has been documented in the rat in which ACE 
specific activity comparisons between various tissues (Cushman and Cheung, 
1971) support the lung as being one of the best tissue sources of the somatic 
enzyme. In contrast, in humans, despite the high ACE levels in lung tissue, a 
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similar homogenate of the kidney cortex contains approximately 6 times more 
enzyme than the lung (Stewart et al., 1981 ). 
ACE is a membrane bound enzyme, necessitating some form of solubilisation 
in order to release it from the plasma membrane. Although in some cases this 
has not found to be required eg. in rat lungs as much ACE is released by 
allowing the homogenate to stand for 20 days at 2°C as after treatment with 
deoxycholate (Lanzillo and Fanburg, 1974). Most purifications have, however, 
relied on the use of some solubilising agent such as the ionic detergent 
deoxycholate or non-ionic detergents such as Triton X-100 and Nonidet P-40. 
Enzyme released through the use of detergents retains the hydrophobic anchor 
peptide and thus has a tendency to aggregate, which can be problematic 
during gel filtration. An alternative is to trypsinise the homogenate (Nishimura 
et al., 1976), releasing soluble, hydrophyllic enzyme devoid of the anchor 
peptide. Human enzyme purified by both these methods were indistinguishable 
physicochemically, including molecular weight, isoelectric point, catalytic and 
immunological properties (Lanzillo et al., 1985). 
Initially ACE purification relied on homogenisation, solubilisation and 
conventional chromatography. These included one or more ion exchange steps 
on resins such as DEAE-cellulose which retains ACE as it is an acidic protein. 
Further purification has relied on hydroxyapatite or calcium phosphate to which 
ACE does not adsorb. Gel filtration on resins such as Sephadex G-200 has 
also been employed. Conventional chromatographic methods, however, are 
laborious and do not result in good yields of active ACE. 
The development and use of various affinity chromatographic methods resulted 
in improved yields and specific activities of the purified enzyme. 
The first of these methods to be employed was immunoaffinity chromatography 
in which antibody against ACE (previously purified by conventional means) was 
coupled to a solid phase. In this manner ACE was purified 60000 fold from 
rabbit serum (Das et al., 1977). Problems of this method include: 1.) the 
necessity to first purify the antigen by conventional chromatographic means; 2.) 
antibodies coupled to a solid phase can act as ion exchange ligands resulting 
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in a high degree of non-specific binding; and finally, 3.) the strong binding 
between antigen and antibody neccessitates harsh elution conditions, resulting 
in some denaturation of the purified enzyme. In an attempt to avoid this 
problem of denaturation, baboon ACE was purified by conventional means, 
used to raise antibodies which were utilised as an immunosorbent for the 
purification of human lung ACE (Lanzillo et al., 1980). Because of the reduced 
affinity of anti-babo~n ACE antibodies for human ACE, less harsh elution 
conditions were required, resulting in maintenance of specific activity. 
Another ingenious method was that of reverse immunoadsorbtion (Weare et al., 
1982). After conventional methods had been used to partially purify human 
lung ACE, it was subjected to chromatography on an immunoadsorbent of anti-
human lung ACE antibodies - the contaminant proteins not bound to the column 
were collected and antibodies against this fraction were raised. An 
immunoaffinity column was then made with these anti-contaminant antibodies. 
When partially purified human kidney ACE was applied to this column, gentle 
elution conditions resulted in ACE of high specific activity in high yields. 
These laborious methods could only be replaced with the advent of specific 
competitive inhibitors of ACE which, when used as affinity ligands, greatly 
simplified ACE purification. 
The development of potent site-directed inhibitors such as captopril, prompted 
various workers to employ these and related analogues as affinity ligands. 
Dipeptide analogues of captopril such as L,D-cysteinyl - L - praline were (Harris 
et al., 1981 a) coupled to CNBr-activated Sepharose, either directly or via a 
short spacer arm. In both cases the capacity of the gel for ACE was low, 
0.025U/mg gel, which was much improved, to 1.23 U/mg gel, when a longer 
spacer arm was used (Harris et al., 1981 b). This method can be used to purify 
human serum ACE 130000 fold with a 20% yield. The problem with this method 
was that pre-affinity columns necessary for optimum results included two 
polyethyleneglycol precipitation steps and two ion-exchange column steps. 
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The development of the N-carboxyalkyl dipeptide ACE inhibitors such as 
enalaprilat and lisinopril heralded a great advance in ACE purification. When 
lisinopril is coupled to a matrix by a 12-atom spacer arm it was found to have a 
capacity of 750µg ACE/ml gel (Bull et al., 1985a). This affinity resin was used 
to purify ACE from human lung and serum but, because free lisinopril was used 
as the eluant it necessitated 10-14 days of dialysis against EDTA, lowering 
overall yeilds to 1.15% and 4% respectively. 
Captopril as an eluant improved the yields of ACE from a variety of human 
tissues markedly as the captopril could be chemically destroyed using N-
ethylmaleimide (Lanzillo et al., 1985). 
The importance of a long spacer arm and the use of a less potent ACE inhibitor 
as a ligand, thus avoiding elaborate elution and reactivation strategies, was 
used for the purification of rabbit lung ACE (Pantoliano et al., 1984). These 
authors synthesised two enalaprilat analogues, N-[1 (S)-carboxy-5-
aminopentyl]-L-PheGly (CA-PheGly) and N-[1 (S)-carboxy-5-aminopentyl]-DL-
Ala-L-Pro (CA-AlaPro). In both cases the use of a long spacer arm resulted in 
capacities of greater than 7mg ACE/ml gel. It was also found that elution could 
be simply effected by raising the pH from 6 to 8.9 resulting in homogenous 
enzyme with an overall yield of 34%. Ehlers et al. (1986) synthesised and 
utilised a related ligand N-[1 (S)-carboxy-5-aminopentyl]-GlyGly (CA-GlyGly) 
resulting also in a facile purification protocol for human kidney ACE with high 
yields. 
It was subsequently found that lisinopril bound via a long spacer arm allowed 
elution by a change in pH (Bernstein et al., 1988; Ehlers et al., 1989) The more 
potent inhibitory nature of lisinopril is particularly useful in the purification of 
ACE from sources with a low ACE concentration. Another advantage is that the 
leaching of bound enzyme from the column during the pre-elution washing 
steps is minimal when compared to that found for a ligand such as CA-GlyGly. 
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2.3. MATERIALS AND METHODS 
HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid]), hippuryl-L-
histidyl-L-leucine, . o-phthaldialdehyde, L-histidyl-L-leucine, PMSF 
(phenylmethylsulphonyl flouride) and trypsin were obtained from Sigma. 
Tris(hydroxymethyl)-aminomethane (TRIS), acrylamide, N,N'-
methylenebisacrylamide, N,N,N',N'- methylethylenediamine (TEMED) and 
bromphenol blue were obtained from BDH. Sodium dodecylsulphate (SOS), 
sodium azide and Comassie Brilliant Blue R250 were from Merck. Trysylol 
(Apoprotinin; 1 oooo_o K.1. U./10ml) from Beyer, ammonium persulphate from 
AAL Chemicals, human serum albumin (>99.5% pure) from Miles laboratories. 
Captopril was a gift from Squibb laboratories, South Africa and enalapril and 
enalaprilat from Logos pharmaceuticals, South Africa. Lisinopril (Merck, Sharpe 
& Dahme) attached via a spacer arm to epoxy-activated Sepharose 68 
(Pharmacia) was a gift from Dr. Mario Ehlers (Boston, USA). 
2.3.1. Tissue 
Human ACE was purified from human cadaver kidney tissue which was 
obtained within six hours of death. The tissue was either immediately 
processed, as described below, or stored at -70°C until required. 
Rat ACE was purified from rat lung tissue. Long-Evans rats (250-400g) were 
sacrificed by ether anaesthesia, the lungs excised, rinsed in saline and either 
used immediately or stored at -70°C till required. 
2.3.2. Purification 
Since purified detergent solubilised ACE is an unstable antigen due to its 
tendency to aggregate, causing many problems in its use in the immunoassays 
described below, the tissue was trypsinised to yield soluble ACE. 
Fresh or thawed tissue was homogenised with an Ultra-Turrax homogeniser 
(Model TP 18/2, Janke and Kunkel KG) on ice in 5mM Tris/HCI, pH 7.4, at 4°C 
to yield a 20% w/v homogenate. This was strained through cheesecloth to 
remove fibrous tissue and homogenised with glass-teflon homogeniser 
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(Thomas, USA). The homogenate was centrifuged at 20000g (Sorvall RC-5 
Superspeed centrifuge in Sorvall GSA rotor) for 30 minutes at 4°C and the 
resulting pellet resuspended in 5mM Tris/HCI, pH 7.4, with a glass-teflon 
homogeniser. This homogenate was again centrifuged at 20000g for 30 
minutes at 4°C. The pellet was resuspended in 50mM Tris/HCI, pH 8.5, with a 
glass-teflon homogeniser to the same volume as the original homogenate. 
The protein content was determined by reading the OD (optical density) at 
280nm and 260nm and the approximate protein concentration calculated by the 
formula; 
[Protein] = ( 1.55 x OD2so ) - ( o. 76 x 00250 ) 
in mg/ml 
Trypsin was added at 1 O mg trypsin per gram protein and incubated at 37°C in 
a shaking water bath for 60 minutes. Digestion was stopped by addition of 1 µI 
1 M PMSF in dimethylsulphoxide (DMSO - Sigma) per ml solution and Trasylol 
1 ml per 100 ml homogenate, followed by centrifugation at 28000g (Sorvall SS-
34 rotor) for 30 minutes at 4°C. The supernatant was placed in dialysis tubing 
and dialysed at 4°C against 3 x 5 litres 20mM Hepes/NaOH, 0.5M NaCl, pH 7.5 
at 21 °C. The dialysis buffer was constantly stirred with a magnetic stirrer 
allowing each dialysis to be completed within four hours. 
The lisinopril-Sepharose column was equilibrated with at least 5 column 
volumes of 20mM Hepes/NaOH, 0.5M NaCl, pH 7.5 at 21°C at a flow rate of 10 
ml/hr. The dialysed supernatant was vacuum filtered through a 0.8µm Millipore 
filter and loaded onto the column at a flow rate of 1 O ml/hr. The column was 
then washed with 10 column volumes of equilibration buffer. 
ACE was eluted with SOmM Borate/NaOH pH 9.5, 21 °C while monitoring A2so. 
Approximately 3ml fractions were collected and protein measured with the 
Biorad assay (Bradford, 1976) and ACE activity with the spectroflurometric 
method (Friedland and Silverstein, 1976). The method is fully detailed in the 
appendix. 
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2.3.3. Characterisation of ACE 
2.3.3.1. Purity 
The purity of the purified enzyme was determined by its specific activity and its 
electrophoretic homogeneity. Specific activity was determined for the substrate 
HHL and expressed ·as Units of activity per mg of protein. Protein concentration 
was determined by the method of Bradford (1976) using Bio-Rad commercial 
reagent and human serum albumin as standard. 
2.3.3.2. Molecular weght determination 
Molecular weight and homogeneity of purified ACE was determined by 
polyacrylamide gel electrophoresis. All gels contained 0.1 % SOS and were run 
using a discontinuous buffer system (Laemmli, 1970). Protein was analysed on 
both 7% homogeneous and 3 to 17.5% gradient polyacrylamide gels, at 50-60V 
for approximately 18 hours. Between 5 and 10 µg ACE was loaded per lane in 
both a reduced (incubated for 15 minutes in 2% SOS and 2% 2-
mercaptoethanol at 60°C prior to loading) and non-reduced states. After 
electrophoresis, proteins were stained with Comassie Brilliant Blue. Details of 
the methodology are to be found in the Appendix. A calibration curve was 
constructed for molecular weight markers (Amersham Rainbow Markers) on 2 
cycle semi-logarithmic paper, by plotting molecular weight versus relative 
mobility. 
2.3.3.3. Inhibition by captopril 
Utilising the spectrofluorimetric assay of HHL hydrolysis described in the 
Appendix (section 9.7), the influence of the specific ACE inhibitor captopril on 
the catalytic activity of the purified enzyme was assessed. Captopril was added 
to the assay mixtures at a range of concentrations (0.92-55.3 nM). 
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2.4. RESULTS AND DISCUSSION 
2.4.1. Rat Lung ACE 
Typically 40 pairs of rat lungs purified by the trypsin/lisinopril-Sepharose 
protocol yielded approximately 5 mg of pure ACE with a specific a~tivity of 91 
U/mg protein. When the pre- and post-column specific activities were 
compared, it was found that almost 90% (eg.120 U loaded, column eluate 
contained 14 U therefore 106 U retained) of loaded ACE activity was retained 
on the column. Very little ACE leached from the column during the washes 
resulting in the purification of significant quantities of homogeneous enzyme. A 
table of yields at stages of purification is in appendix 9.10. 
Application of Washing Elution of pure ACE tissue homogenate 
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Fraction No. 
Figure 2.1. Typical elution profile of ACE from lisinopril column. High absorbances (A to B) correspond to the loading of the homogenate to the column in 20mM Hepes/NaOH, 0.5M NaCl, pH 7.5. After washing the column in the same buffer (B to C), pure ACE was eluted by application of SOmM Borate/NaOH pH 9.5 to the column (after C). 
2.4.2. Human Kidney ACE 
Similar results were obtained for ACE from human cadaver kidneys. Typically 
200g of homogenised kidney tissue yielded at least 4mg of homogeneous ACE 
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with a specific activity of 97 U/mg protein comparing favourably with previous 
reports from the literature. 
2.4.3. Molecular weight determination 
An example of PAGE analysis of purified soluble rat lung ACE is shown in the 
accompanying figure. As was also found for human ACE, single bands of 
homogenous ACE were revealed by Comassie Brilliant Blue staining. It must be 
realised, however, that some contaminating glycoproteins may exist that do not 
stain with Comassie Blue (Soffer, 1976). Molecular weights of both human 
kidney ~nd rat lung ACE were approximately 140000. The glycoprotein nature 
of ACE does affect .the mobility of the enzyme on polyacrylamide gels and thus 








MWM FRACTIO S 
Figure 2.2. Polyacrylamide gel electrophoresis of purified rat lung ACE. The lane marked 
MWM is the molecular weight marker and those marked fractions correspond to samples of 
fractions during enzyme elution from the lisinopril - Sepharose column. 
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2.4.4. Inhibition by captopril 
Further proof that the purified protein was indeed ACE was obtained by 
demonstration of the inhibitory effect of captopril, a specific ACE inhibitor, in 
the spectrofluorimetric assay. The purified enzyme was sensitive to captopril. 
Using the method of Dixon (method detailed in appendix 9.11 ), Ki values of 
approximately 3nM were obtained which is in good agreement with previously 
published data for rat lung ACE (Strittmatter et al., 1985). 
2.5. CONCLUSION 
A rapid and facile method has been presented to allow the purification of high 
specific activity homogeneous ACE from rat lung or human kidney tissue. 
Highly purified ACE could be prepared by lisinopril-sepharose chromatography 
of a partially purified trypsin solubilised tissue extract. ACE was eluted with a 
high pH buffer as described in Methods and the entire procedure can be 
completed within two days. This contrasts with earlier multiple stage 
conventional chromatographic methods and is amongst the fastest of the 
affinity methods. 
This method allows the purification of enzyme from a variety of sources and 
should prove useful in any experiments studying the enzyme. As will be 
described in the following chapters, ACE purified in this way was used as an 
antigen to raise polyclonal and monoclonal antisera and also as standards in 
radioimmunoassays and ELISAs (enzyme linked immunosorbent assays). 
Chapter 3 




Since no commercial source for ACE antisera was available, our own 
polyclonal and monoclonal antisera had to be produced. These were required 
for ACE immunoassays and immunohistochemistry. 
3.2. INTRODUCTION 
Production of antisera to ACE has been described in the literature. One of the 
earliest reports was the production of a polyclonal antiserum in goats to rabbit 
ACE (Caldwell et al., 1976). This antibody was used for the 
immunohistochemical localisation of ACE in a variety of organs. Goat anti-pig 
ACE antibodies (Hall et al., 1976) were subsequently utilised in a 
radioimmunoassay for pig ACE (Odya et al., 1979), and rabbit antiserum to 
human ACE has been used (Takada et al., 1981) in a radioimmunoassay for 
human ACE (Alhenc-Gelas et al., 1983). 
The production of monoclonal antibodies has also been reported. In 1984, 
Moore et al. (1984), developed monoclonal antibodies to rat lung ACE and 
studied their in vitro and in vivo binding to ACE by immunohistochemistry. 
Monoclonal antibodies to human lung ACE have also been produced (Danilov 
et al., 1987a) and utilised for immunohistochemical localisation of ACE (Danilov 
et al., 1987b), the radioimmunoimaging of lung blood vessels (Danilov et al., 
1989) and recently in an ELISA for human ACE (Stevens et al., 1990). 
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3.3. PRODUCTION OF POL YCLONAL ANTISERA 
3.3.1. Materials 
ACE was purified to homogeneity as described in the previous chapter. 
Antisera were raised in New Zealand white rabbits obtained from the Animal 
Unit at the University of Cape Town Medical School. Protocols for the utilisation 
of animals were first submitted for the approval of the University Animal 
Research Review Committee. Freund's complete and incomplete adjuvant was 
obtained from Difeo. Ammonium sulphate was from Sigma and a Hitachi Himac 
centrifuge was used in the purification of the antisera. 
The ELISA utilised 96 well strips and frames from Nunc. NaCl, Tris, Triton X-
100, 2,2' azino-di-(3-ethylbenzthiazoline sulphonic acid (ABTS), citric acid 
monohydrate were all obtained from Sigma. Tween-20 was obtained from Bio-
Rad, goat anti-rabbit peroxidase conjugate from Amersham and fetal calf serum 
(FCS) from Highveld Biologicals. Plates were read in a Titertek Multiscan MCC-
340 ELISA plate reader. 
3.3.2. Methods 
Purified ACE (50µg) in normal saline was thoroughly mixed with complete 
Freund's adjuvant to form a stable emulsion using the double hubbed needle 
method (Berlin and McKinney, 1958) and administered at multiple sites 
intradermally. Three weeks later a booster dose of ACE (25µg) was 
administered with Freund's incomplete adjuvant in the same manner. Booster 
injections were repeated at intervals until a sufficient titre of anti-ACE 
antibodies was detected in samples of blood obtained from ear vein bleeds, 
utilising a simple ELISA method described below. At this point serum was 
obtained from the rabbits and stored at -70°C until used. 
For most purposes the antiserum obtained required further purification. This 
was achieved by ammonium sulphate fractionation. A saturated solution of 
ammonium sulphate was prepared by adding 800g to 1 litre of distilled water at 
35°C which was then stirred for 2 hours. The temperature was then lowered to 
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20°c with continued stirring overnight. The pH of the solution was slowly 
adjusted to between pH 7 - 8 with ammonium hydroxide after the testing of 
small aliquots of the solution to avoid errors in pH measurements of the 
saturated solution. 
Precipitation of immunoglobulins in the antiserum was achieved by the addition 
of the saturated ammonium sulphate solution to a final concentration of 33%. 
This was stirred for an hour at room temperature and centrifuged at 4000g for 
15 minutes. The pellet was redissolved in phosphate buffered saline (pH 7.4) 
(PBS) to the original volume and reprecipitated and centrifuged as before. The 
resulting pellet was redissolved in PBS and the excess salt removed by gel 
filtration on a pre-packed Sephadex G-25 column. Complete removal of the 
ammonium sulphate was demonstrated by the absence of a precipitate in a 
small quantity of the purified preparation on the addition of Barium Chloride. 
3.3.2.1. Assessment of the antibody titre 
In order to assess the titre of the polyclonal antiserum to ACE, an ELISA 
method was employed. This allowed the test bleed from the rabbits to be tested 
to determine when sufficient antibody titre had been achieved. Blood was 
collected in serum separation tubes (SST, Vacutainer), allowed to clot for 30 
mins at room temperature and centrifuged at 1 OOOrpm for 5 mins to obtain 
serum. 
The ELISA plate wells were prepared as follows; Purified ACE was diluted in 
1 OmM Na2HP04, 150mM NaCl (pH9) (PBS-9) at a concentration of 5µg/ml. 50 
µI was dispensed into each well and the antigen was allowed to adsorb 
overnight at 4°C. The wells were flicked dry, washed six times with PBS-9, filled 
with 200µ1 of blocking buffer (PBS-9 with 1 % FCS) and incubated at room 
temperature for 20 minutes. The wells were emptied and 50µ1 of doubling 
dilutions of the rabbit serum diluted in blocking buffer (initial dilution was 1 :50 
then 1:100, 1:200, 1:400 and so on to 1:6400) were added and incubated at 
room temperature for an hour. The wells were flickad dry and washed ten times 
with TST (0.05M Tris/HCI pH 8, 0.1 OM NaCl and 0.05% Tween-20). After drying, 
the wells were filled with 50µ1 of 1: 100 goat anti-rabbit peroxidase conjugate 
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diluted in ELISA diluent (0.5M NaCl, 0.5% Triton-X100 and 0.01 M Na2HP04) 
and incubated at room temperature for 30 minutes before being washed twice 
with TST. 
The 2,2'-azino-di(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) substrate was 
then added which was prepared as follows; stock solutions of 40mM ABTS in 
distilled water were stored at -20°C. When required, an aliquot was thawed and 
diluted 1: 100 in citrate buffer (525mg citric acid monohydrate dissolved in 50ml 
distilled water, pH 4 with NaOH) - to the ABTS dilution was added 0.01/volume 
of 30% hydrogen peroxide. 100µ1 of the substrate solution was added to each 
well and incubated for 30 minutes at room temperature before the absorbances 
were read in a ELISA plate reader at 414nm. 
At each incubation step the plate was wrapped in clingwrap to prevent 
evaporative losses. 
3.3.2.2. Assessment of antibody specificity by Western Blotting 
The specificity of the antibody for ACE was assessed by Western blotting 
(Towbin et al., 1979). This technique allows protein to be electrophoretically 
transferred to a nitrocellulose membrane which, after blocking non-specific 
binding, is probed with a specific antibody. Binding of this antibody is detected 
using a peroxidase conjugate of an antibody directed against the first antibody. 
The presence of peroxidase is determined by incubation with a peroxidase 
substrate, 4-chloro-1-naphthol with hydrogen peroxide, to yield a black 
insoluble precipitate on the membrane. 
Duplicate lanes of a SOS-PAGE gradient (3-17.5%) gel were loaded with ACE 
to provide a seperate lanes for staining and blotting. Purified ACE was 
denatured in 2-mercaptoethanol and boiled prior to loading. 
One gel section was stained and the other was electroblotted onto a piece of 
nitrocellulose membrane (lmmobilon) using an electroblotting apparatus (G.T. 
Series Gel Electrophoresis unit with a Transphor Power-Lid model TE 50 from 
Hoefer Scientific Instruments, San Fransisco) placed in an ice-filled polystyrene 
cool box. The unit was filled with protein transfer buffer (0.025M Tris-HCI, pH 
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8.8, 0.20M Glycine, 0.1 % SOS and 20% [v/v] Methanol). Blotting was 
performed at 400mA for 2 hours in a cold room at 4°C. 
The membrane was removed and blocked with 1 % foetal calf serum, 0.3% 
Tween-20 in 0.2M NaCl, 0.05M Tris/HCI pH 7.4 (blocking buffer) for one hour. 
Polyclonal antibody was diluted in the blocking buffer at a dilution of 1 :500 and 
incubated with the membrane for 1,5 hours at room temperature. After the 
membrane was washed six times with 0.05% Tween-20 in 0.2M NaCl, 0.05M 
Tris/HCI pH 7.4 (Tris buffered saline), it was incubated for one hour with a 
1 :500 dilution (in blocking buffer) of goat anti-rabbit peroxidase conjugate 
(Amersham). The substrate, 4-chloro-1-naphthol 24mg was dissolved in 8ml 
methanol, to which was added 40ml of Tris buffered saline and 5µ1 hydrogen 
peroxide. The membrane was transferred into this solution and once the colour 
had developed sufficiently, the membrane was rinsed in water and dried onto 
graphic arts film in the dark. 
3.3.3. Results 
An adequate titre of polyclonal antibody, as assessed by the ELISA assay, was 
achieved after four booster innoculations. At this point the animal was bled and 
the serum separated by centrifugation. The serum was either purified by 
ammonium sulphate precipitation or stored in its crude state at -70°C using 
0.02% sodium azide (Merck) as a preservative. Rabbit No.217 was the source 
for the anti-human ACE antibody and rabbit No.556 the source of the anti-rat 
ACE antibody. 
Antibody specificity was assessed by Western blotting. Doubling dilutions of 
purified human kidney ACE were loaded into wells of a SOS-PAGE gel and 
blotted. As little as 180ng ACE could be detected by a 1 :500 dilution of the 
rabbit anti-human ACE antiserum (see figure). 
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2840 1430 710 3SO 180 90 4S 2S ng 
---
Polyacrylamidc gel 
2860 1430 710 3SO 180 90 4S 25 
WcatcmBlot 
Figure 3.1. Upper panel. Polyacrylamide gel electrophoresis of doubling dilutions of purified 
human kidney ACE. Lane 1 = 2860ng ACE, lane 2 = 1430ng, lane 3 = 710ng, lane 4 = 350ng, 
lane 5 = 180ng and so on to lane 8. 
Figure 3.2. Lower panel. Corresponding western blot of the above gel. The lowest amount of 
ACE detected by the polyclonal antiserum is to be found in lane 5 ie. 180ng. 
3.3.4. Conclusion 
Utilising the above methods, polyclonal antisera to rat and human ACE were 
produced. These allowed for the development of immunoassays for rat and 
human ACE as will be described in the following chapters. 
3.4. PRODUCTION OF MONOCLONAL ANTIBODIES TO 
HUMAN ACE. 
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This section describes the development of monoclonal antibodies to human 
ACE, as well as the isolation of an antibody that cross-reacts with rat ACE. This 
allows for a continuing supply of specific antibody without the usual problems of 
cross-reactivity demonstrated by many polyclonal antisera. The main purpose 
of obtaining these monoclonal antibodies was to allow the development of 
sandwich ELISAs using these as second antibodies. 
3.4.1. Materials and Methods 
All reagents were of the highest grade obtainable. Sterile procedures were 
performed in a laminar flow hood (Laminair) and cell cultures were grown in a 
CO2 incubator. BALB/c mice were obtained from Animal Unit at the University 
of Cape Town. Experimental protocols were submitted for the approval of the 
University Animal Ethics Committee. 
3.4.1.1. Antibody production 
3.4.1.2. Stock reagents 
Penicillin and streptomycin (P and S) 1 OOx was made by mixing 10000 U/ml 
penicillin and 10000 µg/ml streptomycin in sterile PBS (0.14M NaCl, 2.6mM 
KCI, 8mM Na2HP04, 1.5mM KH2P04) and then frozen in aliquots. 
Human umbilical cord serum (HUCS) was heated at 56°C for 30 minutes, 
filtered and sterilised before use. 
"HT" 1 OOx stock: To 0.68g hypoxanthine powder was added 250ml water then 
up to 5ml of 1 ON Na OH was added dropwise until dissolved. Then 0.1935g 
thymidine, 0.011 g glycine and 5.503g sodium pyruvate was added and made 
up to 500ml with water. This was then filter sterilised and stored frozen at -
20°c. 
Aminopterin 1 OOx . stock: 25ml water was added to 1. 76mg aminopterin, 
followed by 0.5ml of SN NaOH. This was then neutralised with 5N HCI and 
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made up to 100ml with water. This solution was filtered and stored, protected 
from light at -20°C. 
3.4.1.3. Immunisation of mice 
Mice were injected intraperitoneally with 30 µg of purified human ACE 
emulsified in complete Freund's adjuvant. Two weeks later the mice were re-
immunised with 30 µg ACE, this time in incomplete Freund's adjuvant. After two 
weeks the presence of antibody was determined utilising the ELISA assay 
described above. Three days prior to fusion, the mice were injected 
intraperitoneally with 50 µg ACE in PBS. 
3.4. 1.4. Fusion 
Myeloma SP2/0Ag14 cells were grown in 2-3 100mm petri dishes. The 
suspension was centrifuged to pellet the cells, and the supernatant filtered 
through a 0.45 micron filter and stored as "conditioned medium". 
10ml Versene solution (0.69mM EDTA in 0.14M NaCl, 2.6mM KCI, 1.5mM 
KH2P04, 6mM Na2HP04, pH7.4) was added to dishes containing viable 
myeloma cells. This was incubated at 37°C for 10 minutes before the cells were 
dislodged by pipetting and transferred to centrifuge tubes. Cells were pelleted 
at 500g for 15 minutes and resuspended in RPMI 1640 medium. The cells were 
counted and their viability assessed by trypan blue exclusion. 
The mouse was sacrificed and the spleen removed under sterile conditions. It 
was placed in RPMI medium in a petri dish at 37°C and strained through a 
sterile stainless steel sieve into the RPMI medium. The clumps were broken up, 
the resulting suspension transferred to a 50ml centrifuge tube and allowed to 
stand for 3 minutes before the supernatant was transferred to a clean tube. 
This was centrifuged at 500g for 5 minutes and the pellet resuspended in 30ml 
RPMI. The cells were washed in RPMI once before being counted in white cell 
diluting fluid (2% acetic acid), which lyses red cells. 
Spleen cells and SP-2 cells were mixed in a 9: 1 ratio in RPMI in a 50 ml 
centrifuge tube which was centrifuged at 500g for 5 minutes. The supernatant 
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was poured off leaving a little within which to resuspend the pellet. Two grams 
of polyethylene glycol (PEG 4000) was autoclaved and to this was added 2ml 
of RPMI at 37°C. This solution was added dropwise (1.5ml over 1.5 minutes) to 
the cell suspension with gentle mixing which was continued for a further 0.5 
minute. RPMI (1.5ml) at 37°C was added slowly over 1 minute to the 
suspension with gentle mixing. This was repeated before a further 8ml of warm 
RPMI was added to the suspension over 2-3 minutes. The volume was then 
made up to 45ml and was centrifuged at 500g for 5 minutes and the 
supernatant removed. 
The pellet was resuspended in HAT-HUCS-Condi medium (1ml HT 11ml 100x 
Aminopterin / 5ml HUCS / 1 ml 1 OOx Pen. and strep. / 20ml of SP2 conditioned 
medium / 72ml RPMI) and the volume made up to 50ml. 0.5ml aliquots of this 
suspension was pipetted into the wells of 24 well plates to which was added 
0.5ml of HAT-HUCS-Condi medium. This volume of suspension was 
appropriate for a yield of +108 spleen cells. Plates were incubated at 37°C in 
5% CO2 and 100% humidity. 
Clones were allowed to grow for 10 - 14 days. When the culture medium 
started to turn yellow, the supernatants were tested for antibody using the 
ELISA technique described above (Section 3.3.2.1.). 
Good positives were selected and the contents of the source wells were stored 
as follows. Cells were suspended in 20% heat inactivated foetal calf serum in 
RPMI, without antibiotics, and were transferred to cryotubes (Nunc). These 
were wrapped in paper towel and stored at -?0°C overnight prior to being 
transferred to liquid nitrogen. 
3.4.1.5. Cloning of cells. 
Those cells selected for cloning were dislodged by pipetting and transferred to 
sterile tubes. Cells were counted using a counting chamber while the remaining 
cells were fed with HT-HUCS (1ml 100xHT / 5ml HUCS / 1ml 100x Pen. and 
strep. 193ml RPMI) and returned to the incubator. Cells were diluted to give 1-2 
cells/50µ1. 
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50µ1 of the cell suspension was added to wells of a 96 well flat bottomed 
microtitre tray, followed by 50µ1 of medium. The presence of one cell in each 
well was ascertained by microscopy. 
The remaining cells were frozen in a cryotube. Harvest fluid was retained for 
testing by ELISA and once the cells in the 24-well tray had grown these were 
also frozen. 
The 96-well plate was incubated in a CO2 incubator at 37°C and after 1 week 
0.1 ml of HT-HUCS medium was added. When this medium was noted to have 
yellowed ,it was screened for antiboby production by ELISA. Strong positives 
were selected and expanded to a 24-well plate. Once again a strong positive 
was selected and recloned, the rest being frozen as before. 
When the final clones had been selected these were expanded in 100mm 
dishes in 10% FCS for preparation of ascites fluid. Mice were pristane primed 
by an intraperitoneal injection of 0.5ml pristane. Ten days later these mice 
received another intraperitoneal injection of 5-1Ox106 cells in 0.5ml PBS. Mice 
were examined daily for the development of ascites. Once this was assessed 
as having progressed sufficiently, the mice were sacrificed. The abdominal skin 
was carefully sterilised with alcohol before the abdomen was opened and the 
ascites aspirated with a pasteur pipette. 
Cells were spun down (500g for 5 minutes), the supernatant filtered through a 
0.45 micron filter and stored at -70°C. 
3.4.1.6. Maintenance of myeloma cells. 
Myeloma cells were grown in 10% FCS in RPMI containing antibiotics and 
passaged 3 times per week. Semi-adherent cells were dislodged by pipetting 
and the remaining cells nourished with fresh medium. Cells were not passaged 
for more than 30 days. 
3.4.1. 7. Thawing of cells. 
Cells were removed from liquid nitrogen and thawed in a 37°C waterbath. The 
contents of the tube was then transferred to a 15ml centrifuge tube and slowly 
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diluted by the addition of 10% FCS at room temperature. Cells were then 
centrifuged at 500g for 5 minutes, resuspended in fresh medium and placed in 
a CO2 incubator. Cells maintained in this way were useful as a source of 
harvest fluid rich in monoclonal antibody. 
3.4.1.8. Detection of an anti-human ACE monoclonal antibody that 
cross reacts with rat ACE. 
In order to find a monoclonal antibody from the positive clones already 
obtained, the ELISA technique was utilised. Purified rat ACE was adsorbed to 
the wells of ELISA plates at a concentration of 5µg/ml in carbonate buffer. The 
assay was identical to that described earlier in this chapter except that culture 
medium was used undiluted in the ELISA (section 3.3.2.1.) 
3.4.1.9. Assessment of antibody specificity. 
The specificity of the antibodies for ACE was assessed by the technique of 
Western blotting. The method employed was identical to that described in 
section 3.3.2.2. 
3.4.2. Results 
Clone 14/5/16/65 ascites proved to be the most potent of the monoclonals 
directed against human ACE, reacting well against both kidney and serum ACE 
on ELISA and by Western blotting. 
Clone 187/18 produced a monoclonal antibody directed against human kidney 
ACE with the highest degree of cross-reactivity for purified rat lung ACE as 
assessed by ELISA. In an ELISA in which 5µg/ml rat ACE was adsorbed to the 
wells of an ELISA plate an absorbance of 0. 705 at 414nm was recorded versus 
a negative control absorbance of 0.025. 
Unfortunately, although ascites from clone 187 /18 was produced it proved to be 
of a lesser titre than the harvest fluid derived from the growing cells due to a 
problem later discovered to involve a less than optimal batch of SP-2 cells. This 
ascitic fluid was therefore retained for use in immunohistochemistry of rat ACE, 
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while the harvest fluid was used in the ELISA assay for rat ACE. Both these 
methods are to be fully described in later chapters. 
3.4.3. Conclusion 
A panel of monoclonal antibody secreting clones was produced as a source of 
antibody directed against human and rat ACE. Thus an abundant supply of 
these two, and other clones, were available with which to engage in 
immunoassay and immunohistological studies of human and rat ACE. 
In the following chapters the use of these polyclonal and monoclonal antisera 
in the development of immunoassays for ACE will be described. The anti-
human ACE polyclonal antiserum was used as both an antibody in a 
radioimmunoassay for human ACE as well as a capture antibody in a sandwich 
ELISA for human ACE, utilising the anti-human ACE monoclonal as a second 
antibody. Similarly, the antibodies against rat ACE were used in the 
development of an ELISA to measure rat ACE as well as in 
immunohistochemistry. 
Chapter 4 




To develop reliable and sensitive immunoassay techniques to quantitate 
human ACE protein in body fluids. 
4.2. INTRODUCTION 
Usual methods for measuring ACE (Kessler, 1987), assess enzyme activity and 
employ fluorescence, chromophore- or radioactively-labelled synthetic peptide 
substrates. Although the clinical value of serum ACE activity measurements is 
well accepted, it should be recognised that in certain circumstances these may 
not reflect the true concentration of enzyme in the sample. ACE activity assays 
may provide falsely high values when other serum peptidases are present, or 
be falsely low in the presence of endogenous or pharmacological enzyme 
inhibitors, a situation more likely to occur in disease. This possibility has 
prompted the development of assays of ACE protein concentration, but these 
have not been widely applied. 
Previously published methods of immunoassay for human ACE have included 
radioimmunoassays for human serum ACE (Alhenc-Gel~s et al., 1983; Hiwada 
et al., 1987). A competitive ELISA or CELIA (competitive enzyme linked 
immunosorbent assay) has also been described and used to study human ACE 
(Lanzillo and Fanburg, 1982). 
In order for the concentration of ACE to be measured in human sera in our 
laboratory, immunoassay methods were established. This chapter describes 
the development of both a radioimmunoassay (RIA) (SECTION A) and a 
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sandwich ELISA for human serum ACE (SECTION B). A comparison between 
these assays is also made on a group of patient sera (SECTION C). 
4.3. SECTION A: RADIOIMMUNOASSAY FOR HUMAN SERUM 
ACE. 
4.3.1. Materials and methods 
Early efforts in the establishment of this assay involved attempts to utilise 
detergent-solubilised, purified human kidney ACE as the standard. This, 
however proved to be extremely unreliable as this hydrophobic antigen tended 
to aggregate in solution, providing inconsistent results. For this reason, and 
because the assay was to be used to assay the soluble form of the enzyme as 
found in serum, trypsin-solubilised human kidney ACE was found to give 
reliable and reproducible results. 
ACE proved to be susceptible to damage during labelling with 1251. 
Chloramine-T labelling was attempted according to the method of Greenwood 
et al. (Greenwood et al., 1963) but this provided an extremely poor tracer, 
probably due to extensive denaturation of ACE. Lactoperoxidase labelling was 
also attempted, both as described in the method of Lanzillo and Fanburg 
(1982) and using Enzymobeads (Biorad) according to the manufacturers 
directions. Although this was a better tracer than chloramine-T, it still was not 
optimal. 
The lodogen method (Salacinski et al., 1981 ), which labels proteins extremely 
gently, thereby minimising the effects of oxidation of the antigen was then 
employed. 
The RIA involved the purification of ACE from human cadaver kidneys to 
homogeneity on SOS-PAGE, by affinity chromatography (as described in 
section 2.3.) on a Sepharose-lisinopril resin, ACE elution being achieved using 
a chloride-free buffer (pH 9.5). 
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Polyclonal antisera to ACE were raised in rabbits as described in the previous 
chapter (3.3). 
ACE was labelled with 1251 (Amersham) using the lodogen (1,3,4,6-
Tetrachloro-3a,6a-diphenyl glycoluril) method (Salacinski et al., 1981) and the 
tracer purified by gel filtration on a prepacked G-25 Sephadex column 
(Pharmacia) as follows. 
4.3. 1.1. Preparation of /odogen tubes. 
lodogen tubes were prepared by coating 1.5ml Eppendorf microfuge tubes with 
lodogen (Sigma) dissolved in dichloromethane (Merck). 1 mg lodogen was 
dissolved in 1 ml dichloromethane and 20µ1 of this solution dispensed into each 
Eppendorf vial. The vials were coated by allowing the solvent to gradually 
evaporate under a constant, gentle stream of nitrogen while turning the vial. 
This resulted in an even coating of lodogen on the vial wall. Vials showing 
uneven coating were discarded. Vials were stored, protected from light, at -
70°C until used. 
4.3.1.2. Iodination. 
19µ1 0.05M Phospate buffer was dispensed into an lodogen coated tube. To 
this was added 1 OOµCi of 1251 (1 µI) and 1-2µg ACE in 1 OµI PBS (purified ACE 
was concentrated into PBS using Amicon Centricon-30 miniconcentrators in 
accordance with the manufacturers directions). 
The reaction mixture was incubated at room temperature for 10 minutes, 
agitating the tube by flicking once each minute. The reaction was terminated by 
addition of 500µ1 0.05M phospate buffer, removal of the mixture from tube and 
transfer to a glass tube for 10 minutes. This prevents the lodogen from 
retaining activity on the column which could result in the iodination of the 
albumin carrier. 
The reaction mixture was loaded onto a P 0-1 O Sephadex G-25 column pre-
equilibrated with 0.05M phosphate buffer containing 1 % BSA (bovine serum 
albumin). 
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Fractions were collected (6 drops per fraction) into 250µ1 of column 
equilibration buffer. 5µ1 of each fraction was counted in a Cobra gamma 
counter (Packard). Fractions of highest activity were pooled and stored at 4°C. 
Tracer stored in this manner lasted approximate!y 3 weeks. Before use, the 
tracer was centrifuged in a microfuge at 10000g for 5 minutes to remove any 
aggregates. 
4.3. 1.3. Assessment of tracer. 
The maximal fraction of added tracer bound in the presence of an excess of 
antiserum was asse~sed by performing an antibody dilution curve as follows; 
4 tubes containing 100µ1 tracer with 1 OOOOcpm/tube (total count or TC tubes). 
4 tubes to assess non-specific binding (NSB) containing 1 OOOOcpm tracer 
(100µ1), 400µ1 RIA assay buffer (1 OmM sodium phosphate-buffered saline, pH 
7.4, containing 0.5% w/v BSA and 0.1 % sodium azide). 
Duplicate tubes containing 1 OOOOcpm tracer, 300µ1 buffer and 100µ1 of 
doubling dilutions of antiserum starting at 1 :200 and extending to 1: 102400. All 
tubes were briefly vortexed, covered with parafilm and the primary incubation 
was allowed to proceed for 48hrs at 4°C. 
Cellulose-complexed anti-rabbit precipitating antiserum (Sac-Cel - Wellcome) 
was used to separate bound from free tracer according to the manufacturer's 
directions. Briefly 100µ1 of Sac-eel was added to all tubes, except for the TC 
tubes, vortexed and allowed to incubate at room temperature for 30 minutes 
before 1 ml of deionised water was added to each tube (except TC tubes) and 
being centrifuged at 3000g for 1 O minutes. The supernatants were decanted 
and the tubes inverted and allowed to drain on paper towel. The tubes were 
then individually counted for one minute each in a Cobra gamma counter 
(Packard) and an antibody dilution curve constructed utilising the counter's 
data-reduction and curve-fitting software. The maximum percentage of tracer 
bound was noted, as was the dilution of tracer required for approximately 33% 
of tracer to be bound. 
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4.3. 1.4. Determination of specific activity of tracer. 
Tracer specific activity (ie. assessment of 1251 incorporation into ACE) was 
determined by the method of self displacement (Chiang, 1987). Briefly the 
method involves two sets of tubes. The first set was essentially a standard 
curve prepared as described above. The second set of tubes contained the 
same concentration of antibody with different amounts of tracer, no unlabelled 
ACE was present. The two sets of results were plotted on the same graph: 
total/bound counts (T/B) vs. concentration of unlabelled ACE, and T/B vs. cpm 
of tracer. By interpolation from the two curves the specific activity was derived. 
4.3.1.5. Assay of human serum. 
As in the antibody dilution curve, 4 TC tubes and 4 NSB tubes were prepared. 
4 Maximum binding tubes (Bo) were prepared with 1 OOOOcpm tracer, 100µ1 
diluted antiserum (1 :25600 - determined to result in the binding of 
approximately 33% of tracer) and made up to 500µ1 with assay buffer. Twelve 
standard tubes containing 1 OOOOcpm tracer were prepared in duplicate, to 
which was added 100µ1 antibody, 100µ1 diluted ACE in doubling dilutions from 
200ng to 0.097ng ACE per tube and 200µ1 assay buffer. The concentration of 
ACE was determined by the method of Bradford (1976) using Bio-Rad 
commercial reagent and human serum albumin as standard. 
The assay of serum utilised 25µ1 sample, incubated with 100µ1 anti-ACE 
antibody at a dilution of 1 :25600 , and 100µ1 of tracer diluted in assay buffer 
(1 OmM sodium phosphate-buffered saline, pH 7.4, containing 0.5% w/v bovine 
serum albumin and 0.1 % sodium azide) to obtain 1 OOOOcpm per tube. Samples 
were assayed in triplicate. The assay volume of each tube was adjusted to 
500µ1 with assay buffer and the primary incubation allowed to proceed for 48 
hrs at 4°C for standard, sample, NSB and Bo tubes. 
Sac-eel (Wellcome) was used to separate bound from free tracer according to 
the manufacturer's instructions. Following centrifugation at 3000g for 1 O 
minutes at 4°C the supernatant was decanted and the resulting pellet in each 
tube counted for 1 minute in a Cobra gamma counter (Packard). 
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Sample ACE concentrations, in ng/ml, were calculated using the Cobra RIA 
data reduction computer program from a standard curve of the dilutions of 
purified ACE. 
4.3.1.6. Correlation of serum ACE concentration with activity. 
As part of a study investigating the serum concentration of ACE in a large 
group of subjects (n=165), sera of both normal controls (n=32) and those 
suffering from a variety of respiratory diseases (n=133) were assayed for ACE 
concentration (using the RIA) and activity (using the spectrofluorimetric assay 
described in section _9. 7). 
Blood from each patient was drawn into SST tubes (Serum separation tubes -
Vacutainer), was allowed to clot, and the serum separated by centrifugation. 
Sera were stored at -70°C until assayed. 
ACE activity (in U/ml) were plotted against RIA assayed concentration (in 
ng/ml). The correlation coefficient was determined by the method of least 
squares. 
4.3.1.7. Assessment of within and between assay variation. 
For the intra-assay coefficient of variation (CV), the same sample was assayed 
6 times and the CV% calculated by conventional methods. The inter-assay 
CV% was calculated using the results of the same internal standard that had 
been assayed in 6 successive assay runs. 
4.3. 1.8. Assessment of the assay in the presence of pharmacological 
ACE inhibitors. 
As this assay was to be used to assay samples of patients being treated with 
ACE inhibitors, it was vital to ensure that these inhibitors would not affect assay 
results. This was determined by assaying the same samples both without and 
with added captopril or enalaprilat (the active metabolite of enalapril) at a final 
concentration of 1 o-6 M in the assay volume of 500 µI. 
4.3.1.9. Assessment of immunological identity between sample serum 
ACE and purified ACE standard. 
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A logit-log transformation of the RIA standard assay binding data was made by 
calculating the logit of the standard curve binding data using the formula; 
logit b = loge(b/100-b) where b is the proportion of the tracer 
bound expressed as a percentage of that in the zero standard 
(Bo). The logits for each of the standards was then plotted on the 
y axis against the log ACE concentrations on the x axis. 
Likewise four different amounts of each of the samples was assayed and the 
results plotted in the same way on the same graph. 
Thus a logit-log plot was made of the standard curve and various dilutions of 
the serum of a normal control and sarcoid patient and the slopes of the curves 
compared. This was to assess the parallelism of the displacement curves, 
which suggests immunological identity between sample and standard. 
4.3.2. Results 
4.3.2.1. Iodination of ACE. 
ACE was iodinated using the lodogen vial method described above. Typically, 
well over 95% of the 1 OOµCi used in the labelling reaction was incorporated 
into the ACE. Tentative evidence for this high degree of incorporation could 
firstly be noted from the cpm/fraction eluted from the PD-10 column with 
virtually all counts being associated with the protein peak (see accompanying 
figure). Proof of this high degree of 1251 incorporation was noted from the 
results of the self-displacement assay which demonstrated an average of 1 
atom 1251 incorporated per molecule ACE (method detailed in appendix 9.12). 
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Figure 4.1. Elution profile of 1251 labelleled ACE from a PD-10 column. Each fraction of 6 
drops was collected into 250µ1 of 0.05M phosphate buffer, 1%8SA. 5µ1 of each fraction was 
collected and counted. CPM for each fraction were plotted as shown. The first peak (fractions 
11-20) contained the labelled ACE, while the small peak at fraction 50 contained unbound 
tracer. 
4.3.2.2. Antibody dilution curve 
The antiserum raised to purified ACE routinely bound more than 85% of 
labelled ACE when incubated in excess, in the absence of competing antigen. 
The dilution of tracer giving approximately 33% tracer binding was 1 :25600 in 
100µ1 and thus this concentration, representing a final dilution of 1: 128000 in 
the 500µ1 assay volume, was chosen for all assays. 
4.3.2.3. RIA of serum samples. 
A typical standard curve is shown in the accompanying figure. Non specific 
binding was commonly less than 3% of Bo. Intra-assay and interassay 
reproducibility coefficients were normally approximately 5% and 8% 
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respectively. The RIA detected 0.25 ng ACE/25 µI serum and results were 
unaffected by the presence in the assay medium of either captopril or 
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Figure 4.2. Typical standard curve for RIA of human serum ACE. Percentage of tracer bound 
on the y-axis is plotted against known concentrations of purified human kidney ACE on the x-
axis.Crosses denote actual values obtained and the fitted line is shown. 
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4.3.2.4. Correlation of serum ACE concentration with activity 
The assay results obtained for each sample group are detailed in the 
accompanying table. 
Group n Activity [ACE] Sp.Act. 
(U/ml) (ng/ml) (U/mg) 
Normal 32 37.2 ± 2.1 453.7 ±28.3 83.9 ± 2.0 
Sarcoid 51 78.7 ± 5.81 979.3 ± 77.41 83.6 ± 2.4 
Silicosis 21 51.9 ± 4.62 646.5 ± 52.22 81.2 ± 3.2 
MTB 20 50.0 ± 2.82 627.0 ± 48.52 82.8 ± 3.0 
CTB 12 32.5 ± 3.5 387.4 ± 46.2 87.2 ± 6.9 
COPD 26 40.2 ± 2.23 396.2 ± 53.13 113±4.01 
IPF 7 39.7 ± 2.7 437.2 ± 52.7 96.4 ± 9.13 
Table 4.1. ACE activity, Concentration ([ACE]), and Specific Activity (Sp.Act.) by patient group. 
n represents the number of subjects in each group; COPD, Chronic Obstructive Pulmonary 
Disease; CTB, Cavitating Pulmona~ Tuberculosis; MTB, Miliary Tuberculosis; IPF, Interstitial 
Pulmonary Fibrosis. 1 p < 0.0001, p < 0,01 and 3 p = N.S. compared with normal control 
group. Expressed as mean±SEM. 
The ACE concentration ( mean (± 1 S.D.)) of normal subjects was 
453. 7(±159.8) ng/ml. Significant elevations in serum ACE concentration were 
found in the M.T.B., silicosis and sarcoidosis groups. 
A plot of ACE activity vs. concentration is shown in the figure below. Least 
mean squares analysis demonstrated an excellent correlation (r=0.93; 
p<0.0001) between these two measurements. 
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Figure 4.3. Plot of Serum ACE concentration (ng/ml) vs. serum ACE activity (U/L). The line 
represents the least mean squares correlation. 
4.3.2.5. Assessment of parallelism 
A legit-log plot of dilutions of purified ACE and samples demonstrated 
parallelism, suggesting immunological identity between standard and samples 
from both a control and a sarcoid subject. 
4.3.3. Conclusions 
The labelling of ACE by the lodogen technique has not previously been 
described and it is interesting to note that the degree of 1251 incorporation and 
retention of immunoreactivity is superior to previously reported methods for 
which such data are given (Alhenc-Gelas et al., 1983). 
A RIA assay for human serum ACE has been established which is capable of 
measuring the quantity of ACE protein in human sera. It is unaffected by the 
presence of ACE inhibitors and is therefore of great value in the assay of 
patient sera in the presence of pharmacological ACE inhibitors or in the 
detection of endogenous ACE inhibitors, unlike assays measuring ACE activity. 
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The assay is very sensitive, being able to detect as little as 250 pg ACE per 25 
µI serum. Multiple runs of this assay incorporating internal standards have 
attested to the reliability and reproducibility of the assay. 
The close correlation between ACE activity and concentration found in the 
study of a large group of patients (r=0.93) is higher than that reported in other 
RIA studies (Alhenc-Gelas et al., 1983; Hiwada et al., 1987). The ACE 
concentration in normal human serum was found to be 453. 7(±159.8) ng/ml 
which is in close agreement with previously reported values of 400(±131) ng/ml 
(Alhenc-Gelas et al.,· 1983) and a little higher than the value of 320.9(±105.2) 
ng/ml reported by Hiwada et al. (1987). 
The ACE RIA has the disadvantage of requiring the use of a radio-isotope, but 
is easier to perform, allows processing of samples in large batches, is more 
specific, and has a lower level of detection for ACE than the 
spectrofluorometric assay. 
4.4. SECTION B: ELISA FOR HUMAN ACE 
An ELISA for human ACE has also been developed, avoiding the need for 
isotopically labelled tracer. There are many potential disadvantages in 
radioimmunoassays: apart from the obvious saftey and disposal problems 
attached to the use of radioisotopes, there is also the need for specialised, 
expensive radioactivity measuring apparatus and the need to repeatedly 
relabel tracer due to its short half-life. 
As polyclonal and monoclonal antisera to human ACE had already been 
developed (see section 3.3. & 3.4.), their use in a sandwich ELISA was 
considered. 
ELISA methods for the measurement of human ACE have been described. In 
their paper detailing four different configurations of a competitive ELISA or 
CELIA, Lanzillo and Fanburg (1982) used a primary incubation of sample or 
standard ACE with a polyclonal antibody, before a second incubation in 
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another well allowed any remaining antibody to bind a fixed amount of purified 
ACE immobilised on the solid phase. The authors found that the most sensitive 
configuration employed was that using the avidin biotin-horseradish peroxidase 
conjugate. This resulted in an assay which required approximately 24 hours to 
complete. The assay had a useful range of between 39 and 700 ng/ml. This 
assay was suitable for the measurement of ACE in human serum. 
More recently, the first method of ACE ELISA utilising monoclonal antibodies 
has been reported (Stevens et al., 1990). In this assay one monoclonal Ab acts 
as a capture antibody, extracting the ACE from the sample or standard. This 
ACE is then detected with a second monoclonal directed against a different 
epitope as compared to the first antibody. The second antibody was conjugated 
to alkaline phosphatase. Detection involved the NADP/NAD cycling reaction 
method (Johannsen et al., 1985). The reported sensitivity of this assay was 94 
pg/ml making this assay suitable not only for the assay of ACE in serum or 
tissue but also in cell culture experiments. It is the most sensitive immunoassay 
for human ACE reported to date. 
It was decided that an ELISA would be developed using a polyclonal capture 
antibody immobilised on a solid phase and detecting bound ACE with a 
monoclonal antibody. 
4.4.1. Materials and methods. 
ACE was trypsin solubilised and purified to homogeneity from human cadaver 
kidney tissue as described in chapter 2. 
As the capture antibody required purification prior to use in the ELISA, 
polyclonal antiserum No. 217 was subjected to DEAE Affigel-Blue (Biorad) 
chromatography. This method removes all contaminating proteins from the 
immunoglobulin except for transferrin. 2 ml of antiserum was dialysed overnight 
against 0.02M potassium phosphate buffer, pH8. A column of DEAE Affigel 
Blue (bed volume approximately 10 ml) was equilibrated with the same buffer. 
After loading the column with the dialysed antiserum, the lgG was eluted with 
the same potassium phosphate buffer (contaminants are retained on the 
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column). The absorbance was monitored continuously at 280 nm and fractions 
collected. The column was regenerated by washing with 6M KSCN. 
The appropriate fractions were pooled after analysis on SOS-PAGE. The 
approximate lgG concentration was assayed using the method of Bradford 
(Bradford, 1976) using the Biorad reagent. 
Monoclonal antibody 14/5/16/65 ascites was used unpurified. 
Initially the assay was set up using the avidin-biotin method. This entailed 
detection of the second (monoclonal) antibody with a biotinylated anti-mouse 
antibody (Amersham) and subsequent incubation with Avidin-horseradish 
peroxidase before reaction with the substrate, ABTS. Although this method 
provided sensitivity, it was found that use of a goat anti-mouse peroxidase 
conjugate reduced the number of steps and time required without sacrifice of 
sensitivity. 
Optimum concentrations for all reagents were determined by running multiple 
checkerboard titration assays. This method allows for a range of concentrations 
of two reagents to be simultaneously tested in the same assay. 
The final assay configuration was as follows; 
Nunc round-bottomed U-96 microtitre plates were filled with 100µ1 of purified 
antiserum 217 diluted 1 :20 in 0.1 M carbonate buffer pH 9.6. Incubation was 
allowed to continue overnight at 4°C. 
The wells were then emptied and flicked dry on paper towels before being filled 
with 200 µI of 2% casien in the above carbonate buffer. This blocking step was 
for 30 minutes at room temperature. 
The blocking buffer was then drained and the samples and standards diluted in 
ELISA diluent (0.5M NaCl, 0.01M Na2HP04·12H20, 0.5% Triton X100). All 
samples and standards were in duplicate with samples being diluted in 1 :2, 1 :4 
and 1 :8. These were incubated for 1.5 hours at room temperature. The wells 
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were then drained and washed 5 times with Tris-saline-Tween (TST, 0.1 M 
NaCl, 0.05M Tris, 0.5% Tween-20). 
The monoclonal ascitic fluid was diluted 1 :2500 with ELISA diluent and 100 µI 
dispensed into each well. This was incubated at room temperature for 1.5 
hours before the wells were drained and washed 5 times with TST. Goat anti-
mouse peroxidase conjugate (Amersham) was diluted 1 :30 in ELISA diluent 
and 100 µI dispensed into each well and incubated at room temperature for 1 
hour. This was drained and the wells washed 5 times with TST. 150 µI of the 
substrate ABTS (made up as described previously) was added to each well, 
incubated at room temperature for 10 minutes before the absorbances were 
read at 414 nm on a Titertek Multiscan MCC-340 ELISA plate reader. 
Samples were also assayed in the presence of the ACE inhibitors captopril and 
enalaprilat at a concentration of 1 o-6 M to assess the effect of these inhibitors 
on the assay. 
4.4.2. Results 
Polyclonal antibodies from antiserum 217 purified on DEAE Affigel Blue is 
shown in figure 4.4. The fractions eluted were electrophoresed on SOS-PAGE 
(also shown in figure 4.5) demonstrating that most contaminating proteins were 
removed from the serum leaving lgG and transferrin. The final purified lgG was 
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Figure 4.4. Polyclonal antiserum No. 217 was subjected to DEAE Affigel-Blue (Biorad) 
chromatography removing all contaminating proteins from the immunoglobulin except for 
transferrin. 2 ml of antiserum was dialysed overnight against 0.02M potassium phosphate 
buffer, pH 8. A column of DEAE Affigel Blue (bed volume approximately 1 O ml) was 
equilibrated with the same buffer. After loading the column with the dialysed antiserum, the lgG 
was eluted with the same potassium phosphate buffer in fractions 8 - 16 (contaminants are 
retained on the column). The absorbance was monitored continuously at 280 nm and fractions 
collected. The column was regenerated by washing with 6M KSCN. · 
lmmunoglobulin 
Transferrin 
1 2 3 5 6 
Figure 4.5. Polyacrylamide gel electrophoresis of fractions eluted from DEAE Affigel-Blue 
column. Lanes 1 - 6 correspond to fractions 8, 10, 12, 14, 16 and 18 respectively. The bold 
band in each lane is the lgG, minor contaminants are noted in the latter two fractions. 
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The assay performed as described demonstrated high sensitivity with as little 
as 5 ng/ml being reliably assayed. There was no interference from added 
captopril or enalaprilat in assay results. A typical standard curve is show.n in 








Figure 4.6. A typical ELISA standard curve for human serum ACE. Known concentrations of 
purified human kidney ACE is plotted on the x - axis against optical absorbance at 414nm on 
they - axis. The regression line from which sample values were read, is shown. 
4.4.3. Conclusion 
An ELISA for human serum ACE was developed utilising a polyclonal 
antiserum as a capture antibody and a monoclonal second antibody. The assay 
demonstrated a sensitivity roughly equivalent to that of the RIA described 
earlier. Unlike the RIA which requires a sample-to-result time of at least 55 
hours, the eqivalent time for the ELISA is 16 hours. Most of this time is the 
overnight ( 1 O hour) coating of the wells with the capture antibody which can be 
reduced to 2 hours without loss of sensitivity (data not shown). 
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Although this did not have the same degree of sensitivity as the recently 
published monoclonal sandwich ELISA for human ACE (Stevens et al., 1990), it 
is sensitive enough for most purposes, excluding perhaps cell culture 
experiments. Its assay characteristics compared favourably with the results of 
the only other published ELISA assay for human ACE (Lanzillo and Fanburg, 
1982). 
Like the RIA, this assay is unaffected by the presence of ACE inhibitors in the 
sample, making it useful for studies of patients sera for ACE in the presence of 
these drugs. 
4.5. SECTION C: CORRELATION OF ACE RIA vs. ELISA. 
In order to assess the correlation between RIA and ELISA results a random 
group of patients sera were assayed by both methods and the results 
compared. 
4.5.1. Methods 
Sera were obtained from samples (n = 13) submitted to our laboratory for 
routine ACE activity assay. The samples were processed as described above 
The samples were assayed in accordance with the described methods and only 
once the assays were completed were the results correlated. 
The concentrations obtained from each sample, assayed in duplicate, were 
meaned and the correlation between both methods was determined by the 
method of least squares analysis. 
4.5.2. Results 












































Table 4.2. Table showing values for ACE concentration by RIA and ELISA for each of 13 
subjects. 
A graph demonstrating the correlation between RIA results and those of the 
ELISA was also constructed and is shown in the figure below. A correlation of r 
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Figure 4.7. Graphical representation of the correlation between ACE concentration measured 
in patients by both RIA and ELISA. Excellent correlation is evidenced by the r2 value of 97.4. 
The pairs of dotted lines represent the 95% confidence and prediction limits. 
4.5.3. Conclusion 
An excellent correlation was shown between both assays and thus they are 
valuable in studies of ACE in human serum. As the ELISA is both quicker and 
has equivalent sensitivity as compared to the RIA, and avoids the hazards of 
radioisotope usage, ELISA appears to be the assay of choice for future studies. 
The only potential advantage of RIA is in the simultaneaous processing of 
many specimens. As one generally tends to only process one ELISA plate at a 
time, this only allows for a maximum of about 25 samples to be assayed per 
run. The RIA, in contrast, has been used in runs of 250 samples in duplicate. 
Thus, the greater throughput possibilities with the RIA may be of advantage in 
some studies. 
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Niether of these assays have been applied to tissue extracts, although RIAs 
are often more susceptible to interference from tissue proteins as compared to 
ELISAs. As it is often necessary to detergent solubilise ACE from tissue, and 
ELISA diluent already contains detergent, it is likely that the ELISA will be 
useful in this setting. The RIA, however, fails to produce a standard curve in the 
presence of Triton X100 (data not shown). The exact reason for this has not 
been determined but may involve a conformational change of either antigen or 
antibody abolishing any mutual interaction. 
These assays should prove valuable in future studies of ACE, and the 
application of the RIA to the study of patients receiving ACE inhibitors will be 
described in chapter 7. 
79 
Chapter 5 
DEVELOPMENT OF ELISA FOR RAT ACE 
5.1. OBJECTIVE 
To develop an ELISA assay to measure ACE in the serum and tissues of rats. 
5.2. INTRODUCTION 
As the study encompassed by this thesis was, in the main, to investigate serum 
and tissue ACE responses to pharmacological inhibition, it was necessary to 
develop a sensitive immunoassay capable of accurately quantitating ACE in rat 
serum and tissues. A rat model for our studies was chosen because the 
animals are readily available, easily handled, and the rat is a frequent model 
employed in cardiovascular, and more particularly, ACE research. 
The only other ELISA assay described to measure non-human ACE was for 
bovine ACE (Dasarathy et al., 1990), and has been employed to measure ACE 
from cultured bovine endothelial cells under the influence of various 
pharmacological agents. 
The ELISA technique was chosen, since in the human assays it had been 
shown to be as sensitive as the RIA and potentially more useful in assay of 
tissue samples (see previous chapter). 
Having raised a polyclonal antiserum to rat ACE and having found an anti-
human ACE monoclonal antibody that cross-re:3cted with rat ACE, it was 
possible to develop a sandwich ELISA, similar to that developed to measure 
human ACE. The development of this assay is described in this chapter, while 
its application to the measurement of serum and tissue ACE will be covered in 
a later chapter. 
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5.3. MATERIALS AND METHODS 
Rat lung ACE was purified to electrophoretic homogeneity as described in 
Chapter 2 on ACE purification. 
Polyclonal antiserum no. 556, directed against rat lung ACE, was raised as 
described in Chapter 3. This antibody required purification on DEAE Affigel 
Blue before use as a capture antibody in the ELISA The isolation of 
monoclonal antiserum 187 /18, raised against human kidney ACE but cross-
reacting with rat lung ACE, is also described in section 3.4.1.8. Monoclonal 
187 /18 was used in· the form of harvest fluid collected from antibody-secreting 
cells. 
Optimum concentrations for all reagents were determined by running multiple 
checkerboard titration assays. This method allows for a range of concentrations 
of two reagents to be simultaneously tested in the same assay. 
The final assay configuration was as follows; 
Nunc round-bottomed U-96 microtitre plates were filled with 100 µI of purified 
antiserum 556 diluted 1 :20 in 0.1 M carbonate buffer pH 9.6 (final concentration 
9µg/ml). Adsorbtion was allowed to continue overnight at 4°C. 
The wells were emptied and flicked dry on paper towels before being filled with 
200 µI of 2% casien in the above carbonate buffer. This blocking step was for 
30 minutes at room temperature. 
The blocking buffer was drained and the samples and standards diluted in 
ELISA diluent (0.5M NaCl, 0.01M Na2HP04·12H20, 0.5% Triton X100). All 
samples and standards were in duplicate with serum samples being diluted in 
1:5 and 1:10. The standard curve ranged from 5000 ng/ml to 4.9 ng/ml in 
doubling dilutions. Two wells were filled with ELISA diluent to provide the zero 
standard. These were incubated for 1,5 hours at room temperature. The wells 
were then drained and washed 5 times with Tris-saline-Tween. 
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The monoclonal harvest fluid was used undiluted and 100 µI dispensed into 
each well. This was incubated at room temperature for 1.5 hours before the 
wells were drained and washed 5 times with TST. Goat anti-mouse peroxidase 
conjugate (Amersham) was diluted 1 :30 in ELISA diluent and 100 µI dispensed 
into each well. Incubation was at room temperature for 1 hour. This was 
drained and the wells washed 5 times with TST. 
150 µI of the substrate ABTS (made up as described previously) was added to 
each well. Incubation was allowed to proceed at room temperature for 10 
minutes before the absorbances were read at 414 nm on a Titertek Multiscan 
MCC-340 ELISA plate reader. 
To assess the utility of this assay in the measurement of rat ACE and to obtain 
a normal rat serum ACE concentration, normal serum was obtained from a 
group of eight female Long-Evans rats of similar mass (approximately 350 g). 
ACE was assayed by ELISA at two dilutions, each being in duplicate. 
Samples were also assayed in the presence of the ACE inhibitors captopril and 
enalaprilat at a concentration of 1 o-6 M to assess the effect of these inhibitors 
on the assay. 
5.4. RESULTS 
Polyclonal antiserum 556 was purified on DEAE Affigel Blue and the fractions 
eluted were electrophoresed on SOS-PAGE to ensure that most contaminating 
proteins were removed from the serum leaving lgG and transferrin. The final 
purified lgG was at a concentration of 170 µg/ml. 
The assay could detect as little as 5ng/ml ACE and there was no interference 
of assay results when captopril or enalaprilat were added to the samples. A 
typical standard curve is shown in the accompanying figure. An internal 
standard of pooled rat serum ([ACE]=1980 ng/ml) was included in all assays 
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Figure 5.1. A typical standard cuNe for the rat ACE ELISA. The crosses represent 
absorbances read for known concentrations of rat lung ACE vs. a log scale of the standard 
[ACE] up to SOOOng/ml. The line linking the crosses represents a best fit cuNe from which the 
concentrations of samples could be read. 
Assay of serum ACE from the group of eight rats showed a normal serum ACE 
concentration of 1189±213 ng/ml (mean±SD). 
5.5. CONCLUSION 
An ELISA measuring rat ACE was developed utilising a sandwich technique. 
This assay, the first rat ACE ELISA to be described in the literature, is sensitive 
enough for use in the study of the effects of pharmacological ACE inhibition on 
serum and tissue levels of ACE. The ELISA is simple to perform and, following 
overnight coating of wells with antibody, the assay can be completed within six 
hours. 
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The level of a serum ACE concentration in rats is approximately three times 
that of humans, and this is not surprising as it has previously been noted that 
rat serum ACE activity is elevated compared to human serum ACE (Kase et al., 
1986). 
This assay should prove to be a valuable tool in the study of ACE in the rat, an 
animal frequently utilised in cardiovascular research. Although this assay was 
used in this study to assess the effect of ACE inhibitors on ACE levels in serum 
and tissues, it may well be useful for other studies examining the renin-
angiotensin system in the rat. 
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Chapter 6 
CLONING AND SEQUENCING OF RAT ACE. 
6.1. OBJECTIVE 
To obtain a nucleic acid probe that could be used to study the changes in ACE 
RNA in rats during t~eatment with ACE inhibitors. 
6.2. INTRODUCTION 
This study set out to examine ACE expression in rats in response to 
pharmacological ACE inhibition, not only in terms of ACE protein, but also ACE 
mRNA. This was vital as any detected increase in ACE protein could either be 
due to increased synthesis of new ACE or to decreased clearance of pre-
existing ACE. If elevations of ACE-specific mRNA could be detected in tissues 
in response to ACE inhibition, strong evidence for the former possibility would 
be obtained. 
The expression of specific mRNAs in tissues can most easily be determined by 
the technique of northern blotting where RNA extracted from tissue is 
separated on an agarose gel, transferred to a solid support, and specific mRNA 
detected with a suitable labelled DNA or RNA probe (Thomas, 1980). In order 
to perform such a study, a suitable probe was required. Fortunately, a partial 
cDNA clone of human testicular ACE (designated 10A see Ehlers et al., 1989) 
was obtained and, on the assumption that considerable homology existed 
between rat and human ACE, this human clone was used for northern blots of 
rat RNA The clone, however, hybridized weakly to rat ACE mRNA; at least 20 
µg total RNA had to be loaded per lane to obtain a barely detectable signal 
(data not shown). It was therefore decided to isolate a rat clone for ACE. A rat 
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lung cDNA library was screened for ACE sequences using clone 1 OA as a 
probe. 
This chapter details the isolation of two partial rat ACE cDNA clones and 
comparison of the sequence obtained with mouse and human ACE sequences 
already published. 
6.3. MATERIALS AND METHODS 
A cDNA library of lung mRNA obtained from a male Sprague-Dawley rat of 9 
weeks of age in lambda gT11 was purchased from Clontech (Catalogue No. 
RL 1008b). 
6.3.1. Labelling of clone 1 OA 
Clone 1 OA is a partial cDNA clone of human testicular ACE and was supplied 
subcloned into the pBluescript (Stratagene) vector at an approximate 
concentration of 1.3 µg/µI. The clone spans 2056 base pairs (bp) and covers 
most of the testicular ACE sequence. The insert was released by digestion with 
EcoRI and the purified insert used in the library screening. 
Clone 1 OA was transfected into competent E.coli, grown up in L-broth and DNA 
purified by the QIAGEN (Diagen) method (protocols detailed in appendix). 
Clone 10A (50µg) was cut with EcoRI in a volume of 120 µI for 2 hours at 37°C. 
A small portion of the digest was used to assess whether cutting was complete. 
In order to obtain sufficient insert separated from vector, the rest of the digest 
was loaded into 3 wells of a 1x TAE/1% Agarose gel (TAE = 0.04M Tris-
acetate, 0.001 M EDTA). The gel was run at 20mA and the gel containing the 
insert excised from the gel using a scalpel blade. The insert was then isolated 
by electroelution (section 9.1.8.). As the A2so was too low to read, 
concentration was assessed by running alongside various known 
concentrations of lambda DNA on a 1 % agarose gel. 
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1 OOng of linearised insert DNA was labelled with 32P-dCTP by random priming 
(section 9.1.10.). The probe was purified from unincorporated label by 
Sephadex G-50 chromatography prior to use. 
6.3.2. Isolation of rat ACE clones 
The commercially obtained library was titred by plating serial dilutions of the 
library on a lawn of LE392 (section 9.2.) E.coli cells (Borek et al., 1976) on L-
Broth agar/ top agarose plates. This was necessary so as to find the optimum 
ratio of library to cells for plaque screening. 
For the primary screening of the library, four 150mm plates were plated with a 
dilution of the library. After overnight incubation at 37°C, sufficient plaques had 
developed on the lawn for plaque lifts to be performed. The detail of the plaque 
lift procedure is to be found in the appendix (9.2.). The filters were probed with 
32p labelled clone 1 OA insert. Following hybridisation and washing, the filters 
were exposed overnight to X-ray film at -70°C. Positive signals on the 
developed film represented plaques with potential rat ACE containing 
sequences. 
After the initial screening at higher dilution, the positive plaques were cored 
from the plates and replated in order to obtain pure growths of positive plaques. 
Once this was achieved, large scale lambda preparations in NZC medium 
(containing NZ amine, NaCl, bacto yeast extract, casamino acids and 
MgS04•7H20) were made of the positives and the DNA purified by standard 
techniques (see appendix). 
The release of two putative rat ACE inserts (named RACE1 and RACE2) was 
achieved by EcoRI digestion of the purified DNA of each of the clones and the 
digests were analysed on a 1 % agarose gel. Sizes of the inserts were 
assessed by running alongside a marker of Hindlll digested lambda DNA 
6.3.3. Subcloning of RACE1 and RACE2 into pUC19 
In order to facilitate the sequencing of the two RACE inserts they were 
subcloned into pUC19. This was achieved by running EcoRI digested lambda 
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gT11 /RACE on a TAE agarose gel containing ethidium bromide. The gel was 
visualised on a UV light box and a slit cut in the gel just ahead of the insert 
band. Into this slit a small piece of Whatman 3M paper was inserted and 
electrophoresis resumed to move the insert into the paper. When this was 
judged to have occurred, the buffer containing the insert DNA was centrifuged 
from the paper (Errington, 1990). 
The inserts collected in this way were ligated into pUC19 using T4 DNA ligase 
and used to transform competent DK-1 cells. The cells were plated on L-broth 
ampicillin plates. Colonies were picked, DNA isolated and screened for inserts 
by EcoRI digestion. Large scale plasmid isolation was on QIAGEN columns 
according to the manufacturer's recommendations. 
6.3.4. Sequencing 
Double-stranded plasmid DNA of each of the clones was sequenced by the 
dideoxynucleotide chain-termination method (Sanger, et. al. 1977) using 
Sequenase (United States Biochemical). Oligonucleotide primers were 
synthesised on a Beckman model 200A DNA synthesiser. The full sequencing 
method is described in the appendix (9.4.) 
6.3.5. Sequence analysis 
Comparison of the sequence obtained for RACE1 and RACE2 to existing 
sequences contained in the GenEMBL nucleic acid sequence database was 
made using a VAX workstation running the program GCG (University of 
Wisconsin). 
6.3.6. Confirmation of probe utility 
As it is well known that in many mammalian species, somatic or lung ACE is 
larger than testicular ACE (discussed fully in the literature review), this feature 
was used to confirm that RACE1 could be used as a probe for rat ACE. 
RACE1 insert was labelled with 32p by the random primer method as described 
for clone 1 OA above. Sµg rat lung total RNA and 2µg rat testicular total RNA 
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was electrophoresed on a formaldehyde/agarose gel and blotted onto a nylon 
membrane. The blot was hybridised with labelled RACE1 insert and, after 
washing, exposed to X-ray film (full details of method in appendix, 9.5. & 9.6.). 
6.4. RESULTS 
6.4.1. Clone 1 OA insert isolation 
Clone 1 OA was successfully transfected into E.coli and grown up in L-broth. 
EcoRI digestion of the plasmid containing clone 1 OA revealed complete release 
of an insert corresponding to approximately 2kb. 
1 OA insert DNA was purified from vector, 1 OOng of insert was labelled by the 
random priming method and 32P-dCTP labelled DNA separated from 
unincorporated label by Sephadex G-50 chromatography. 
6.4.2. Isolation of rat ACE clones 
Serial dilutions of the library were plated on a lawn of competent LE392 cells 
and the library titre assessed at approximately 1 o9 plaque forming units (pfu) / 
ml. 
To screen the library, it was found that 4 µI of a 1 o-2 dilution of the library 
plated on a 150mm plate with 500µ1 of plating bacteria and 7ml top agarose, 
resulted in the optimum plating density for plaque screening. At this dilution 
there were approximately 50000 pfu per plate. As four plates were used in the 
initial screening, approximately 200000 pfu were screened. 
Plaque lifts were performed and subsequent screening with 1 OA insert yielded 
four strong positive plaques. These plaques were purified by further rounds of 
screening. During this process two of the positives were lost but the remaining 
two were purified to homogeneity after 4 rounds of screening. 
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Once single clones had been obtained, each of the two clones were 
innoculated into flasks of NZC medium (section 9.3.3.) and the DNA purified 
from large scale preparation. 
These two clones were labelled RACE1 and RACE2, and on agarose gel 
electrophoresis, after EcoRI excision from vector, RACE1 appeared to be 
approximately 1.9kb and RACE2 slightly longer at 2.1 kb (see figure 6.1 ). 




Figure 6.1. 1 % agarose gel electrophoresis of RACE 1 and RACE 2 after release from the 
vector. The lane marked ,._contains,._ cut with Hindlll, lane 1 contains RACE1 in pUC19 cut with EcoRI and lane 4, RACE2 treated similarly. 
6.4.3. . Subcloning of RACE1 and RACE2 into pUC19 
Using the technique of obtaining the cloned inserts in filter paper and 
subsequently ligating these into pUC19, subcloning was successfully achieved. 
Out of six random colonies screened for each of RACE1 and RACE2, four of 
each contained inserts. One of each 1 F and 2A were chosen, grown up in a 
large scale preparation and the DNA isolated using QIAGEN columns. 
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6.4.4. Sequencing 
Sequencing was carried out in both directions using the Sequenase method, 
initially using M13 universal primers and then other internal oligonucleotides. 
Usually each sequencing run allowed approximately 200 bases to be read, this 
sequence was used to determine suitable oligonucleotide sequences to 
continue the process. 
6.4.5. Sequence analysis 
Comparison of the RACE1 and RACE2 sequences showed them to be identical 
over the sequence spanned by RACE1, the shorter clone. Sequence 
comparison of the RACE1 sequence to that published for mouse ACE show 
approximately 90% identity for the corresponding section of mouse ACE cDNA. 
A similar comparison with the published human lung ACE cDNA sequence 
revealed identity of only 70%. 
The sequence of RACE1 corresponded closely to bases 1179 - 3134 of the 
mouse ACE sequence. This spans 1955 bp of mouse sequence, similar to the 
length of RACE1 as determined on agarose gel electrophoresis (1.9 kb). 
RACE2 maps alongside bases 830 - 3134 of mouse ACE (2304 bp). 
RACE1 and RACE2 were found to have been subcloned in opposite 
orientations to each other. Thus the forward sequence of RACE1 corresponded 
to the complementary reverse sequence of RACE2. 
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Mouse GGATCATAAAGAAGCTTCAGAACCTGGACCGGGCAGTGCTGCCTCCCAAGGAATTAGAAG 
11 I I I I I I I I I I 11 * 111111 11 * I I I 1111 I I I 1111 I I 11 I 11 I I I I* I I* I I I I I 11 Rat GGATCATAAAGAAGGTTCAGAACGTGGACCGGGCAGTGCTGCCTCCCAACGAGTTAGAAG 
11111111111111111111*11*1*11*1111111*1111111*11*1*111*1*11*1 Human GGATCATAAAGAAGGTTCAGGACCTAGAACGGGCAGCGCTGCCTGCCCAGGAGCTGGAGG 
120 
Mouse AGTACAACCAGATCCTGCTAGACATGGAGACAACTTACAGCTTATCCAACATTTGCTACA 
I I I I I I I I I I I I I I 11 I I I I I I I I I I I I I I I* I I I I I I I I** I I* I I I I** I I I I I I I I I Rat AGTACAACCAGATCCTGCTAGACATGGAGACGACTTACAGTGTAGCCAATGTTTGCTACA 
JI I I I I J l*I I I I JI J J*J*I J*J J J J J*I J*J J*J I JI J*J l*J I J l*I J l*I J l*J J* Human AGTACAACAAGATCCTGTTGGATATGGAAACCACCTACAGCGTGGCCACTGTGTGCCACC 
180 
Mouse CAAATGGCACTTGTATGCCCCTGGAACCTGATCTAACAAACATGATGGCCACATCCCGGA 
J JI J l*J JI I I I I J*J J*J*J I I J J*J JI I JI J l*J I JI J*J l*I I I JI J J J*J JI I JI I Rat CAAATTGCACTTGTCTGTCACTGGAGCCTGATCTGACAAATATAATGGCCACGTCCCGGA 




1111*I1111111111 * 111 I** 11 I 1111 I I 111 *** I 111111III111111111111 
Rat AATACGAAGAATTGCTTTGGGTGTGGAAGAGCTGGCAGGACAAGGTGGGGAGAGCCATCC 










* I I I I I I I I I I I I I I** I I I I I I I I I** I I I* I I* I I* I I I* I I* I I I I I I I I I I I I I I I 
Rat CTGATGCAGGGGATTGGTGGAGATCCTCATATGATTCCGACGACTTGGAGCAAGACCTGG 




I I I I I I l*I I I I I I I I I 11*1111111111*111*1*11*111111111111111*11*1 
Rat AAAAACTATACCAGGAGCTCCAGCCACTCTCCCTAACCCAGCATGCCTATGTGCGCCGCT 
I**** I I* I* I I I I I I I I I* I I I I I I I I I I* I I I* I* I I* I I I I I I I I I* I I I I I I I I** 
Human AGCGGCTCTTCCAGGAGCTGCAGCCACTCTACCTCAACCTGCATGCCTACGTGCGCCGGG 
Mouse CCCTGCACCGCCACTATGGGTCCGAGTACATCAACCTGGATGGCCCCATTCCTGCCCATC 
I I I I I I I I I I I I I* I I I I I I I I* I I I I I I I I I I I I I I I I I I I I* I I I I I I I I I I I I I I* I 
Rat CCCTGCACCGCCATTATGGGTCTGAGTACATCAACCTGGATGGTCCCATTCCTGCCCACC 
I I I I I I I I I I* I I* I I* I I I* I** I I* I I I I I I I I I I I I I* I I* I I I I I I I I I I I* I I I I 
Human CCCTGCACCGTCACTACGGGGCCCAGCACATCAACCTGGAGGGGCCCATTCCTGCTCACC 
Mouse TGCTAGGGAACATGTGGGCGCAGACCTGGTCCAACATCTATGATTTGGTGGCGCCCTTCC 
I I I I 1111111111*1111*11111*11111111111111111*11111111*1111111 
Rat TGCTAGGGAACATGTGGGCACAGACTTGGTCCAACATCTATGACTTGGTGGCACCCTTCC 
I I I I* I I I I I I I I I I I I I I* I I I I I* I I I I I I I I I I I I I I I I I I I I I I I I I** I I I I I I I 
Human TGCTGGGGAACATGTGGGCGCAGACCTGGTCCAACATCTATGACTTGGTGGTGCCCTTCC 
Mouse CTTCCGCCCCCAATATAGATGCCACGGAAGCCATGATAAAGCAGGGATGGACACCCAGAA 
I I I I I I I I I I I I* I I I I I I I I I I I I I I I* I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Rat CTTCCGCCCCCAGTATAGATGCCACGGAGGCCATGATAAAGCAGGGATGGACACCCAGAA 
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Figure 6.3. The 608 base partial sequence obtained from the 5' end of RACE1 showing the 
nucteotide sequence aligned with those of mouse and human ACE. Bases 1-608 of RACE1 
align to bases 1175-1782 of mouse ACE with 86. 7% identity and to bases 462-1069 with 7 4.6% 
homology to the published sequence for human ACE. The underlined portion of the rat 
sequence was used as the template for the riboprobes used in the study of rat ACE expression. 
The partial sequence of RACE1 has been deposited at Genbank, accession number L36664. 
92 
6.4.6. Confirmation of probe utility 
Northern blot analysis of rat lung and testicular total RNA, probed with labelled 
RACE1, revealed the expected difference in size between both ACE RNAs. 
This confirmed that RACE1 was indeed a rat ACE cDNA clone and could be 
used to probe rat ACE in further studies. 
6.5. DISCUSSION 
While it would not have been impossible to use the human testicular ACE clone 
to probe rat ACE, the lesser homology would have required less stringent 
washing with probably more background in order obtain a readable result on 
autoradiography. Indeed, a recent paper (Schunkert et al., 1990) described the 
use of a human ACE cDNA clone as a probe for rat heart ACE. However, each 
lane had to be loaded with 25µg of poly(A)+ RNA to achieve a useable signal. 
Using the methods described above, two partial clones for rat ACE were 
obtained. These proved to be clones of ACE both from sequence homology 
with published mouse and human ACE sequences, and by the finding that 
RACE1 hybridised to both lung and testicular ACE with the expected difference 
in mRNA size. 
The fact that neither of these clones extended 3' to incorporate a polyA tail and 
instead terminating at EcoRI sites, points to deficiencies in the manufacture of 
the commercially obtained oligo dT primed cDNA library. The most likely 
explanation is that rat ACE cDNA contains at least three internal EcoRI sites 
(because of the three distinct ends of RACE1 and RACE2) and that during 
library construction, these sites were not protected from EcoRI digestion, due to 
inadequate methylation. Hence the sequence 3' to the two clones were lost. 
As this study only required a portion of the rat sequence for use as a probe, no 
attempt was made to backscreen the library to obtain a full length clone, if this 
indeed existed in the library. 
93 
6.6. CONCLUSION 
Two partial rat ACE cDNA clones were isolated from a rat lung cDNA library. 
These clones were sequenced and strong homology noted between these and 
previously published sequences of human and mouse ACE. It was now 
possible to use these clones, or parts thereof, as probes of rat ACE in a study 
of the expression of rat ACE mRNA in response to pharmacological inhibition. 
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Chapter 7 
ACE mRNA AND PROTEIN EXPRESSION IN RESPONSE 
TO PHARMACOLOGICAL ACE INHIBITION. 
7.1. OBJECTIVE: 
To study the effects of ACE inhibition on ACE mRNA and protein expression in 
rat tissues. 
7.2. INTRODUCTION: 
The renin-angiotensin system plays a central role in the maintenance of blood 
pressure. Angiotensin II, the main effector of this system, results from the 
action of angiotensin-converting enzyme (ACE) on angiotensin I. Increased 
production of the vasoconstrictor, angiotensin II, maintains vasomotor tone. 
Further studies of the renin - angiotensin system have led to the development 
of ACE inhibitors for the treatment of hypertension and cardiac failure. These 
inhibitors include captopril, enalapril and lisinopril among others. While it was 
initially thought that the renin - angiotensin system was purely a circulating 
system, it has now been realised that local renin-angiotensin systems exist and 
that inhibition of ACE at the tissue level seems to more closely parallel the 
blood pressure response (Ferrario, 1990). 
Hypertensive patients on treatment with captopril were noted to have no 
significant change in serum ACE activity (Larochelle et al. 1979). It was initially 
thought therefore, that inhibition of ACE activity is not the mechanism by which 
captopril decreases blood pressure. Subsequently it was shown that captopril 
readily degrades, making it exceedingly difficult to assess the degree of ACE 
inhibition during therapy with this agent. In another study it was found that 
plasma ACE activity actually increases in hypertensive patients receiving 
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captopril over a period of several weeks, suggesting that ACE inhibitors 
actually enhance ACE production (Boomsma et al., 1981 ). 
The above studies prompted other workers to study the effect of ACE inhibitors 
on cultured endothelial cells, known to express ACE on their plasma 
membranes. These cells, when treated with captopril, were found to have 
increased ACE activity in their culture medium compared to control cells 
(Fhyrquist, et al., 1982a). 
Studies on spontaneously hypertensive rats confirmed that ACE activity is 
elevated in animals treated with captopril. Administration of captopril to rats for 
a period of 24 weeks resulted in a threefold increase in serum ACE activity and 
lung plasma membrane ACE activity compared to control animals (Fhyrquist, et 
al. 1980). Similar results were obtained for normotensive rats treated with 
enalapril for a period of seven days (Forslund, et al. 1982) where serum ACE 
activity increases by 280% and by 34% in lung plasma membranes. 
Spontaneously hypertensive rats treated with captopril show no induction of 
lung plasma membrane ACE following adrenalectomy suggesting that the 
adrenals play some role in the membrane incorporation of ACE (Fhyrquist, et 
al. 1982b ). The tissue specificity of the inductive response was suggested by 
the finding that lung ACE activity increases, whereas kidney ACE activity 
remains unchanged and testicular activity decreases after six weeks of 
treatment with captopril (Forslund et al., 1984). 
All the above studies utilised measurements of enzyme activity to deduce that 
this observed effect was due to increased ACE protein production. This 
necessitated the removal of the administered inhibitor either through extensive 
dialysis, chemical destruction or by allowing time for degradation to occur. 
Recently a novel method to assess both ACE inhibition and induction during 
inhibitor therapy has been described (Kohzuki et al., 1991 ). This technique 
involves quantitative in vitro autoradiography of serial sections from tissues of 
interest. The degree of ACE inhibition was determined by direct probing of 
sections with an 1125 labelled ACE inhibitor, MK 351A which is a tyrosyl 
derivative of the ACE inhibitor, lisinopril. After 14 days of treatment with 
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lisinopril, plasma ACE increases 75% while lung ACE as measured by 
autoradiography of the sections increases by 30% compared to untreated 
animals. These results showed no significant change in ACE concentration in 
the kidney, adrenal, aorta or testis. 
A greater insight into this induction mechanism is required as it may explain the 
observation that the degree of ACE inhibition decreases with chronic inhibitor 
therapy and also the tolerance that patients can develop to previously effective 
doses of ACE inhibitors ( Johnston, et al. 1988). Furthermore, the cost of these 
agents makes such an investigation all the more relevant. 
This study set out, first, to confirm that ACE inhibitor treatment in human 
subjects induces an increase in the concentration of circulating ACE as 
detected by radioimmunoassay; and second, to investigate the possible 
mechanism for this response, by studying the acute effects of ACE inhibition at 
both the protein and mRNA level in rat tissues. Unlike previous studies of rat 
ACE mRNA expression that utilised human cDNA probes, all experiments were 
performed using specific rat ACE cDNA-derived riboprobes. Also, ACE protein 
was measured by specific immunoassay, avoiding the need to derive data from 
activity assays. Our findings suggest that the induction mechanism depends on 
a more distal component of the renin angiotensin system pathway than 
angiotensin II, possibly aldosterone, the final effector of the system. 
7.3. SERUM ACE CONCENTRATION IN HUMAN PATIENTS 
UNDERGOING TREATMENT WITH CAPTOPRIL. 
7 .3.1. Methods 
7.3.1.1. Patient selection 
Ten patients undergoing treatment with captopril for congestive cardiac failure 
in the Cardiac Intensive Care Unit at Groote Schuur Hospital were included in 
the study. Blood was drawn for serum ACE concentration assay before the 
onset of treatment and again after four days of treatment with 6.25 mg captopril 
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8 hourly. Most patients received concurrent treatment with other standard anti-
failure therapy such as digoxin and furosemide (most patients had been on 
these latter two agents prior to their intensive care unit admission). 
7.3.1.2. Radioimmunoassay for human serum ACE 
This assay has been fully described in Chapter 4, detailing the development of 
immunoassays for human ACE. Results obtained were analysed using a paired 
t-test. 
7 .3.2. Results 
Of the 10 patients studied, 8 demonstrated significant elevation (p<0.05) in 
circulating ACE concentration after 4 days of captopril treatment. These results 
are shown in table 7.1 and fig.7.1. 
Patient [ACE] ng/ml 
Day 1 Day4 
I.A 158.3 189.9 
0.A. 379.9 299 
M.B. 333.7 289.8 
S.D. 209.5 309.7 
E.G. 406.7 421.5 
E.H. 408.6 504.8 
J.H. 453.7 581.6 
E.M. 335.4 396 
A.O. 287.9 428.9 
P.S. 298 356.6 
Table 7.1. Tabulation of the ACE concentrations, determined by radioimmunoassay, for each 
of the congestive cardiac failure patients treated with captopril for four days. Values on day 1 









Day 1 Day4 
Figure 7.1. Graphical representation of the change in serum ACE concentration, as measured 
by radioimmunoassay, in patients receiving captopril for congestive cardiac failure for three 
days. For most patients a significant increase in concentration was observed {p<0.05) between 
days 1 and 4. 
7.3.3. Discussion 
The results of this pilot study suggest that treatment with captopril elevates 
circulating ACE concentrations either by an inductive mechanism resulting in 
increased de novo ACE production or increased release of pre-existing ACE 
from endothelial surfaces. 
It must be acknowledged that the effect of the other agents used to treat these 
patients, most particularly furosemide, could also have resulted in an increased 
concentration of circulating ACE through diuresis, although the fluid lost during 
the treatment of congestive cardiac failure is predominantly interstitial and 
treatment, especially when it includes vasodilators such as nitrates or ACE 
inhibitors, may in fact initially result in an increase in intravascular volume. 
Therapy with ACE inhibitors such as captopril appears to elevate circulating 
ACE concentrations by an unknown mechanism. 
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The remainder of this chapter is devoted to an elucidation of this mechanism in 
a rat model. 
7.4. STUDY OF TISSUE AND SERUM ACE RESPONSES IN 
RA TS TREATED WITH THE ACE INHIBITOR ENALAPRIL 
BY MEASURING BOTH ACE PROTEIN AND ACE 
SPECIFIC mRNA. 
Many animal models of hypertension and studies of the effects of treatment 
with antihypertensive and other cardiac drugs utilise rats, due to their relative 
ease of breeding and handling. It was therefore decided to use rats in this 
study. 
The first part of the study set out to examine the acute effect of ACE inhibition 
on tissue renin-angiotensin systems in rat lung and testicular tissue. In order to 
study the potential feedback control mechanism of ACE induction, the effects of 
saralasin (an angiotensin II antagonist) and aldosterone (the final effector of 
the renin-angiotensin system) on ACE protein and mRNA were examined. 
Finally, the effect of chronic enalapril administration on circulating and tissue 
ACE was examined. 
In all these studies the ACE inhibitor enalapril (in the form of its maleate salt) 
was utilised. 
Northern blots were probed with a cloned rat riboprobe which has 90% and 
70% sequence homology with the mouse and human ACE genes respectively. 
The digoxigenin (Boehringer) method was used with detection based on the 
chemiluminescent substrate 3-(2' Spiroadamantane)-4-methoxy-4-3-(3"-
phosphoryloxy)-phenyl-1,2-dioxetane (AMPPD). Chemiluminescent detection 
has been reported to provide signals at least as strong as those obtained with 
isotopes such as 32p_ Unlike previous studies of rat ACE mRNA expression 
which utilised human cDNA probes, all experiments were performed using 
specific rat ACE cDNA derived riboprobes. 
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7 .4.1. Methods 
7.4.1.1. Rats 
All rats used in the study were male Long-Evans rats ranging between 250 -
350 grams in mass. All experimental protocols were submitted to the Animal 
Experimentation Committee of the University of Cape Town for their approval. 
All animals were fed normal rat chow and supplied with unlimited access to 
water. Rats were sacrificed by decapitation. Blood was collected into serum 
separation tubes, allowed to clot and then centrifuged briefly. The serum was 
aspirated, placed in Eppendorf microfuge tubes and stored at -70°C till 
assayed. Organs of interest for the tissue studies were rapidly excised, rin_sed 
with physiological saline and snap frozen in liquid nitrogen. Tissue was 
wrapped in aluminium foil and stored at -70°C until required. 
7.4.1.2. /mmunoassays for rat ACE 
Serum and tissue ACE were measured by ELISA (Chapter 5). In order to be 
able to assay tissue sample ACE concentrations with the ELISA it was 
necessary to detergent-solubilise the plasma membrane-bound enzyme. 
Approximately 100 mg of tissue was chipped from the frozen organs and placed 
in 1 ml of 25mM HEPES buffer, pH 7.4. The tissue was then homogenised in a 
glass/glass homogeniser and then a further 1 ml of the same buffer containing 
2% CHAPS (3-[(3-Cholamidopropyl)-dimethylammonio ]-1-propane-sulphonate) 
was added. The homogenate was briefly sonicated and incubated at 37°C for 
thirty minutes. The homogenate was clarified by centrifugation at 10000g for 30 
minutes before the supernatant was drawn off and utilised in the ELISA to 
measure ACE (three dilutions of the sample in duplicate were assayed) and 
total protein was measured by the method of Bradford (Bradford, 1976) using 
BioRad commercial reagent. Tissue concentrations are reported in µg ACE/mg 
protein. 
7.4.1.3. Isolation of rat ACE cDNA 
The isolation of the rat cDNA clones RACE1 and RACE2 was fully described in 
chapter 6. 
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7.4.1.4. Preparation of Digoxigenin-labelled probes 
A 400 bp fragment of RACE1 was obtained by restriction enzyme digestion of 
RACE 1 by the enzymes EcoR1 and Sph1. Complete digestion was 
ascertained by running the digest on a 2% agarose gel and the required 
fragment isolated by allowing it to migrate into a piece of Whatman 3M paper 
that was placed in a slit which was cut in the gel (Errington, 1990). The tiuffer 
containing the insert trapped in the filter paper was collected by brief 
centrifugation in a microfuge tube. This fragment was directionally subcloned 
(technique detailed in appendix) into the vector pGEM-3 which, after 
linearisation, allowed for the generation of sense and antisense strands, using 
the T7 and SP6 promoters of the vector and the corresponding RNA 
polymerases. Digoxigenin-labelled antisense RNA transcripts were obtained by 
using SP6 DNA dependent RNA polymerase in the presence of digoxigenin-11-
UTP (Holtke & Kessler, 1990) after linearisation with EcoRI (full details of the 
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Figure 7.2. Diagrammatic representation of the production of sense and antisense riboprobes from RACE1 in pGEM3. 
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As an internal standard, human 13,-Actin cDNA (Gunning et al., 1983) was cut 
with Xholl and Sal1 and the resulting ±540 bp restriction fragment directionally 
subcloned between the Sall and BamHI restriction sites of pGEM-3. 
Digoxigenin-labelled probe was prepared in an identical manner to that 
described above. The antisense actin probe was generated by linearising the 
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riboprobes 
Figure 7.3. Diagrammatic representation of the production of sense and antisense riboprobes 
from human ~ Actin in pGEM3. 
7.4.1.5. Assessment of probes 
Labelled probe was run on a formaldehyde agarose gel and then northern 
blotted in the standard manner. The membrane was then washed, blocked and 
probed with an anti-digoxigenin antibody and the labelled probe was visualised 
directly utilising the colorigenic substrate X-gal/nitroblue tetrazolium. In this 
way the purity of the labelled transcript could be assessed and the relative titre 
of different probes compared. 
Antisense probes to rat ACE and actin were also tested for their ability to detect 
their respective mRNA targets in total RNA in northern blots. 
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7.4.1.6. Northern blotting 
For all studies total RNA was isolated by the guanidinium isothiocyanate 
method (Chomczynski & Sacchi, 1987) as described in the appendix from rats 
immediately after sacrifice. Frozen tissue was retained in liquid nitrogen until 
required when approximately 100 mg was chipped off with a sterile blade. The 
tissue was then processed to obtain total RNA. RNA purity was assessed by 
running on 1 % agarose gels in the presence of ethidium bromide and 
observing the intensity of the 28s and 18s ribosomal bands. Evidence of lack of 
protein contamination was obtained from the OD 260/280 ratio which was 
always > 1.8. 
To assess the baseline ACE mRNA expression in normal rat tissue, total RNA 
was isolated from various tissues - lung, liver, kidney, testis, small bowel, 
spleen, brain and heart. Five µg of total RNA from each source ( except for 
testis where only 2 µg was used) was loaded into wells of a formaldehyde 
agarose gel and northern blotted as described in the appendix. 
For the studies of the effect of ACE inhibitor therapy on ACE mRNA, 5 µg of 
total lung RNA or 2 µg of testicular RNA (quantitated spectrophotometrically) 
was run on a formaldehyde agarose gel. After electrophoresis at 30 mA for 
approximately 3 hours, the RNA was transferred to a nylon membrane 
(Hybond-N, Amersham) overnight by capilliary blotting in the presence of 1 Ox 
SSC. After briefly rinsing the membrane in 6x SSC the RNA was fixed to the 
membrane by UV-crosslinking. The membrane was prehybridised and then 
probed with a mixture of the digoxigenin-labelled ACE and Actin probes. High 
stingency washes (final washes 0.1 x SSC, 0.1 % SOS at 68°C) and subsequent 
chemiluminescent detection of RNA using the substrate AMPPD was according 
to the manufacturer's instuctions (Boehringer). Normally an exposure to X-ray 
film of two hours at room temperature was sufficient. 
The relative intensity of the hybridisation signals obtained were quantified with 
a Hoefer GS300 Transmittance/Reflectance scanning densitometer (Hoefer 
Scientific Instruments, San Fransisco). Results were expressed in arbitrary 
transmission units and the ACE mRNA signal strengths controlled for loading 
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by hybridisation to actin. Equivalence of gel loading was also assessed by 
post transfer staining of the gel with ethidium bromide and post detection 
staining of the membrane with methylene blue. 
To assess the baseline ACE mRNA expression in normal rat tissues, total RNA 
was isolated from various tissues - lung, liver, kidney, testis, small bowel, 
spleen, brain and heart. Five µg of total RNA from each source (except for 
testis where only 2 µg was used) was fractionated on formaldehyde agarose 
gels and transferred u onto nylon membranes using standard techniques. 
7.4. 1. 7. Rat studies 
The effect of enalapril on rat ACE protein and mRNA levels were also 
assessed. Enalapril maleate, dissolved in physiological saline and filter 
sterilised (0.22µm filters Millipore), were given by intraperitoneal injection at a 
dose of 1 mg / kg body mass. 
Study 1: The effect of a single dose of enalapril maleate on lung ACE mRNA 
and protein was studied at the following time points, t = 0, 1, 2, 3, 4 and 6 hours 
(n = 3 per time point). Serum ACE activity was measured simultaneously 
utilising the spectrofluorimetric assay of Cushman and Cheung (1971 ). 
Testicular tissue was studied for ACE mRNA expression at the same time 
points . 
Study 2: The effect of a single dose of the angiotensin II antagonist, saralasin 
(Sigma) dissolved in physiological saline, administered by bolus intraperitoneal 
injection at a dose of 100 ng/kg body weight, was studied at t = 0, 2 and 4 
hours (n = 3 per time point). 
Study 3: The effect of a single dose of aldosterone administered 
subcutaneously at a dose of 15 µg/kg body weight with rats sacrificed at t = 0, t 
= 2 and t = 4 hours (n = 3 per group). 
Study 4: The effect of pretreatment with aldosterone administered 
subcutaneously at a dose of 15 µg/kg body weight followed, two hours later, by 
an intraperitoneal dose of enalapril. Rats were sacrificed at t = 0, t =: 2 and t = 4 
hours (n = 3 per group). 
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Study 5: Daily doses of enalapril were administered and animals (8 per group 
for serum levels and 3 per group for lung ACE mRNA and protein analysis) 
studied at Day 0, day 7 and day 14. 
7.4.2. . Results 
7.4.2.1. mRNA analysis 
The antisense ACE riboprobe sucessfully detected the two distinct forms of rat 
ACE when lung RNA (5 µg) and testicular total RNA (2 µg) were run on a 
formaldehyde agarose gel and northern blotted. An identical blot was probed 
with the actin ribopr6be. A marker lane was run with unlabelled mRNA markers 












Figure 7.4. Northern blot analysis of lung and testicular ACE. 5 µg total lung RNA and 2 µg 
total testicular RNA were fractionated on formaldehyde agarose gels. The RNA was blotted 
onto nylon membranes and the blot on the left probed with the antisense ACE riboprobe while 
the other blot was probed with the antisense actin riboprobe . 
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The ACE riboprobe hybridised to a lung mRNA of approximately 5.3 kb and a 
testis mRNA of approximately 3.5 kb. The actin riboprobe detected mRNA 
migrating at approximately 2.6 kb in both tissues. This demonstrated that the 
ACE antisense riboprobe was indeed specific. The human actin riboprobe 
detected rat actin mRNA with which it is known to share close sequence 
homology. 
Analysis of the labelled antisense riboprobes for ACE and actin showed both of 
these to migrate as a single band, suggesting that most transcripts were of 
equal length. 
7.4.2.2. Baseline ACE mRNA expression 
When 5 µg of total RNA from lung, liver, kidney, small bowel, spleen, brain and 
heart, and 2 µg total RNA from testis, were northern blotted and hybridized with 
the ACE riboprobe, only lung, testis and small bowel ACE mRNA were 
detected, whereas mRNA expression from the other organs appeared to be too 
low to detect. 
Figure 7.5. Northern blot of total mRNAs from the following rat tissues; Lanes 1-8 respectively, 
lung, liver, kidney, testis, small bowel, spleen, brain and heart. All samples were 5 µg total 
mRNA except testis which was 2 µg. Hybridisation signal were seen for lung, testis and small 
bowel. 
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7.4.2.3. Rat studies 
In order to perform a single dose time course, eighteen rats were divided into 6 
groups of 3 each and all animals were given an intraperitoneal injection of 
enalapril, the dose calculated according to their body weight (1 mg/kg body 
weight). 
ACE mRNA expression in lung tissue harvested from each group at t=O, 1, 2, 3, 
4, 6 hours was assessed by northern blotting. The autoradiographic results are 
depicted in figure 6 and show a significant elevation in ACE mRNA levels at t = 
1 hours with a peak at t = 3 and the t = 6 hour group demonstrating an ACE 
mRNA level less than that observed at t = O. 
Samples were also processed for lung ACE protein determination and the 
results are incorporated into figure 6 below. It can be seen that lung ACE 
concentration more than doubled within 4 hours to a value of 22.8 µg ACE/mg 
protein. 
Within the first hour of treatment, the serum ACE activity had fallen to less than 
10% of that observed in the t=O group (data not shown). 
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Figure 7.6. Effect of single dose on rat lung ACE mRNA (solid bars) and protein (open bars) at various 
time points. Eighteen rats were each given a single intraperitoneal injection of enalapril diluted in saline 
( 1 mg/kg body weight). Groups of rats ( each n = 3) were sacrificed at t = 0, 1, 2, 3, 4, 6 ( and 8 and 1 O hrs 
for ACE protein) hours. Lung tissue was obtained and total RNA subjected to formaldehyde agarose gel 
electrophoresis and northern blotting to a digoxigenin-labelled rat ACE and human actin riboprobe. 
Results of ACE mRNA levels were obtained by densitometric scanning of the resulting chemilumigrams, 
and are expressed as means±standard deviation. The actin signal was used for correction of track 
loading. Lung ACE protein was assayed by ELISA and expressed as mean µg ACE/mg total protein as 
measured by Bio-Rad assay. A significant peak elevation of ACE mRNA level was observed at t = 3 
(p<0.05 as compared tot= 0). 
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Testicular tissue from the same animals was also studied by northern blotting. 
Results indicate that ACE mRNA expression doubled within two hours and 
returned to baseline levels within six hours of enalapril administration (figure 
7.7). ACE protein was not assayed in these tissues. 
12 
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Figure 7.7. Effect of enalapril on testicular ACE mRNA. Eighteen rats given 1 mg enalapril/kg 
body weight by intraperitoneal injection were sacrificed in groups (each n = 3) at t = 0, 1, 2, 3, 
4, 6 hours after drug administration. Total RNA was extracted from samples of testicular tissue 
and subjected to formaldehyde agarose gel electrophoresis and northern blotting. Blots were 
probed with digoxigenin-labelled rat ACE and human actin riboprobes (to correct for track 
loading variations). Signals from chemilumigrams were analysed by densitometric scanning 
and results (in relative intensity units) for each group are depicted in this bar graph. One 
standard deviation is shown above each bar. A significant elevation of ACE mRNA level was 
observed at t = 2 (p<0.05 as compared tot= 0). 
Administration of the angiotensin II antagonist saralasin to rats resulted in a 
marked increase of lung ACE mRNA expression, with the t = 4 hour level 
almost eight times that at t = 0. Graphical representation of the results obtained 
is shown in figure 7 .8. 
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Figure 7.8. Effect of saralasin on lung ACE mRNA expression. Nine rats were each given a 
single intra peritoneal dose of saralasin (100 ng/kg body weight). Groups (each n = 3) were 
sacrificed at t = 0, 2 and 4 hours after dosage. Total RNA was extracted from samples of lung 
tissue and subjected to formaldehyde agarose gel electrophoresis and northern blotted. These 
were probed with digoxigenin-labelled riboprobes for rat ACE and human actin. Hybridisation 
signals were detected by chemiluminescence and analysed by densitometric scanning. The 
results, expressed in relative intensity units (corrected for loading variation by the actin 
hybridisation) are shown for each of the three groups. In each case the bar represents the 
mean and the line the standard deviation. A significant elevation of ACE mRNA expression was 
observed at t = 4 as compared to that at t = 0 (p<0.0001). 
In order to assess the effect of aldosterone alone, a time course study following 
a single intraperitoneal dose of aldosterone was pursued. ACE expression was 
unaffected, as can be seen by the relatively constant ACE expression for all 
time points (figure 7.9a). This indicated that aldosterone itself has no effect on 
normal unstimulated ACE mRNA expression. 
However, when animals were given aldosterone intraperitoneally followed 2 
hours later by a dose of enalapril at the same site, the previously demonstrated 
enalapril induced increase in ACE-specific lung mRNA was not observed. 
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Indeed ACE mRNA expression appeared to be greatly diminished compared to 
that found in untreated rats as evidenced by virtually no hybridisation signal on 
the northern blot (figure 7.9b). This suggests that the effect of enalapril may 
result from reduced aldosterone levels caused by ACE inhibition and that when 
supplementary aldosterone is given no inductive effect of enalapril is observed. 
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Figure 7.9a. Effect of aldosterone on lung ACE mRNA expression. Nine rats, each given a 
single subcutaneous injection of 15 µg aldosterone/kg body weight, were sacrificed in groups (n = 3) at t = 0, 2 and 4 hours after dosage. Lung ACE mRNA was studied by northern blotting. 
The resulting chemilumigram is shown here demonstrating no change in ACE mRNA 
expression at each of the time points. 
Figure 7.9b. Effect of aldosterone pretreatment on response of lung ACE mRNA expression to 
enalapril. Expression of lung ACE mRNA, where all animals were given a dose of aldosterone 
followed, two hours later, by a dose of enalapril was studied by northern blotting. Groups of 
three rats were sacrificed at t = 0, t = 2 and t = 4 after the enalapril dose. No ACE hybridisation 
signal is seen on the chemilumigram. 
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To study the effect of chronic enalapril administration, five groups of eight rats 
were given either enalapril or saline (controls) for varying periods as 
represented in table 1 and figure 5 (all results expressed as mean±S.D.). At t = 
O the mean serum ACE concentration as assayed by ELISA was 1189±213 
ng/ml. After 7 days of enalapril the mean ACE concentration had risen to 
2397±511.4 ng/ml (7 day saline control 1201.4±367.6 ng/ml) and by fourteen 
days of treatment levels had declined to 1765±379 ng/ml (14 day saline control 
1257.6±250 ng/ml). 
Study Group (each n=8) [ACE]±SEM (ng/ml) 
No Rx 1189±213 
7 days saline 1201±365 
7 days enalapril 2397±511 
14 days saline 1257±251 
14 days enalapril 1765±379 
Table 7.2. Effect of chronic enalapril administration on serum ACE: Groups of rats (each n = 8) 
were given daily intraperitoneal doses of either enalapril (1 mg/kg) or equivalent volumes of 
normal saline. After the required number of days treatment, and two hours after the last dose, 
the animals were sacrificed by decapitation. Blood samples were obtained and the serum 
assayed by ELISA. The results for each group are tabulated showing ACE concentration as 
mean±S.D. 
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Figure 7.10. Bar chart of ACE concentration for each of the rat treatment groups depicted in 
table 1 (each n = 8). One standard deviation is represented above each bar. 
Similar time points and control groups (all n = 3) were studied for lung ACE 
mRNA by northern blotting and the results quantified by densitometric 
scanning. The results showed no marked induction after 7 days of treatment, 
however it was interesting to note a subnormal ACE mRNA expression in the 
14-day treatment group suggesting down-regulated ACE expression ( data not 
shown). 
As with lung ACE mRNA, lung ACE protein was also assayed and revealed a 
mean ACE concentration at t = 0 of 11.6 µg ACE/mg protein, and after 7 days 
treatment no significant increase was observed (10.9 µg ACE/mg protein). 
However, after 14 days of treatment, the mean ACE concentration had risen to 
14.2 µg ACE/mg protein suggesting that accumulation of ACE protein persists 
well after ACE mRNA expression has returned to pretreatment levels. This 
suggests that plasma membrane ACE has a low turnover rate. 
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7 .4.3. Discussion 
This study clearly demonstrated that enalapril induced de nova synthesis of 
ACE in the lung and that the previously observed elevations in serum and 
tissue ACE enzyme activity are due to increased concentrations of ACE 
protein. 
As can be seen from the baseline ACE mRNA expression study in various 
tissues, it was only possible to accurately quantitate changes in lung and testis 
mRNA. Small bowel ACE mRNA detection is consistent with previous 
localisation by in vitro autoradiography of ACE within the villi of the duodenum 
and jejunum (Duggan et al., 1989). In the small bowel ACE is thought to play a 
role in the hydrolysis of dietary peptides. The structure, formation and secretion 
of ACE in the small bowel has recently been detailed (Nairn, 1992 and 1993) 
ACE inhibitors are considered not to affect testicular ACE due to the existence 
of a blood-testis barrier ( Jackson et al., 1988a ). It was therefore surprising to 
find a marked induction of testicular ACE mRNA in our study. A possible 
explanation is that the earliest post-dose sample in previous studies (6 hours) 
(Schunkert et al., 1993) was at a time at which ACE mRNA had already 
returned to baseline in our study. In our study greater sensitivity was obtained 
by utilising an ACE riboprobe derived from a rat ACE cloned template rather 
than utilising a human probe to detect rat ACE mRNA which, in a study of rat 
heart ACE mRNA, required loading of 25µg poly(A) RNA from heart, lung and 
testis in order to get a hybridisation signal (Schunkert et al., 1990). 
The finding that ACE mRNA in untreated tissues appears to be expressed at 
relatively low levels, despite its widespread endothelial distribution, suggests 
that the enzyme has a slow turnover rate (its half-life has been previously 
estimated to be 72 hours (Fhyrquist et al., 1983) ). This is further supported by 
the findings of the single dose time course that demonstrated elevated ACE 
protein concentration in tissue well after ACE-specific mRNA levels have 
declined. This indicates a very slow clearance rate of ACE from the body which 
supports the notion that, in the untreated animal, only a relatively low rate of 
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ACE production is required to maintain physiological tissue and serum ACE 
concentrations. 
In the single dose time course experiment (figure 5) lung ACE mRNA levels 
increased by approximately 156% three hours after administration of enalapril. 
Lung ACE protein concentrations, however reached a peak after 4 hours with 
an increase of more than 100%, suggesting there is a close temporal 
relationship between ACE mRNA expression and ACE protein levels. The 
finding that at 6 hours mRNA expression is near normal (when ACE protein 
levels are still elevated) suggests that excess ACE may indirectly be involved in 
feedback inhibition which down regulates further ACE production. 
ACE inhibitor administration to cultured porcine endothelial cells also results in 
a rapid increase of ACE mRNA expression (Oparil and King, 1992). Within 30 
minutes, ACE mRNA levels were increased, peaking initially at 2 hours and 
then again at 48 hours. A delayed increase in ACE activity in the culture 
medium was also observed. 
Although this study examined the acute effects of ACE inhibitor therapy, 
preliminary chronic studies (data not shown) have demonstrated diminished 
ACE production following the initial induction; after 14 days of ACE inhibitor 
therapy, the serum concentration of ACE is decreased compared to the levels 
attained after only 7 days of therapy. Thus, continuing ACE induction during 
chronic therapy does not appear to occur and a mechanism exists to limit 
production of ACE in the presence of excess enzyme. mRNA levels in animals 
treated for 7 and 14 days, even when harvested 2 hours after their last 
enalapril dose, did not show the same induction as was observed in the single 
dose time course. This provides further support for the presence of a negative 
feedback inhibition on ACE production. 
Down regulation of ACE production during chronic inhibitor therapy is further 
supported by the findings showing that, despite the fact that a single dose of 
enalapril induces a doubling of lung ACE protein, two weeks of daily enalapril 
doses produces an elevation of only 40% in the same tissue. This result is in 
agreement with the finding (utilising the technique of quantitative in vitro 
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autoradiography) that a two week administration of lisinopril (Kohzuki et al., 
1991 ), increased total lung ACE by 30%. 
Saralasin, an angiotensin II antagonist, produced an eight fold increase in lung 
ACE mRNA levels within four hours of administration. This suggests that 
angiotensin II receptor blockade and ACE inhibition provide similar inductive 
effects. The greater degree of induction observed for saralasin is probably due 
to more extensive abrogation of angiotensin II effects. A feedback mechanism 
then operates to overcome this block by stimulating increased ACE production. 
This finding indicates that the feedback mechanism that operates during ACE 
inhibition does not depend directly on angiotensin II levels but rather on the 
extent of angiotensin II receptor stimulation or on a more distal step in the 
pathway, eg. that of aldosterone production. The binding of angiotensin II and 
its role in the feedback inhibition of ACE synthesis has recently been 
suggested from autoregressive modelling of results in a study into the effect of 
captopril and other enzyme inhibitors on ACE in the rat (Wada et al., 1988). 
This prompted the study detailed in this chapter on the effect of aldosterone 
administration on lung ACE gene expression. Pretreatment of animals with 
aldosterone completely abolished the inductive response to enalapril. This 
finding, together with the observation that aldosterone administration on its own 
causes no effect on ACE gene expression, would indicate that the key factor in 
the enhancement of ACE production during ACE inhibitor therapy is the level of 
aldosterone present in the tissue. This finding contrasts with the observation 
that ACE levels are increased threefold when bovine endothelial cells in culture 
are exposed to aldosterone for 48 hours (Dasarathy et al., 1990). The reason 
for this difference between in vivo and in vitro observations is unclear but may 
point to the existence of other mediators in the feedback process. 
Although these studies were performed on lung tissue, it is possible that other 
tissues in which ACE production is elevated by inhibitor therapy respond in a 
similar manner, since aldosterone levels are governed by adrenal synthetic 
activity which could affect diverse tissues. The dependence of the inductive 
mechanism on adrenal activity was suggested by an earlier finding that 
adrenalectomy abolished the increase in lung ACE activity during inhibitor 
116 
therapy (Fhyrquist et al., 1982b). The difference in induction observed by other 
authors, between lung and kidney tissue for example (Kohzuki et al., 1991 ), 
probably relates to a differing degree of inducibility rather than the existence of 
other mechanisms. 
A recent study on the effect of the ACE inhibitor quinapril on tissue ACE activity 
and ACE mRNA in rats concluded that angiotensin II is the most likely agent 
responsible for the feedback regulation of ACE gene expression (Schunkert et 
al., 1993) . Infusion of angiotensin II resulted in decreased lung ACE gene 
expression and administration of quinapril increased lung ACE mRNA levels. 
However, this does not appear to be a complete explanation for the feedback 
process in light of our observations on the effects of saralasin and aldosterone, 
it is unlikely that angiotensin II is exerting a direct, receptor-independent effect 
on ACE mRNA and protein expression. Our data suggest that this feedback 
stimulation is mediated by reduced angiotensin II receptor stimulation, most 
likely by consequently reduced aldosterone levels. Interestingly, in the same 
study (Schunkert et al., 1993), no effect on testicular ACE mRNA was observed 
during ACE inhibitor therapy, but decreased mRNA levels were observed 
during angiotensin II infusion. 
The inductive effect of ACE inhibitors appears to be a general property as it 
has been reported for captopril (Fhyrquist et al., 1980), enalapril (Forslund et 
al., 1982) and lisinopril (Kohzuki et al., 1991 ). The ACE inhibitors vary in their 
degree of tissue distribution and inhibition, as has been shown in studies of 
temporal ex vivo radioligand binding on various tissues and inhibitors 
(Johnston et al., 1987). Multiple factors are thought to influence tissue 
bioavailability of ACE inhibitors (MacFayden et al., 1991 ); these are: 1. Plasma 
concentration; 2. Lipophilicity; 3. Relative quantities of plasma to tissue binding 
sites for the inhibitor; 4. degree and rate of interconversion between the 
inactive precursor and the active inhibitor (eg. enalapril/enalaprilat); 5. the 
presence of membrane barriers eg. blood/brain and blood/testis; and finally, 6. 
the rate of drug elimination from different tissue sites. These could be expected 
to result in differing degrees of induction between different tissues and 
inhibitors. 
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During the treatment of hypertension or cardiac failure, clinical doses of ACE 
inhibitors normally appear to be sufficient to overcome any degree of ACE 
induction, especially during chronic treatment (Jackson et al., 1984; Johnston 
et al., 1987). The results of our studies may explain why variability exists in 
therapeutic response at the inception of ACE inhibitor administration. This 
frequently results in ACE inhibitor dosages being increased in the first few days 
of treatment. It would be interesting to investigate whether, once tissue 
induction has been down-regulated by feedback mechanisms, patients could 
be adequately controlled on lower doses of ACE inhibitors than were initially 
used. 
In summary, ACE gene expression appears to be regulated by a feedback 
mechanism involving angiotensin II binding to its receptor and subsequent 
events such as aldosterone release. While these studies are among the first to 
systematically examine, with specific assays, ACE gene expression and ACE 
protein production following inhibitor treatment, providing greater insights into 
ACE regulation, further studies are required to gain greater understanding of 
the mechanisms involved. These may be aided with the sensitive RNA-PCR 
assays recently described for ACE (Paul and Schunkert, 1992) and the 




LOCALISATION OF THE INDUCTIVE RESPONSE IN VARIOUS TISSUES BY IN SITU HYBRIDISATION AND 
IMMUNO-HISTOCHEMISTRY. 
8.1. OBJECTIVE 
To localise the site of ACE mRNA and protein expression in response to ACE 
inhibition in sections of rat tissue. 
8.2. INTRODUCTION 
In the previous chapter, evidence was presented for the induction of ACE in rat 
lung tissue during treatment with enalapril. It is commonly accepted that the 
endothelium is the source of ACE in lung tissue and therefore, endothelial cells 
are most likely to be the site of the observed inductive effect. Endothelial cells 
in culture have indeed been shown to increase their ACE production during 
treatment with captopril (Fhyrquist et al., 1982). This has however, never been 
conclusively demonstrated, as no in situ hybridisation studies of ACE mRNA 
during enzyme inhibition have been reported to date in the literature. Sibony et 
al. (1993) have reported the use of nucleic acid probes to localise ACE mRNA 
in normal human and marmoset tissues, but, as for immunohistochemistry, has 
never been specifically applied during ACE inhibitor therapy. 
In situ hybridisation was first used to localise specific DNA sequences on 
chromosomes (Gall & Pardue, 1971 ). The technique has since been modified 
to allow for the detection and localisation of specific RNAs within tissues of 
many different organisms. Early studies described the localisation of viral or 
abundant cellular RNAs in cultured cells or tissue sections (Brahic & Haase, 
1978; Singer & Ward, 1982). Methods were developed which permitted 
detection of moderate to low abundance mRNAs and were used to describe the 
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expression and localization of genes regulating the embryonic and larval 
development of Drosophila. The sensitivity of methods using double stranded 
(Hafen et al., 1983) or single stranded (Akam, 1983) probes was further 
increased by the use of single stranded RNA probes (Cox et al., 1984) and 35S 
labelled probes (Augulewitsch et al., 1986). Non radioactive techniques have 
also been developed. Most commonly these have used biotin-substituted 
nucleotides to label probes which are then detected by either a fluorescent or 
colorigenic enzymatic system (Singer & Ward, 1982; Singer et al., 1986). More 
recently, greater sensitivity and decreased background signals have been 
reported for digoxigenin (Boehringer)-labelled probes (Springer et al., 1991 ). In 
the northern blot experiments reported in the previous chapter, digoxigenin-
labelled riboprobes were utilised and these same probes were used for the in 
situ studies reported here. 
While the technique of in situ hybridisation is more useful in localising specific 
mRNAs, it can also be used to provide a semi-quantitative insight into the 
degree of expression of a particular message. Thus, in the studies reported 
below, ACE mRNA expression was observed in tissues from rats at different 
time-points following enalapril administration. 
Both polyclonal and monoclonal antisera have been used for 
immunohistochemical localisation of ACE in a variety of species. From one of 
the earliest immunohistochemical studies (Caldwell et al., 1976) in the rabbit, it 
was known that ACE had a widespread tissue distribution in association with 
vascular endothelial cells. A similar enzyme distribution has been shown in rats 
(Moore et al., 1984) and human tissues (Danilov et al., 1987) using monoclonal 
antisera. ACE has also been demonstrated on the epithelial surfaces of renal 
proximal tubules (Caldwell et al., 1976; Tauc et al., 1988), testicular 
seminiferous tubules, brain ventricles (Auerbach et al., 1982) and intestinal 
epithelium (Bruneval et al., 1986). Recently specific polyclonal antibodies 
capable of differentiating between somatic and testicular ACE have been used 
to localise ACE in adult human and marmoset tissues (Sibony et al., 1993). 
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The monoclonal antisera to ACE and a riboprobe to rat ACE mRNA (described 
in sections 3.4. and 7 .2.1.4.) made it possible to combine the techniques of in 
situ hybridisation and immunohistochemistry to detail the induction of rat ACE 
by enalapril at a cellular level. 
8.3. IMMUNOHISTOCHEMISTRY 
8.3.1. Detection of rat ACE 
As described in Chapter 3, monoclonal 187 /18 was developed in mice against 
human lung ACE, but was found to cross-react with rat ACE. In the 
immunohistochemical studies this antibody was utilised in the form of ascitic 
fluid. 
8.3.2. Digoxigenin-labelled riboprobes 
Riboprobes were produced from the EcoRI/Sphl portion of the rat ACE clone 
RACE1 subcloned into the vector pGem-3. Plamid was linearised by digestion 
with EcoRI and SP6 RNA polymerase used to synthesize an antisense 
riboprobe. As a control, a sense riboprobe was derived by Sphl digestion and 
the use of T7 RNA polymerase. 
Other controls included in the study of mRNA expression were sections where 
no probe was used but the subsequent detection steps were still performed, ie. 
to test for non specificity of the detection system, and pretreatment of the 
sections with RNAse A prior to hybridisation. 
8.3.3. Tissue samples 
Male Long-Evans rats (approximately 250 g) were given a single intraperitoneal 
injection of enalapril maleate dissolved in physiological saline at a final dose of 
1 mg/kg body weight. 
Animals were sacrificed at t = O and t = 3 hours for in situ hybridisation and t = 
0 and t = 4 hours for immunohistochemistry. The organs examined were lung, 
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kidney, testis and heart. After sacrifice these organs were immediately cut into 
smaller pieces, to maximise fixation, and immersed in Bouin's solution (75 ml 
saturated aqueous picric acid , 25 ml 40% formaldehyde and 5 ml glacial acetic 
acid to a final volume of 105 ml). Fixation was allowed to proceed overnight 
before the tissues were processed and paraffin embedded using standard 
methodologies. 
8.3.4. In situ hybridisation 
Sections (3-5 µm) of the various samples were cut using a rotary microtome 
and placed on slides pre-treated with 3- (Triethoxylsilyl)-propylamine (APTES, 
Merck) and diethylpyrocarbonate (DEPC, Sigma). 
The detailed in situ hybridisation method is presented in the appendix (9.8.). 
The sections were dried onto the slides, dewaxed and rehydrated. Proteinase K 
digestion and fixation with freshly prepared 4% paraformaldehyde was 
performed before the sections were acetylated with acetic anhydride. After 
washing, the sections were once again dehydrated, dried and prehybridised for 
2 hours at 50°C. Hybridisation was performed overnight at 50°C with probe at 2 
ng/µI in hybridisation solution. After washing, digoxigenin-labelled probe was 
detected with antidigoxigenin/phosphatase conjugate and a colorigenic 
substrate, X-gal/nitroblue tetrazolium, resulting in a blue-black product. 
8.3.5. lmmunohistochemistry 
ACE protein in the sections was probed with the monoclonal antiserum and 
binding detected using a peroxidase-conjugated anti-mouse antibody. The 
presence of ACE protein in the sections is denoted by the brown reaction 




8.4.1. ACE mRNA and protein localization 
In lung tissue little baseline RNA expression could be seen in from cells, 
probably due to their small size (figure 1 ). The sense probe control section 
revealed no staining (not shown). Two hours after treatment with enalapril, it 
did not appear that there was a change in endothelial ACE mRNA expression, 
but alveolar macrophages were noted to have significantly increased 
expression (figure 2). This result was supported by the findings on 
immunohistochemistry (figure 8). 
In the kidney, ACE mRNA was found, as expected, in the glomerular 
endothelium and in the proximal tubular epithelium (figure 3). Treatment with 
enalapril significantly increased expression at these sites (figure 4). 
lmmunohistochemistry showed increased ACE protein at these sites four hours 
after dosage (figure 9 and 10). 
Cardiac tissue showed no staining of the myocardium, but the endocardial 
tissue did appear to have prominent ACE mRNA expression. On treatment with 
enalapril, ACE mRNA expression was markedly elevated in valvular tissue 
(figure 5). lmmunohistochemistry was not performed on heart tissue. 
Cross-sections of seminiferous tubules in sections of testicular tissue revealed 
ACE mRNA in the germinal epithelium (figure 6). A striking increase in germinal 
epithelial ACE protein could be seen in developing spermatozoa in the t = 4 
hour samples (figure 11 and 12). 
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Figure 1. Section of rat lung tissue (t = 0, x400), probed for ACE mRNA,showing minimal 
signal detection. 
Figure 2. Rat lung tissue (t = 2, x400), probed for ACE mRNA, showing marked alveolar 
macrophage expression. 
Figure 3. Rat kidney tissue (t = 0, x400), probed for ACE mRNA, showing slight glomerular and 
tubular epithelial expression. 
Figure 4. Rat kidney tissue (t = 2, x400), probed for ACE mRNA, showing enhanced 
glomerular and proximal tubular epithelial expression. 
Figure 5. Rat cardiac tissue (t = 2, x400) showing valve with marked endocardial and valvular 
ACE mRNA expression. 
Figure 6. Rat testicular tissue, sections of seminiferous tubule (t = 2, x400), showing germinal 
epithelial ACE mRNA expression. 
Figure 7. Rat lung tissue (t = 0, x400), immunohistochemistry for ACE, showing slight ACE 
expression in alveolar cells. 
Figure 8. Rat lung tissue (t = 4, x400), immunohistochemistry for ACE, showing enhanced 
alveolar endothelial ACE expression. 
Figure 9. Rat kidney tissue (t = 0, x400), immunohistochemistry for ACE, showing slight 
glomerular and tubular epithelial expression. 
Figure 1 o. Rat kidney tissue (t = 4, x400), immunohistochemistry for ACE, showing enhanced 
glomerular and proximal tubular epithelial expression. 
Figure 11. Section of seminiferous tubule (t = 0, x400), immunohistochemistry for ACE, 
showing germinal epithelial ACE expression. 
Figure 12. Section of seminiferous tubule (t = 4, x400), immunohistochemistry for ACE, 
showing marked germinal epithelial ACE expression extending with the developing spermatids 







In these studies the localization of ACE mRNA and protein were examined in 
rat tissues and the changes in response to ACE inhibition. 
While baseline lung ACE mRNA expression located in endothelium was to be 
expected, a novel observation was the fact that ACE expression was induced in 
macrophages, rather than in endothelial cells, during enalapril treatment. 
Macrophages are known to express ACE in sarcoid granulomata (Allen et al., 
1986). This effect appears to result from stimulation of ACE producing 
monocyte-derived granuloma epithelioid cells by T lymphocytes (Vuk-Pavlovic 
et al., 1988 and Vuk-Pavlovic et al., 1989) and has also been noted in 
circulating monocytes in sarcoid patients (Okabe et al., 1985). Steroids have 
also been observed to induce ACE production by rabbit alveolar macrophages 
in culture (Fiedland et al., 1977), but there are no reports of ACE induction in 
alveolar macrophages during ACE inhibitor therapy. 
Despite having identified alveolar macrophages as being the dominant site of 
inhibitor induced ACE induction in lung tissue, an important question still 
remains as to the exact nature of the mediator of feedback induction of ACE in 
tissues. A response to low levels of aldosterone is supported by decreased 
ACE mRNA expression in lungs of rats treated with aldosterone and an 
abrogation of inhibitor-induced induction when aldosterone is administered 
concurrently. However, adrenalectomy decreased lung and serum ACE activity 
and, when combined with inhibitor therapy, markedly reduced lung plasma 
membrane ACE activity, whereas an elevation in serum ACE activity was still 
observed (Fyhrquist et al., 1982b). This finding suggests that a more complex 
mechanism involving an adrenal-derived product other than aldosterone is 
responsible for the feedback mechanism, especially in the lung. 
It is interesting to note that bovine endothelial cells in culture (Mendelsohn et 
al., 1982; Dasarathy et al., 1990), perfused rat lungs ( lalenti et al., 1986) and 
rat lungs in vivo (Mendelsohn et al., 1982) increase ACE production when 
exposed to dexamethasone. 
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Steroid induction of ACE has recently been demonstrated to have a molecular 
basis with the finding of steroid responsive elements in the human and mouse 
ACE genes (Shai et al., 1990; Hubert et al., 1991). Mineralocorticoids such as 
aldosterone may act at these sites. Whether glucocorticoids play any role in the 
inhibitor mediated ACE induction of alveolar macrophages is unknown, but as 
yet there appears to be no evidence in the literature of ACE inhibitors inducing 
endogenous steroid production. 
The localisation of ACE mRNA and protein in the glomerular endothelium and 
the proximal convoluted tubules of renal tissue is consistent with previous 
immunohistochemical and in situ hybridisation studies reported in the literature 
(Tauc et al., 1988; Sibony et al., 1993). The potential consequences of 
induction of ACE production at these sites during ACE inhibitor therapy, 
particularly in the proximal tubules, are unknown. ACE is thought to be involved 
in sodium transport through the production of angiotensin II (Liu & Cogan, 
1987). Recently, angiotensinogen mRNA has been localised to the rat proximal 
tubule by in situ hybridisation (lngelfinger et al., 1990). Thus angiotensinogen 
and ACE are produced in the proximal convoluted tubule, implying that 
angiotensin II (Taugner et al., 1987) is locally generated at this site. As with 
ACE mRNA, angiotensinogen mRNA (lngelfinger et al., 1990) has been located 
in the glomeruli where a local RAS might have a role in glomerular tubular 
feedback, glomerular contractility and distal tubular function. 
The testis is protected from direct access by ACE inhibitors by a blood/testis 
barrier (Jackson et al., 1988a; 1988b). Finding evidence for ACE induction both 
in the kidney and in the seminiferous tubules of testicular tissue is in conflict 
with observations made with the technique of quantitative in vitro 
autoradiography (Kohzuki et al., 1991 ), where no induction was observed for 
either tissue. A possible explanation for this is that the Kohzuki study observed 
changes after two weeks of inhibitor treatment, by which time down-regulation 
of induction, observed in the previous chapter, would have occured. 
The localisation of ACE mRNA in the germinal tissue of the testis is consistent 
with the results of Sibony et al. (1993). Marked ACE protein induction after 
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enalapril therapy (seen in figures 11 and 12) shows ACE present in the 
germinal epithelium and extending into the lumen of the seminiferous tubules. 
The induction of testiclar ACE by enalapril points to the existence of an as yet 
unknown mechanism mediating the inductive process since ACE inhibitors 
such as perindopril (Jackson et al., 1988b) and quinapril (Fabris et al., 1990) 
are known not to penetrate the blood/testis barrier to any significant degree. 
Quinalapril did however, inhibit testicular ACE by up to 30%, which may 
indicate that certain ACE inhibitors can gain access to testicular tissues. The 
influence of testicular ACE induction, even if transient, on male fertility is also 
unknown. 
Finally, the localisation of ACE mRNA on endocardium and most markedly in 
cardiac valve leaflets, is consistent with results of in vitro autoradiography 
(Yamada et al., 1991 ). The physiological significance of this observation is 
unknown, but may suggest a role for ACE in the valve leaflets where it is well 
positioned for the intracardiac conversion of angiotensin I to angiotensin II, as 
well as the degradation of bradykinin and other circulating peptides. Little ACE 
mRNA was found in the myocardium except in association with the occasional 
coronary vessel. 
8.6. CONCLUSIONS 
• ACE mRNA and protein have been localised in sections of rat lung, heart, 
testis and kidney. 
• In all these tissues ACE was found to be induced by treatment with 
enalapril. 
• In the lung ACE, induction appears to be predominantly localised in alveolar 
macrophages rather than endothelium. 
• Marked induction was noted in the testis despite the existence of a putative 
blood/testis barrier. 
• In renal tissue, ACE was detected and induced in glomerular endothelium 
and proximal convoluted tubules. 
• Cardiac ACE was markedly induced in the valve leaflets. 
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SUMMARY AND FUTURE DIRECTIONS 
In this thesis methods have been perfected for the purification of rat somatic 
ACE. Polyclonal and monoclonal antibodies have been raised and these have 
been used to develop a sensitive ELISA for the measurement of rat ACE in 
serum and tissue extracts. 
A partial rat ACE cDNA clone has been isolated from a rat cDNA library, its 
identity confirmed, and used as a probe in a study of the expression of ACE 
mRNA in response to ACE inhibition in various rat tissues. The observed 
inductive response was localised by the method of in situ hybridisation using 
non-isotopic techniques. 
The studies described in the thesis have demonstrated that ACE mRNA and 
protein are induced in lung and testicular tissue during pharmacological 
inhibition with enalapril. This response is observed within hours of dosage. The 
effects of saralasin, an angiotensin II antagonist, and aldosterone have 
suggested that the induction of ACE by enalapril results either directly from 
reduced angiotensin II receptor or from a consequent reduction in aldosterone 
levels. Aldosterone itself does not appear to have any effect on ACE 
production. 
There are examples in the literature of the product of an enzymatic reaction 
regulating the expression prior enzymatic steps in a pathway. One such 
example is in the heme biosynthetic pathway in which a mechanism similar to 
that observed for ACE may be operating. Aminolaevulinic acid (ALA) 
synthetase is known to be regulated by heme, probably at the transcriptional 
level, where lack of the repressive effect of heme results in the feedback 
upregulation of ALA synthetase (Srivastava et al., 1988). Another example of 
defective binding of a substrate to receptor causing upregulation of precursor 
enzymatic steps is seen in the syndromes of glucocorticoid resistance 
(Chrousos et al., 1982). In these syndromes, production of intermediates of 
steroidogenesis by the adrenal is observed as a result of defects in the 
interaction of glucocorticoids with target tissues. 
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In situ hybridisation techniques have not only localised ACE in expected sites 
of rat tissues, such as renal tubular tissue and testicular germinal epithelium, 
but have confirmed the induction of ACE at these sites. Of particular interest, is 
that ACE induction in rat lung tissue, following enalapril dosage, is most 
marked in lung macrophages, and not solely in the capilliary endothelium. 
The various investigative tools established during the course of the studies 
toward this thesis should allow further detailed study of angiotensin converting 
enzyme in the rat. Having demonstrated that aldosterone may play an 
important role in the mechanism of ACE induction by enzyme inhibitors, a 
search for, and a study of, an aldosterone responsive element in the genomic 
DNA of rat ACE would conclusively prove this hypothesis. 
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Appendices 
9.1. CLONING AND LABELLING. 
9.1.1. Analysis of DNA fragments on 1 °/o agarose gels 
1% agarose in O.Sx TBE (0.045M Tris-borate, 0.001M EDTA prepared from 10x 
solution pH8) was prepared as follows; for 40 ml gel mix add 0.4 g agarose to 
40 ml TBE in a conical flask. The flask was weighed and swirled to mix 
contents before warming on "High" in microwave oven. To prevent from boiling 
over the heating was stopped regularly and the flask swirled. This was 
continued until no more "lenses" of undissolved agarose were visible. The flask 
was reweighed and more buffer added to replace vapour losses during heating. 
The flask was allowed to cool slightly, 2 µI Ethidium bromide (giving an 
approximate concentration of 0.5 µg/ml) added and the contents poured into a 
horizontal gel apparatus. The comb was inserted and the gel allowed to set at 
room temperature. 
The gel was then immersed in a gel tank filled with O.Sx TBE. Samples were 
prepared by the addition of 116th volume sample dye (0.25% bromophenol 
blue, 0.25% xylene cyanol FF, 30% glycerol in water). A marker consisting of 
unmethylated lambda DNA digested with either EcoRI of Pvull was added to a 
well as required. Samples were then denatured at 55°C for 1 O minutes, rapidly 
cooled on ice and loaded into the wells. Gels were run at 40 mA until the 
tracking dye was considered to have advanced sufficiently. The gel was then 
removed and viewed on a UV viewing box. 
9.1.2. L-Broth. 
For 1 liter: 
1 O g Tryptone / 5 g yeast extract I 5 g NaCl / 2 g glucose made up with 
deionised water and autoclaved. 
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9.1.3. L-broth agar plates. 
15 g bacto-agar per liter of L-broth. This was sterilised and plates poured. 
9.1.4. Ampicillin plates. 
The following solution was autoclaved and allowed to cool before adding 2.5 ml 
of 10 mg/ml ampicillin to a final concentration of 50 µg/ml. 
Tryptone 5 g / Yeast extract 2.5 g I NaCl 2.5 g I Glucose 1 g / Bacto-agar 7.5 g 
in 500 ml water. 
20 ml of this solutio.n was poured into each 100mm plate and allowed to set. 
The plates were either used immediately or stored inverted, protected from 
light, at 4°C for up to a few weeks. 
9.1.5. Transformation of plasmids. 
100 µI of competent E.coli (DK-1) cells in suspension were thawed on ice for 30 
minutes. 0.5 µI of plasmid ligation mix was added, the tube mixed and placed 
on ice for 30 minutes. The cells were heat shocked in 42°C waterbath for three 
minutes before 1 ml L-broth was added, which had been prewarmed to 37°C, 
and incubated for 1 hour in 37°C waterbath. 100 µI of the solution containing 
the transformed cells were plated onto a prewarmed L-broth agar/ampicillin 
plate and spread with flame sterilised shaped glass rod. After a few minutes the 
plate was inverted and incubated overnight at 37°C. Transformation control 
was always included using circularised (uncut) pUC19. The next morning, the 
plates were examined for colonies and some selected for rapid prep. screening. 
9.1.6. Rapid prep. screening. 
Sterile 10ml centrifuge tubes were filled with 7 ml L-broth under sterile 
conditions. 70 µI ampicillin stock (to give 50 µg/ml) was added to each tube. 
Individual colonies were picked with a sterile Gilson pipette tip and expelled 
into individual tubes. The capped tubes were swirled and placed in an orbital 
shaker set at 37°C, overnight. The following morning, glycerol stocks of each 
tube were made by adding 600 µI culture to 400 µI sterile glycerol. This was 
mixed and allowed to stand at room temperature for a few hours before storing 
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at -70°C. Tubes were then spun for 10 minutes at 2000 rpm. The supernatant 
was poured off and the pellet resuspended in 200 µI of 25mM Tris pH 8, 1 OmM 
EDT A, 50mM glucose and transferred to a microfuge tube. The tubes were left 
to stand at room temperature for 5 minutes. The 400 µI of a 1 % SOS, 0.2N 
NaOH solution was added, the tubes mixed and stood on ice for 5 minutes. 
Finally 300 µI of a solution of 3M KAc pH4.8 was added, the tubes mixed gently 
and placed on ice for 5-1 O minutes. Tubes were centrifuged twice in a 
microfuge at 10000 rpm, each time saving supernatant and transferring to new 
tube. DNA was precipitated by adding cold isopropanol at a ratio of 0.8 
suspension:0.6 isopropanol and incubating at -20°C for 2 hours. Then the tube 
was centrifuged in microfuge for 10 minutes, the supernatant poured off and 
750 µI cold 70% ethanol added. This was repeated. The pellet was vacuum 
dryed and resuspended in a small volume of TE buffer (1 OmM Tris/HCI 1 mM 
EDTA, pH 8). 
Restriction digest was usually performed to check for inserts on agarose gel 
electrophoresis. 
9.1. 7. Large scale plasmid preps. using QIAGEN method. 
Plasmids were grown up in in 500 ml L-broth with ampicillin overnight in orbital 
shaker at 37°C. Pelleting of the bacteria was achieved by centrifugation of the 
overnight culture at 9000 rpm for 1 O minutes at 4°C. The bacterial pellet was 
then resuspended in buffer P1 (1 OOµg/ml RNAseA, 50mM Tris/HCI, 1 OmM 
EDTA, pH 8.0). Once resuspended, 10 ml of buffer P2 (200mM NaOH, 1% 
SOS) was added and incubated at room temperature for 5 minutes. Then 10 ml 
of buffer P3 (2.SSM KAc, pH 4.8) was added, this was gently mixed and then 
centrifuged at 16000xg for 30 minutes at 4°C. According to the kit 
manufacturers, a QIAGEN column was equilibrated with buffer QBT (750mM 
NaCl, SOmM MOPS, 15% ethanol, pH 7.0, 0.15% Triton X-100). The 
supernatant from the preceding centrifugation step was applied to the column 
and allowed to enter the resin by gravity flow. The column was then washed 
with 30 ml buffer QC (1 M NaCl, 50mM MOPS, 15% ethanol, pH 7) and the DNA 
eluted with 15 ml buffer QF (1.25M NaCl, SOmM MOPS, 15% ethanol, pH 8.2). 
The DNA was precipitated with 0. 7 volumes isopropanol at room temperature 
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and pelleted at 1 OOOOg for 30 minutes. The DNA was washed with 70% 
ethanol, air dried and redissolved in a volume of TE buffer to achieve an 
approximate DNA concentration of 1 µg/µI ( as assessed 
spectrophotometrically). 
9.1.8. Electroelution of DNA into dialysis bags 
The restriction digest was run on a 1xTAE (0.04M Tris-acetate,0.001 M EDTA) / 
1 % Agarose gel at 20 mA. The gel was viewed on a UV lightbox and working as 
rapidly as possible, the insert containg gel slices excised with a scalpel blade. 
Sterile dialysis tubing was prepared by boiling in 1 mM EDTA for 5 minutes, 
rinsing with deionised water and placed in a Schott bottle and autoclaved. The 
slices were placed in a small piece of dialysis tubing (Spectrapor) which was 
filled with 1xTAE. The dialysis tubing was immersed in a gel tank filled with 
1xTAE and power applied at 25 mA for 2-3 hours. For 1 minute polarity was 
reversed and run at 100 mA to dislodge DNA from inner wall of tubing. The 
dialysis tubing was removed from the tank and all the buffer surrounding the 
gel slices collected. DNA was purified by phenol/chloroform extraction and 
precipitated with 2.5 volumes 96% ethanol and 1/10 volume 3M sodium 
acetate. The pellet was washed twice with 70% ethanol, vacuum dryed and 
resuspended in a small volume of TE buffer. 
9.1.9. Chloroform-isoamyl alcohol. 
Chloroform : lsoamylalcohol = 24: 1 
9.1.10. Labelling of DNA by the technique of random priming. 
100 ng of linear DNA was denatured by heating at 90°C for 1 O minutes then 
placing on ice. The denatured DNA was incubated with 1 x primer mix 
(containing random primers), 50µCi of 32P-dCTP (3000 Ci/mole - Amersham), 
25µM dATP, 25µM dGTP, 25µM dTTP and 2 units of DNA polymerase I in a 
final volume of 20 µI at 37°C for 30 minutes. The reaction was terminated by 
the addition of 2 µI 0.2M EDTA pH8 and 78 µI TE buffer. The free 32P-dCTP 
was separated from that incorporated by chromatography on Sepahadex G-50. 
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9.2. PLAQUE SCREENING. 
9.2.1. Stock of LE392 plating cells. 
To 50 ml of L-broth, 1 ml 20% maltose and 20 µI of a glycerol stock of LE392 
(derived from a sinle colony by prior plating). The cells were grown overnight in 
an orbital shaker at 37°C. The next morning 50 ml of sterile L-broth with 0.2% 
maltose was innoculated with 1 ml of the overnight culture and was incubated 
in an orbital shaker at 37°C until the 00500 had reached between 0.5 and 0.7. 
The cells were then cooled on ice for a few minutes before being pelleted at 
2000rpm for 1 O minutes at 4°C. The cell pellet was then resuspended in 15 ml 
of 1 OmM MgS04. The cells were kept at 4°C and were used for up to 3 weeks. 
9.2.2. Top Agarose. 
0.6g agarose was added to 100 ml L-broth and autoclaved. Just before plating 
the top agarose was melted in a microwave oven allowed to cool slightly and 1 
ml 1 M MgS04 added. 
9.3. PLATING OF LIBRARY FOR PLAQUE SCREENING. 
9.3.1. Plaque lifts 
LE392 cells, an aliquot of the cDNA library and top agarose were mixed and 
overlaid on a L-broth agar plate, allowed to cool and incubated at 37°C. After 
sufficient plaque growth had occured, the plates were stored at 4 °C for 
approximately one hour. The plaques were then overlaid with Hybond-N filters 
and the filter orientation marked by piercing both filter and agar with a sterile 
needle. The filters were left in contact with the plaques for 10 minutes before 
being removed and laid, plaque side up, on blotting paper to air dry for 10 
minutes. Two glass trays were prepared by placing a piece of Whatman paper 
at the bottom and soaking that in the first tray with denaturing solution (0.2N 
NaOH, 1.5M NaCl) and that in the second tray with neutralising solution (0.5M 
Tris pH 7.4, 1.5M NaCl). The plaque lift filters were then laid firstly in the 
denaturing tray for 2-3 minutes and then in the neutralising tray for 5 minutes 
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before being allowed to air dry. The filters were then baked in an oven set at 
80°C for 2 hours and were then ready for prehybridisation. 
9.3.2. Hybridisation of filters 
The baked filters were placed in separate glass bottles and each was filled with 
5 ml of prehybridisation solution (6x SSC, Sx Denhart's solution, 0.5% SOS and 
SOµg/ml denatured herring sperm DNA). Prehybridisation was allowed to 
proceed for 2 hours at 65°C in a Hybaid hybridisation oven. The 
prehybridisation solution was then replaced with the same volume of 
hybridisation solution (prehybridisation solution with 2 million cpm/ml of 32p 
labelled clone 1 QA Hybridisation was carried out overnight at 65°C. The filters 
were then washed twice with 50 ml 2x SSC, 0.1 % SOS for 15 minutes each and 
then twice with 50 ml 0.1 x SSC, 0.1 % SOS also for 15 minutes each. The filters 
were sealed in plastic bags and exposed to X-ray film (Cronex) in cassettes 
which were placed at -70°C overnight. The autoradiographs were developed 
and the location of positives found. 
Areas containing positive plaques that were selected for rescreening were 
cored out using a sterile pasteur pipette. The cores were expelled into 
individual Eppendorf microfuge tubes filled with 1 ml SM buffer (5.8g NaCl, 2g 
MgS04•7H20, 50ml 1M Tris•CI pH 7.5, 5 ml 2% gelatin solution and water to 1 
liter, autoclave sterilised). The plaques were allowed to elute into the SM on ice 
with occasional shaking before the buffer was drawn off and placed in a new 
tube. 20 µI chloroform was added to stop bacterial growth and the plaque 
extract stored at 4°C till required. 
9.3.3. NZC medium with casamino acids. 
To 950 ml deionised water, 10 g NZ amine, 5 g NaCl, 2 g MgS04•6H20 were 
added and shaken until dissolved. The pH was adjusted to 7.0 by the addition 
of 200 µI SN NaOH. The volume was brought up to 1 liter with deionised H20 
and was autoclaved. Then 250 µI of a sterile solution of 20% casamino acids 
was added. 
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9.3.4. Large scale lambda preparation. 
In a tube the following were mixed; 1 ml of an overnight culture of LE392 cells, 
1 ml of phage lysate with 106-109 pfu and 1 ml 10mM MgCl2,CaCl2 and this 
was placed at 37°C for 15 minutes before being added to a flask of 500 ml NZC 
medium with casamino acids. This culture was allowed to grow at 37°C in an 
orbital shaker for approximately 6 hours until lysis had been noted and then a 
further 45 minutes shaking was performed. 1 ml chloroform was added to 
promote lysis. The flask was placed on ice for 1 O minutes before the contents 
was centrifuged at 9000rpm for 15 minutes at 4°C. The supernatant was 
collected and was tr·eated with 150 µI 1 O mg/ml RNAse and DNAse to destroy 
host nucleic acids. To dissociate bacteriophage from the debris NaCl was 
added to a final concentration of 1 M and was dissolved by swirling and then 
placed on ice for 1 hour. Polyethylene glycol (PEG 8000) was added to a final 
concentration of 10% and the flasks were allowed to stand on ice for at least 1 
hour. Bacteriophage was recovered by centrifugation at 9000rpm for 13 
minutes at 4°C and the pellet resuspended in 8 ml SM buffer. This was 
transferred to a glass Corex tubes and 8ml chloroform/isoamyl alcohol added. 
This was vortexed and then centrifuged at 5000 rpm at 4°C for 15 minutes to 
pellet the PEG and debris. The phages were collected by centrifugation at 
27000 rpm for 2 hours at 15°C and the pellet resuspended in 400 µI SOmM 
Tris•CI pH 8. Phage coats were removed by treatments with centrifugation; 
twice with phenol, twice with phenol/CIAA and twice with CIAA alone. The DNA 
was then precipitated with ethanol/Na acetate, pelleted by centrifugation, 
washed twice with 70% ethanol, vacuum dryed and redissolved in 
approximately 300 µI TE buffer. 
9.4. SEQUENCING 
Modified T7 DNA polymerase (Sequenase) was used for the sequencing of 
double stranded, pUC19 derived plasmids. The primer was annealed to the 
plasmid as follows. 1-2 µg of pUC 19 double stranded plasmid in 8 µI water was 
denatured at 37°C for 30 minutes by the addition of 2 µI of 1 N NaOH. The 
plasmid was then neutralised by the addition of 7 µI of TE and 2 µI of 1 N HCI. 
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The M13 universal primer or the reverse primer (1 µI of 0.5 pg/µI) was then 
added and left at 37°C for 30 minutes. Precipitation was carried out by the 
addition of 50 µI of 96% ethanol at -20°C overnight. The annealed 
plasmid/primer was centrifuged for 10 minutes, washed with 70% ethanol, dried 
and reconstituted in 8 µI water and 2 µI Sequenase buffer (200mM Tris/HCI, 
1 OOmM MgCl2, 250mM NaCl pH 7.5). The annealed DNA mix was incubated at 
room temperature for 5 minutes with 6.25mM fresh dithiothreitol, 0.2µM dNTPs 
(dATP, dGTP, dTIP), 10µCi 32P-dCTP and 2 units of Sequenase (modified T7 
DNA polymerase) in a final volume of 15.5 µI. The reaction was terminated by 
adding 3.5 µI of the above to 2.5 µI of prewarmed termination mix at 37°C. 
There were four termination mixes, each containing a specific 
dideoxynucleotide. Termination was continued for 5 minutes at 37°C and was 
then stopped by the addition of 4 µI Sequenase stop buffer (95% formamide, 
20mM EDTA, 0.05% Bromophenol blue and 0.05% Xylene cyanol). This 
mixture was heated for 2 minutes at 75°C and placed on ice. The samples (3 
µI) were then loaded onto a 1 meter vertical polyacrylamide gel and 
electrophoresed for 6-18 hours at a constant voltage of 2400V. 
9.4.1. Sequencing Gel 
A polyacrylamide/urea gel was prepared as follows: 
For a 10% gel the following were mixed and heated until the urea had 
dissolved: 







to final vol. of 200 ml 
After degassing the solution, 300 µI of ammonium persulphate and 50 µI of 
TEMED were added to a 50 ml aliquot and poured. Once poured the gel was 
allowed to set overnight and electophoresed for an hour prior to loading. 
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9.5. RNA EXTRACTION. 
9.5.1. Solution D. 
Guanidinium thiocyanate 125 g was added to 146,5 ml water to which was 
added 8.8 ml 0.75M Na citrate, pH 7 and 13.2 ml 10% Sarkosyl. This stock 
solution was kept for up to three months at room temperature. To make the 
solution D working solution, 360 µI of 2-mercaptoethanol was added to 50 ml of 
the stock solution. This solution had a shelf life of 1 month. 
9.5.2. RNA extraction from tissues. (Chomczynski & Sacchi, 
1987) 
Tissue were stored at in liquid nitrogen until utilised. A pea sized piece of 
tissue was cut with a scalpel blade and placed immediately in 5 ml solution D. 
This was then thouroughly homogenised with a small Ultra-turrax till all tissue 
was disrupted. To this was added 0.5 ml 2M Na acetate pH 4, 5 ml 
diethylpyrocarbonate (DEPC) water saturated phenol and 1 ml 
chloroform/isoamylalcohol ( 49: 1) and the tube was mixed and placed on ice for 
15 minutes. Samples were then centrifuged at 10000g for 20 minutes at 4 °C 
after which the RNA containing aqueous phase was transferred to a new tube. 
1 ml isopropanol was added and the RNA precipitated for 1 hour at -20°C. 
Centrifugation at 1 OOOOxg for 20 minutes was repeated, the supernatant 
discarded and the pellet resuspended in 300 µI of solution D. An equal volume 
of isopropanol was added and precipitation allowed to proceed at -20°C 
overnight. The samples were then centrifuged at 1 OOOOxg for 10 minutes at 4°C 
and the pellet washed with 70% ethanol in DEPC treated water. The pellet was 
vacuum dried and resuspended either in a small volume of DEPC water or in 
0.5% SDS/DEPC water. 
Concentration of RNA was assessed by measuring the absorbance at 260nm. 
RNA concentration (µg/ml) = A250 x 40. The A25ofA280 ratio was taken as a 
measure of RNA purity, the ratio was always greater than 1.8, 1.9-2.0 being 
optimal. 
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9.6. NORTHERN BLOTS 
9.6.1. Denhart's solution. 
0.02% Ficoll 400 I 0.02% polyvinylpyrolidone / 0.02% BSA 
9.6.2. 5x RNA gel running buffer. 
0.2M Morpholinopropansulphonic acid (MOPS)/ 50mM NaAc / 50mM EDTA pH 
7. 
9.6.3. 20x SSC.' 
0.1 SM NaCl I 0.015M Na citrate pH 7. 
9.6.4. Preparation of Formaldehyde/agarose gel for northern 
blots 
0.4 g of agarose was melted in 23.3 ml water. To this solution was added 5 ml 
5x RNA running buffer and 8.53 ml formaldehyde. This was thouroughly mixed, 
poured into a horizontal gel former and allowed to set at room temperature in a 
fume hood. 
5 µI of sample total RNA (in a volume of not more than 1 OµI) was dispenssed 
into a DEPC treated Eppendorf microfuge tube. To each tube was added; 3.3 µI 
DEPC-H20, 1.5 µI 10x RNA running buffer, 7.5 µI deionised formamide, 2.7 µI 
formaldehyde and 1.5 µI RNA loading buffer. Normally the above was premixed 
and added in a single step to each sample. After mixing each sample was 
denatured at 55°C for 15 minutes before being rapidly ice cooled and loaded in 
to the gel wells. After electrophoresis at 30 mA for approximately 3 hours, the 
RNA was transfered to a nylon membrane (Hybond-N - Amersham) by 
overnight capilliary blotting in presence of 1 Ox SSC ( from 20xSSC stock -
0.15M NaCl/ 0.015M Na citrate pH 7). After briefly rinsing the membrane in 6x 
SSC the RNA was fixed to the membrane by UV-crosslinking. The membrane 
was prehybridised in hybridisation solution (5x SSC, 5% blocking reagent, 50% 
formamide, 0.02% SOS, 0.1 % Sarcosyl) and then hybridised in the same 
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solution containing 50ng/ml digoxigenin-labelled ACE and actin probes. High 
stingency washes (final washes - 0.1x SSC, 0.1 % SOS at 68°C) and 
subsequent chemiluminescent detection of RNA using the substrate AMPPD 
was according to the manufacturer's instuctions (Boehringer). 
9.7. ACE ENZYME ASSAY 
ACE activity was assayed using the spectrofluorimetric method utilising the 
artificial substrate Hip-His-Leu. This assay relies on the formation of a 
fluorescent adduct of o-phthaldialdehyde and the histidyl group of the L-
histidyl-L-leucine product formed from Hip-His-Leu. The molar quantity of the 
product formed by the ACE containing sample was estimated by interpolation 
from a standard curve of flourescent readings determined for five standard 
dilutions of the product L-histidyl-L-leucine. The standard curve was obtained 
by subjecting the flourescence data of the standards to least-squares linear 
regression analysis on a Hewlett-Packard HP97 programmable calculator using 
a curve fitting program. 
9.7.1. Solutions 
Buffer: Phosphate-buffered saline (PBS) 0.5M potassium phosphate (pH 8.3), 
1.5M sodium chloride. 
Substrate: 8. 735 mg Hip-His-Leu (HHL) was dissolved in 0. 75 ml of 0.025M 
sodium hydroxide (dissolution effected by agitation and immersion in hot 
water). The substrate buffer solution was made by adding 0. 75 ml PBS and 2.1 
ml water to the substrate solution. Thus in the final assay mixture of 120 µI 
substrate-buffer solution and 5 µI enzyme sample, the concentrations were: 
5.4mM substrate, 1 OOmM potassium phosphate and 300mM sodium chloride. 
Standard solution: 1.386 mg L-His-L-Leu (HL) dissolved in 1 O ml water. 
0-phthaldialdehyde solution: 60 mg o-phthaldialdehyde was dissolved in 3 
ml methanol (prepared immediately before use). 
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Preparation of standard dilutions 
Standards S1 - S5 were prepared by adding 0.08, 0.17, 0.2, 0.6 and 1 ml of HL 
solution to 1 ml of PBS respectively and making up the volume of each to 4.8 ml 
with water. A blank was prepared containing no HL. The standards thus 
contained the following concentrations of HL. 
S1 = 1.033 µM 
S2 = 2.196 µM 
S3 = 2.583 µM 
S4 = 7.749 µM 
S5 = 12.915 µM 
Assay Procedure 
0.12 ml of each standard or blank was pipetted into a test tube. 0.12 ml of 
substrate-buffer solution was pipetted into a test tube for each sample to be 
assayed, as well as a zero-time blank (all in duplicate). The latter tube was 
placed on ice. 
Reaction was initiated by the addition of 5 µI of the enzyme sample to each 
sample tube, vortex mixed and immediately placed in a 37°C water bath for 15 
minutes. The reaction was terminated by adding 0. 725 ml of 0.28M sodium 
hydroxide to each tube. 
0.05 ml of the o-phthaldialdehyde solution was added, the tubes vortexed and 
incubated at room temperature for 10 minutes. This reaction was terminated by 
the addition of 3M hydrochloric acid to all test tubes with vortexing. 
Flourescence was measured immediately. 1 unit of activity was defined as 
1 µmol of His-Leu released at 37°C/minute. 
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9.8. IN SITU HYBRIDISATION 
9.8.1. Preparation of APTES coated slides 
Washed microscope slides were placed in a rack and were immersed in 
Chromic acid and left to stand overnight. The chromic acid was poured off and 
slides were washed for 3-4 hours in running tap water. They were then rinsed 
with deionised H20 and then left to stand in water overnight. Water was poured 
off and slides immersed in acetone for 2 hours. This was poured off and slides 
immersed in a 2% solution of APTES (3-Amino propyl tri-ethoxy silane) for 1 
hour and slides then- baked in oven at 80 °C overnight. 
Slides were then immersed in a 0.1 % solution of Diethyl pyrocarbonate 
(DEPC) in water for 2 hours. This was poured off and slides autoclaved and 
then dried at 80 °C in an oven. 
9.8.2. Preparation of tissues 
Rats were sacrificed and organs harvested on ice, cut into small pieces and 
placed overnight into Bouin's fixative. The tissue pieces were then processed 
and wax embedded following standard methodologies. 
9.8.3. In situ hybridisation 





2 x 10 minutes 
2 x 2 minutes 
1 x 2 minutes 
1 x 2 minutes 
Sections were then dipped in DEPC treated water and then in phospate 
buffered saline (DEPC treated) for 5 minutes. Slides were drained. 
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Proteinase K digestion 
1 µg/ml Proteinase K solution in 10 mM Tris/HCI, 5mM EDTA, pH 7.5 was 
prepared. 500 µI was laid over each section and incubated in humidified 
container at 37 °C for 15 minutes. Proteinase K digestion was stopped with 2 
mg/ml glycine in PBS for 30 secs. Slides were dipped in PBS twice for 1 minute 
each. 
Optional step for RNAse controls - prepared 40 µglml solution of RNAse A in 
TE buffer and incubated at 37°C for 30 minutes in humidified container. 
Reaction stopped with paraformaldehyde in following step. 
Fixation of sections 
500 µI of 4% paraformaldehyde in PBS was placed onto sections and left at 
room temperature for 5 minutes before being dipped in DEPC water for 30 
seconds. 
Acetylation of sections. 
Prepared 0.1 M Triethanolamine as follows; 
4 ml Triethanolamine 
296 ml DEPC H20 
Slides were placed in above solution and while stirring solution added 750 µI of 
acetic anhydride. Continued stirring for 1 O minutes then dipped slides in PBS 
for 5 minutes. 
Dehydration of sections 
70 % ethanol 
90 % ethanol 
Absolute ethanol 
Slides were air dried. 
1 x 2 minutes 
1 x 2 minutes 




Dextran Sulphate 0.5 g 
1M Tris/HCI pH8 50 µI 
1 OOx Denhart's solution 50 µI 
0.5M EDTA 10 µI 
1 M Dithiothryitol 50 µI 
dH20 (DEPC treated) 565 µI 
Salmon sperm DNA 250 µI 
tRNA 1 Omg/ml 25 µI 
before use diluted 1: 1 with deionised formamide 
Placed 100 µI for each section on parafilm and inverted slide on this. Incubated 
at 42 °C in humidified container for 2 hours. 
Hybridisation 
Hybridisation solution 
Dextran Sulphate 0.25 g 
1 M Tris/HCI pH8 25 µI 
1 OOx Denhart's solution 25 µI 
0.5M EDTA 5 µI 
1 M Dithiothryitol 25 µI 
dH20 (DEPC treated) 283 µI 
20x SSC 250 µI 
Salmon sperm DNA 1 µI 
tRNA 1 µI 
before use diluted 1: 1 with deionised formamide. 
Labelled RNA probes were heated for 30 secs. at 80°C then hold at 50°C. 
Diluted riboprobes to approximately 1 ng/µI in hybridisation solution. Applied 20 




2x SSC, 2x15 minutes at room temperature 
optional: RNAse treatment; 30 min at 37°C with boiled RNAse A in 0.5M NaCl 
and 10mM Tris.Cl, pH 8. 
Then washed twice with 2xSSC as above. 
0.1 x SSC, 2x15 minutes at 50°C 
Digoxigenin detection 
a. Slides washed in 1 OOmM Maleic acid, 150mM NaCl pH 7.5 buffer (buffer 1 ). 
b. Blocked for 20 minutes in 1 OOmM Maleic acid, 150mM NaCl pH 7.5 buffer 
with 2% Normal Sheep Serum (NSS) (buffer 2). Apply 150 µI per slide. 
c. Washed with 0.05% Tween-20 in buffer 1 in tank for 5 minutes at room 
temperature. 
d. Diluted anti-digoxigenin antibody 1 :200 in buffer 2 . Applied 20 µI/slide 
inverted on parafilm. Incubated for 30 minutes at 37°C. 
e. Washed 2x 15 minutes in buffer 1 at room temperature. 
f. Dipped slides for approximately 2 minutes in substrate buffer 1 OOmM 
Tris/HCI pH 9.5, 100 mM NaCl, 50 mM MgCl2 (buffer 3). Then drained slides. 
g. To prepare substrate solution - to 1 ml buffer 3 added 4.5 µI NBT solution 
and 3.5 µI X-phosphate solution. 
Added 100 µI to each section and then covers lipped. Incubated in dark at room 
temperature for approximately 1 hour or until colour reaction was clearly visible. 
h. Stopped colour reaction with 10mM Tris/HCI, 1mM EDTA pH8. 
i. Dehydrated sections and mounted with Enkitt. 
j. Examined under microscope and photographed. 
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9.9. IMMUNOHISTOCHEMISTRY 
Small pieces of tissue were fixed in Bouin's solution, dehydrated in a series of 
ethanol solutions and then xylene. Embedding in paraffin wax followed 
standard techniques and 5µm sections were mounted onto slides. The sections 
were rinsed in phosphate buffered saline (PBS) and incubated in diluted normal 
rat serum for thirty minutes at room temperature. The slides were washed in 
PBS before being incubated with monoclonal antibody diluted 1/50 in PBS with 
normal rat serum for 30 minutes at room temperature. After a further PBS wash 
the slides were incubated in a solution containing peroxidase conjugated 
antimouse antibody for 30 minutes. The slides were washed and incubated in a 
solution containing 3-3' diaminobenzidine and H202 until staining was 
considered adequate. Sections were washed, counterstained with 
haematoxyllin and then mounted. 
9.1 O Rat lung ACE purification 
Purification Volume Total Total units Specific Purification 
step (ml) Protein (U) activity (fold) 
(mg) (U/mg) 
Tissue 400 5424 108 0.02 
homogeni-
sation 
Column 360 5300 477 0.09 4.5 
load 
Affinity 18 5 455 91 1130 
chromate- ' 
graphy 
N.B. The column load volume of 360 ml was loaded over four purification runs. 
9.11 Inhibition of purified ACE by captopril 
The purified rat ACE was found to be sensitive to captopril inhibition. In order to 
derive a value for Ki , standard Dixon plots (Dixon, 1953) of the data were 
constructed using the values obtained from Hip-His-Leu (1 mM) hydrolysis in 
the presence of concentrations of captopril in the range 0.92-55.3nM. ACE was 
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at a concentration of 0.4µg/ml in 0.1 M potassium phosphate (pH 8.3), 0.3M 
NaCl and 0.12mg/ml albumin. 



















As is to be expected with tight binding inhibitors, the resulting plots were non 
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Figure 9.1. Rat ACE inhibition by captopril. Studies were performed with purified rat lung 
ACE at a concentration of 0.4µg/ml in 0.1 M potassium phosphate (pH 8.3), 0.3M NaCl and 
0.12mg/ml albumin. Dixon plot of 1 N vs. [I] for Hip-His-Leu (1 mM) hydrolysis in the 
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Figure 9.2. Graphical method for the derivation of K. 1N vs. [I] is plotted and a family of 
lines drawn between V0 and the various concentrations of captopril. These lines intersect at 
integral divisions of V0 giving equally spaced intersection points on the abscissa. The 
distance between these points is equal to K. 
Assuming the Km for the substrate to be 2mM, the formula for the derivation of 
Ki was used; 
Ki = KI (1 +[SJ/Km) where K is obtained from the 
graph. 
Captopril was shown to be a competitive inhibitor with K dependent on [SJ, and 
a Ki of 2.BnM obtained. 
9.12 Analysis of spcific activity of radioiodinated ACE 
The specific activity of the radioiodinated human ACE tracer was determined by 
the self displacement method (Chiang, 1987). A standard RIA assay was 
prepared and note taken of the Bound/Total (BIT) counts for each of the 
standards. The results are subjected to linear regression analysis and plotted 
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on a graph vs. the actual standard concentrations on a linear scale. In the 
same assay, tubes are included with varying excess amounts of radiolabelled 
tracer. The tubes are assayed in the same way and the resulting BIT values 
plotted on the same graph vs. total counts in each tube (fig. 9.3). Values for 
R1,R2,Q1 and Q2 are obtained from the graph by interpolation. The specific 
activity of the tracer is derived from the formula; 
Specific activity= (R1-R2) cpm / (Q1-Q2) ng 
The count data and graph obtained are shown below. 
Radioactivity cpm 












































































































Fig 9.3. Plot of standard curve data from table 9.1. (bold dots), T/B vs. concentration of 
unlabelled ACE (lower horizontal axis), and tracer self displacement data (small dots), T/B 
vs. quantity of radioactivity, upper horizontal axis. 
Specific Activity= (9800000-3900000)cpm/(40-1 O)ng = 198000cpm/ng ACE 
Counter efficiency = 74%. Therefore tracer specific activity is 
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